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GENERAL INTRODUCTION
Enzymes in industrial processes
Enzymes have been in use for industrial purposes for thousands of years, for example in the 
preparation of cheese or alcoholic beverages [1]. Since the 1980s, the number of industrial 
processes for the synthesis of ﬁne chemicals that make use of biological catalysts has increased 
rapidly, and it still continues to grow [2, 3] (Figure 1). Partly responsible for this increase is the 
development of novel molecular biological techniques, such as recombinant DNA technology, 
that took a ﬂight in the 1980s [4]. These techniques enabled overexpression of enzymes in 
heterologous hosts, which made them available in higher quantities and at lower cost.
Enzymes are remarkable catalysts. The wide variety of enzymes in nature collectively accept 
a wide range of organic substances as substrates, and the number of different reactions they 
perform, both simple and complex, is enormous [6]. Many of the reactions that are performed 
by enzymes with apparent ease are difﬁcult to achieve through organic chemistry. Enzymes 
are able to catalyse reactions under mild, environmentally friendly conditions, resulting 
in cleaner industrial processes, so-called ‘green chemistry’ [7]. The most striking feature 
of enzymes is their high regio- and stereoselectivity. This is especially important for the 
pharmaceutical industry, since it is expected that in the near future, approximately 70% of 
the pharmaceuticals has to be enantiomerically pure [8]. Blocking and deblocking of reactive 
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Figure 1: Cumulative number of biotransformation processes that have been started on industrial scale 
(adapted from [5]; based on 134 industrial biotransformation processes).
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groups, which is often used in organic chemistry to achieve regio- or stereospeciﬁcity, is not 
required in enzymatic reactions. This reduces the number of synthetic steps and therefore 
the production costs [9]. In addition, their selectivity results in efﬁcient reactions with few 
by-products, thus facilitating product isolation [6].
To date, several classes of enzymes are used in industrial processes. Hydrolases are the most 
commonly used enzymes in industry (Figure 2), which is in part because of their broad substrate 
range and their relatively high activity, and in part because of their cofactor-independence. 
They catalyse the hydrolytic cleavage of C-O, C-N and C-C bonds. Depending on the type of 
bond they hydrolyse, hydrolases can be classiﬁed as esterases, lipases, acylases, amidases, 
peptidases, cellulases, nucleosidases, β-galactosidases or glycosylases. Esterases and lipases 
are used most frequently as biocatalysts [9]. An example of an industrial process that 
involves a hydrolase is the enantiospeciﬁc hydrolysis of S-glycidate to S-oxiranyl methanol, 
an intermediate in the synthesis of S-betablockers [1].
Like hydrolases, lyases also catalyse the cleavage of C-O, C-N and C-C bonds, but not through 
hydrolysis. For industrial purposes, their ability to form new bonds under non-natural reaction 
conditions (high reactant concentrations) is most interesting. One industrial example of such 
a reaction is the use of L-Tyrosine phenol lyase for the synthesis of L-DOPA [1].
Transferases comprise another group of enzymes that is used in industrial processes. They 
catalyse the transfer of a chemical group from a donor molecule to an acceptor molecule. 
For example, D-aspartate transaminase is used for the synthesis of amino acids from 
keto acids, which can be applied as food additives or as intermediates for the synthesis of 
pharmaceuticals [1]. Transferases perform much more complex chemical reactions compared 
to hydrolases and lyases [10], however, so far their general application in industry has been 
hampered by their limited availability caused by low expression levels [9], and by their 
dependence on expensive group-transferring cofactors [10].
Isomerases, a relatively small class of enzymes, catalyse isomerisation reactions within 
one molecule. So far, they have not been applied often as biocatalysts. The most renowned 
example is glucose isomerase, which is used to convert glucose to fructose that can be used 
as sweetener [1]. 
Figure 2: Enzyme types used in industrial biotransformations. (Adapted from [5]; based on 134 industrial 
biotransformation processes).
GENERAL INTRODUCTION
15
C
H
A
PTER
1The oxido-reductases constitute a very diverse group of enzymes, catalysing a wide range of 
different oxidation and/or reduction reactions. All oxido-reductases are cofactor dependent, 
which is a drawback for their use in industry, because these cofactors are often expensive. 
Therefore, for their use as biocatalysts, cellular systems are required that supply the enzymes 
with these cofactors. The most commonly used cofactors are NADH, NADPH, FADH and PQQ. 
Cofactor regeneration systems, often involving a second enzyme, have been described for 
most cofactors [10], but they have so far not been applied on industrial scale. As for yet, oxido-
reductases are not used very often in biotechnology, but they do receive increasing attention 
because of their broad substrate range and the wide variety of different reactions they can 
perform. One example is the use of benzoate hydroxylase to form catechols from benzene 
derivatives. These catechols are used as intermediates in the synthesis of antiviral agents [1].
Protein engineering
Despite their intrinsically promising characteristics, most enzymes have not yet been used 
to their full potential in biotechnology [4]. Some critical limitations of enzymes are their low 
expression levels, their high cost, requirement for expensive cofactors, poor stability under 
process conditions, and poor activity or speciﬁcity [4, 11]. The development of novel molecular 
biological techniques over the past decades has provided several solutions for most of these 
problems. Recombinant DNA techniques have allowed the production of enzymes at levels 
more than 100-fold their native expression. This has strongly increased the availability of 
enzymes [4]. Moreover, mutagenesis techniques such as directed evolution and metabolic 
engineering have led to the production of enzymes with customised properties for 
biotechnological use [3, 12]. In Table 1, examples of enzymatic properties that can be improved 
by genetic engineering have been summarised.
Mutagenesis techniques - Site-directed mutagenesis
Rational design can be used to obtain enzymes with improved properties for the use as 
biocatalysts, such as the properties listed in Table 1. A prerequisite for the successful use of 
site-directed mutagenesis is detailed structural and mechanistic knowledge of the target 
enzyme. Preferably, a high-resolution protein structure should be available, either derived 
from X-ray crystal structure analysis, or from homology modeling based on closely related 
proteins. Iterative computer design and experimental characterisation of the designed 
mutants can lead to the desired improvements of the enzyme. Some examples are known 
where site-directed mutagenesis has been successfully employed to obtain mutant enzymes 
with the desired properties. Several examples of successful rational design are mentioned in 
Table 1, such as altered functionality, increased expression levels, increased coupling and the 
use of alternative cofactors. Other examples include the alteration of the substrate speciﬁcity 
of an amidohydrolase based on analysis of the three dimensional structure [25], and the 
improved enantioselectivity (E = 6.5 to E = 12.4) of C. antarctica B-lipase toward 1-bromo-2-
octanol by molecular modeling [26].
However, because site-directed mutagenesis is relatively laborious and often unsuccessful, 
other techniques such as random mutagenesis are often preferred [12, 27]. The low success 
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rate of site-directed mutagenesis is partly due to the fact that rational design is often biased 
for active site mutations, while mutation of residues outside the active site, that are involved 
in, for example, enzyme conformation or substrate recognition, often has a much larger 
effect on enzyme activity. Additionally, the full evolutionary space is too big to be explored 
by site-directed mutagenesis only; even when restricting the mutations to the active site, 
an active site consisting of 20 amino acids that can each be mutated into 19 different amino 
acids already gives 2019 possibilities. Site-directed mutagenesis is still frequently used to 
elucidate the role of speciﬁc residues in binding and catalysis. Experimentally, the effect of 
the mutation can be determined, and using computational studies on protein models, the 
effects can be rationalised [28-32]. This will eventually lead to an increased understanding of 
the enzyme and validation of the model, and it may lead to revision and improvement of the 
protein model.
Engineered property Example Method Reference 
(year)
substrate speciﬁcity aspartate aminotransferase; able to 
accept β-branched substrates
DNA shufﬂing [13] (1998)
enantioselectivity lipase: E = 1.1 to E = 25.8 for 
2-methyldecanoate
directed evolution [14] (1997)
catalytic activity hydroxybiphenyl monooxygenase: 
increased activity toward 2-
substituted phenols
gene shufﬂing [15] (2003)
functionality oleate desaturase: altered to 
hydroxylase
rational design [16] (1998)
solvent resistance p-nitrobenzyl esterase: 60-fold 
increased activity in DMF
directed evolution [17] (1996)
thermostability p-nitrobenzyl esterase: > 14 °C 
increased Tm
directed evolution [18] (1998)
pH resistance α-amylase: higher activity at 
alkaline pH
directed evolution [19] (2003)
regioselectivity biphenyl dioxygenase: metabolises 
PCBs at different positions
DNA shufﬂing [20] (1998)
solubility monooxygenase: increased water 
solubility
chimeragenesis [21] (1998)
expression levels monooxygenase: increased 
expression levels by modiﬁcation of 
N-terminus
rational design [22] (1991)
cofactor requirement monooxygenase: use of cheaper 
NADH instead of NADPH
rational design [23] (2005)
coupling efﬁciency monooxygenase: increased coupling rational design [24] (2006)
Table 1: Examples of improvements accomplished by mutagenesis techniques.
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Mutagenesis techniques - Random mutagenesis and directed evolution
When using random mutagenesis to generate enzymes with improved properties for the 
use as biocatalysts, structural knowledge of the enzyme is not required, as opposed to 
site-directed mutagenesis. Random mutagenesis is the introduction of random mutations 
into a target gene. It is also possible to target speciﬁc residues or stretches of residues, for 
example active site residues or regions, instead of the entire gene [33]. This technique is 
often referred to as cassette mutagenesis. When only one residue is targeted for random 
mutagenesis, this is called site-saturation mutagenesis. Directed evolution is deﬁned as an 
iterative process of random mutagenesis and selection of mutants with improved activity, 
followed by a subsequent round of random mutagenesis on the selected genes (Figure 3) [33]. 
The most common procedure to introduce random mutations into a target gene is error-
prone PCR. For this technique, low ﬁdelity Taq polymerase is used, which is an enzyme that 
lacks proofreading activity [33]. The error rate can be controlled by varying the concentrations 
of magnesium chloride or manganese chloride; high concentrations increase the error rate 
of the polymerase. A disadvantage of the high error rate of error-prone PCR, however, is that 
deleterious mutations can accumulate together with the beneﬁcial mutations, resulting in 
large numbers of inactivated mutants [27, 33]. Therefore, it is advisable to keep the error rate 
down to 2-3 mutations per gene.
After the resulting random mutants have been cloned into an expression vector and 
transformed into an expression host, a screening or selection method has to be used to 
Figure 3: Directed evolution is an iterative process of random mutagenesis and selection of mutants with 
improved activity, followed by a subsequent round of random mutagenesis on the selected genes.
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identify mutants with desirable properties. These mutants can be subjected to subsequent 
rounds of random mutagenesis for further improvement. Because of the large number of 
mutants that are created in the process, the screening procedure is usually the bottleneck of 
the directed evolution approach.
A drawback of error-prone PCR is that it doesn’t explore the full functional sequence space 
because it lacks combinatoriality [27]. In the natural process of evolution, recombination 
of parent genes and natural selection allows beneﬁcial mutations to accumulate. With 
error-prone PCR, recombination of beneﬁcial mutations does not occur, rather, deleterious 
mutations can accumulate which results in inactive enzymes. A breakthrough was made in 
1994 by Stemmer with the introduction of DNA shufﬂing [34, 35]. DNA shufﬂing is a technique 
that allows the recombination of homologous genes, such as a closely related gene family, 
or a library of random mutants generated by error-prone PCR (Figure 4A). The resulting 
Figure 4: DNA shufﬂing and StEP: two procedures to recombine mutations in a library of mutants [33].
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DNA shufﬂing, the genes are digested with DNaseI, and reassembled into full-length genes 
by repeated cycles of PCR. This technique closely resembles sexual recombination as it occurs 
in nature. Another way to recombine homologous genes is Staggered Extension Process 
(StEP) [36]. This procedure involves a PCR reaction with multiple templates that are subjected 
to cycles of denaturation and short annealing/extension steps (Figure 4B). Because the 
extension time is kept very short, only a small part of the gene will be ampliﬁed in one cycle, 
and in the next cycle it can anneal to a different template containing different mutations. 
This repeated ‘template switching’ causes recombination of the mutations in the template 
DNA. Recombination techniques greatly enhance the success of directed evolution, because 
it allows the recombination of beneﬁcial mutations in a similar way to sexual recombination 
in nature.
Screening methods
The bottleneck of random mutagenesis and directed evolution is the availability of a good 
screening assay [37]. To select mutants with the desired properties from a library of random 
mutants, a screening method is required that is sensitive, simple, fast and efﬁcient. The 
different types of assays that are available for screening purposes are described below. 
Most ideal for this purpose are assays that can be performed in whole cells or permeabilised 
cells, because enzyme isolation from thousands of mutants is usually not feasible. Screens 
where the formation of a coloured or ﬂuorescent product can be measured for a large 
number of samples simultaneously, for example in 96- or 384-well format in a platereader, 
are preferred over assays that require individual analysis of each sample, such as high-
performance liquid chromatography (HPLC)-, gas chromatography (GC)- or mass spectrometry 
(MS)-based assays. Because the samples need to be injected individually, this results in much 
longer measurement time compared to platereader assays. In addition, analysis of thousands 
of HPLC, GC or MS chromatograms is a labour intensive task. The advantage of GC and MS is 
that it is very sensitive, and it gives a lot of information on the metabolism of the screening 
substrate. With MS, selective ion monitoring is possible, which allows the simultaneous 
measurement of cocktails of multiple substrates [38].
Selection assays can be used when the mutant enzymes with the desired properties give 
their host organism a growth or survival advantage. For example, in the development of 
β-lactamases with increased activity toward the antibiotic cefotaxime, the bacterial cells 
expressing the mutant enzymes were grown on agar plates containing a high concentration 
of cefotaxime. Only cells that expressed a mutant that could degrade cefotaxime with high 
efﬁciency survived and formed colonies [35]. Other examples of selection include assays 
where the substrate is supplied as the sole carbon source in the growth media. However, 
for most directed evolution studies these selection methods are not applicable, because the 
mutant with the desired properties does not give the host organism a growth or survival 
advantage.
Visual screens that can be performed on bacterial colonies can be rapid and straightforward. 
For example, in the search for a mutant of haloalkane dehalogenase with higher activity 
toward trichloropropane, a pH sensitive visual screen was used. Dehalogenation of 
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trichloropropane is accompanied by the formation of HCl, and by incorporating a pH indicator 
in the agar plates, colonies with increased activities could be selected based on their colour 
[39]. Drawbacks of such visual screens are that they are not quantitative, and often they’re 
not sensitive enough to detect small changes in enzyme activity [33].
When the screening substrate cannot enter the cell of the host organism, whole cell based 
screening is not possible. In this case, permeabilised or lysed cells could be used instead. A 
disadvantage is that these assays are not colony-based, and are therefore more laborious. 
First, the colonies have to be transferred from the agar plate to 96- or 384-wells plates. 
Subsequently, the screening substrate, the cofactor and a permeabilising agent have to be 
added. Product formation can then be monitored using a (ﬂuorescence) platereader. In many 
cases, no colorimetric or ﬂuorescent screening method is available for the desired reaction 
product of the mutant enzymes. In such cases, two-step assays can be used that involve the 
addition of a second reagent, that can react with the desired product and be detected by 
ﬂuorescence or spectroscopy. One example of such an assay is the detection of aromatic 
hydroxylation after reaction with 4-aminoantipyrine [40].
Oxygenases
The mutagenesis techniques described in the previous paragraphs are very useful for 
biotechnology purposes. These biological tools can be used to develop enzymes into cheap, 
efﬁcient and selective biocatalysts for the synthesis of ﬁne chemicals and pharmaceuticals, or 
for bioremediation of chemical deposits in the environment. In the early 2000s, at the start 
of the research project described in this thesis, enzymes in biotechnology were mainly used 
for hydrolysis and isomerisation reactions. Despite the importance of oxidation reactions in 
the chemical and pharmaceutical industry, enzymes catalysing oxidation reactions have not 
been utilised on industrial scale [41-43] (Figure 1). Of the different types of oxygenases that 
are known, Cytochrome P450 monooxygenases are one of the best-known examples. Other 
widespread oxyenases are non-heme monooxygenases, copper-dependent monooxygenases, 
ﬂavin-dependent monooxygenases and dioxygenases (Table 2). The monooxygenases are 
able to catalyse a wide range of oxidation reactions on a wide range of substrates with 
often remarkable speciﬁcities. Their use in industry, however, is hampered by several 
practical limitations. In addition to their complexity, they have low expression levels, are 
often unstable and display low catalytic rates [33, 44]. Furthermore, they rely on expensive 
cofactors such as NAD(P)H to supply the electrons required for the catalytic reaction. Many 
oxygenases also require electron transfer partners such as ﬂavin reductases and iron-sulfur 
proteins [43]. However, because of their ability to perform complex chemistry, such as the 
hydroxylation of unactivated carbon atoms, with high selectivity and speciﬁcity on a wide 
variety of substrates, oxygenases have in principle very good perspectives for biotechnology. 
With mutagenesis techniques such as directed evolution that have become available over 
recent years, it is now possible to engineer these enzymes to overcome many of the problems 
that have so far limited their use as biocatalysts.
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Cytochromes P450
One family of oxygenases in particular is currently evaluated for its use in biocatalysis. The 
Cytochromes P450 (P450s) constitute a large family of monooxygenases, in fact, it is one of 
the largest enzyme superfamilies known to date. So far, collectively over 6000 P450-encoding 
genes have been found in virtually all living organisms and tissues (drnelson.utmem.edu 
and www.cypalleles.ki.se). These 6000 genes are arranged in approximately 700 families. 
The majority of the P450 families originate from fungi (300 families) and bacteria (175 
families). In plants and in animals, 100 families have been identiﬁed. The name Cytochrome 
P450, abbreviated as P450, is derived from the characteristic absorption band at 450 nm of 
the reduced CO-bound complex [46]. Their nomenclature is based on sequence homology; 
if two P450s show less than 40% sequence identity, they are assigned to different families, 
indicated by a number. Two P450s with more than 40% but less than 55% sequence identity 
are assigned to the same family, but different subfamilies, indicated by a capital letter. Within 
a subfamily, the various isoforms are distinguished by a unique number [47].
The P450 family is able to convert an extremely wide variety of substrates. In humans, they are 
involved in various endogenous processes such as the synthesis and catabolism of steroids, 
eicosanoids and vitamins. However, historically P450s have become most known for their
role in the biotransformation of mainly hydrophobic drugs and other xenobiotics, such as 
environmental contaminants and food components.
Class Characteristics
ﬂavin-dependent monooxygenases ubiquitous, well studied, wide variety of 
reactions, regio/enantioselective
heme-containing Fe-dependent
monooxygenases (cytochromes P450)
abundant, many isoforms, many reactions, 
hydroxylate unactivated carbon atoms
non-heme Fe-dependent monooxygenases often use 2-oxoglutarate as co-substrate
Cu-dependent monooxygenases 3 forms known: tyrosinase; methane- and 
ammonia monooxygenase [45]
S-adenosyl-L-methionine-dependent
monooxygenases
rare
cofactor-independent monooxygenases rare
dioxygenases ring cleavage or hydroxylation, less complex 
than monooxygenases. Transfer 2 O-atoms to 
substrate
peroxygenases use H2O2 instead of O2 as oxygen donor
Table 2: Different classes of oxygenases.
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Xenobiotic metabolism
When xenobiotics such as drugs, food components and environmental contaminants enter 
the human body, they are metabolised by a large number of different enzymes. The aim of 
xenobiotic metabolism is to increase the solubility of these compounds, which facilitates 
urinary and biliary excretion and causes the chemicals to leave the body. Metabolism or 
biotransformation of drugs and other xenobiotics is generally divided into phase I and phase 
II reactions. Phase I metabolism involves the introduction of functional groups by oxidation or 
reduction. P450s are responsible for approximately 80% of the phase I metabolism occurring 
in the human liver. The three most abundant P450s in human liver are P450 3A4, the 2C family 
and P450 1A2 (Figure 5A). However, when looking at the contribution to phase I metabolism, 
P450 2D6, although it constitutes only 2% of the total P450 content in liver, is also one of the 
major players (Figure 5B) [48, 49].
During phase II metabolism, nucleophilic functional groups, for example introduced by phase 
I metabolism, are conjugated to cofactors such as glucuronic acid, sulfates, glutathione or 
amino acids. This type of metabolism also increases the water solubility of the compounds and 
facilitates elimination from the body by urinary excretion. Phase I and phase II metabolism 
are followed by the export of the resulting metabolites by various transporters, such as
Figure 5: Relative P450 content in human liver (A) and relative contribution of the enzymes involved in 
phase I metabolism (B) [48, 49].
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P-glycoprotein (P-gp), multidrug resistance proteins (MRPs) and organic anion transporting 
polypeptides (OATPs) [50, 51]. This is indicated as phase III.
Biotransformation of drugs can have different effects. Most often, the compound is detoxiﬁed 
and readily leaves the body as described in the previous paragraph. Sometimes, an inactive 
prodrug is biotransformed into the pharmacologically active compound. For example, P450 
2B6 is able to activate the anticancer prodrugs cyclophosphamide and iphosphamide [52]. 
Other examples of drugs that are converted into pharmacologically active metabolites by 
biotransformation reactions are listed in Table 3. On the other hand, biotransformation can 
also lead to the formation of toxic metabolites. A well-known example is the formation of the 
hepatotoxic N-acetyl-p-benzoquinonimine (NAPQI) from paracetamol by P450 1A2, 2E1 and 
3A4 [53]. Activation of drugs to toxic or carcinogenic compounds can result in very serious 
adverse drug reactions (ADRs), and to prevent this it is crucial to investigate in an early stage 
in drug development whether a clinical candidate can be biotransformed into potentially 
toxic metabolites.
Drug Metabolite Clinical use
acetohexamide hydroxyacetohexamide antihyperglycemic
codeine morphine analgesic
diazepam demethyldiazepam tranquiliser/anticonvulsant
dothiepin dothiepinsulfoxide antidepressant
ﬂuoxetine norﬂuoxetine antidepressant
hydroxyzine cetirizine antiallergic
imipramine desimipramine antidepressant
loratadine desloratadine antiallergic
β-methyldigoxin digoxin heart failure
nalidixic acid hydroxynaldixic acid antibacterial
phenacetin acetaminophen analgesic
prednisone prednisolone asthma
proguanil cycloguanil antimalaria
propafenone 5-hydroxypropafenone antiarrhythmic
propranolol 4-hydroxypropranolol antiarrhythmic
risperidone 9-hydroxyrisperidone antipsychotic
simavastatin 6β-hydroxymethyl-simavastatin hypercholesterolemia
terfenadine fexofenadine antiallergic
verapamil norverapamil arrhythmias, antianginal
Table 3: Drugs that are biotransformed into pharmacologically active metabolites [54].
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Structural organisation of P450s
P450s need an external electron donor to supply the electrons required for binding and 
activation of molecular oxygen. P450s can be divided into two main classes based on their 
redox partners (Figure 6) [55]. Class I P450s require two redox proteins: an FAD containing 
reductase and an Fe-S ferredoxin. Mitochondrial P450s belong to this class, as well as most 
soluble bacterial P450s [56]. The microsomal P450s, that are attached to the endoplasmatic 
reticulum, belong to Class II. These enzymes require only one reductase that contains an 
FAD and an FMN domain. Although most bacterial P450s belong to Class I, there are some 
exceptions. In 1981, the bacterial enzyme Cytochrome P450 BM3 (P450 BM3) from Bacillus 
megaterium was identiﬁed [57]. P450 BM3 is soluble and uses a Class II redox system [56]. 
A special feature of P450 BM3 is that its reductase domain is fused to the C-terminus of the 
heme domain, thus making P450 BM3 an entire Class II enzyme in a single polypeptide. The 
construction of active chimerae of the heme domain of mammalian P450s and the reductase 
domain of P450 BM3 showed that the reductase domain of P450 BM3 closely resembles the 
mammalian reductase [58]. For over 20 years, P450 BM3 has been the only known enzyme 
Figure 6: The structural organisation of P450s: Class I (mostly bacterial P450s), Class II (mostly microsomal 
P450s) and P450 BM3. FAD is the FAD containing P450 reductase, Fe-S is the Fe-S ferredoxin, and FAD/FMN is 
the FAD and FMN containing P450 reductase.
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enzymes have been discovered in Bacillus subtilis. These enzymes, CYP102A2 and CYP102A3, 
are also composed of a heme domain and a Class II reductase domain on a single polypeptide 
chain [59].
Catalytic mechanism
The general catalytic cycle for substrate hydroxylation by P450s is depicted in Figure 7 [60-
62]. In the resting state, in the absence of substrate, the heme iron is in the ferric state and 
complexed with a water molecule (1). Binding of a substrate results in displacement of the 
water molecule that acts as a 6th ligand (2). Donation of the ﬁrst electron from NAD(P)H results 
in the formation of ferrous iron (3). Subsequently, the ferrous iron binds molecular oxygen, 
resulting in the formation of a peroxo iron complex, Fe2+-O2 (4). In the next step, a second 
Figure 7: The catalytic cycle of P450s, adapted from [60-62]. The three uncoupling pathways are indicated 
by u1-u3, and the two peroxide shunt pathways are indicated by s1 and s2.
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electron enters the catalytic cycle (5). Addition of a proton results in the hydroperoxo iron 
complex, Fe3+-OOH (6). Addition of a second hydrogen atom followed by loss of water results 
in the oxenoid iron species (7). This complex abstracts hydrogen or an electron from the 
substrate, ﬁnally resulting in formation of the product. Although traditionally, the oxenoid 
iron species was considered to be the reactive species, it is now believed that the peroxo 
iron complex and the hydroperoxo iron complex can also result in product formation [63]. 
These species have different oxidative properties, and lead to different types of reactions 
[64, 65]. The occurrence of three reactive oxygen species in the P450 catalytic cycle therefore 
contributes to their catalytic diversity.
The oxygenating species in stage 6 and 7 can also be formed using ‘artiﬁcial oxygen’ such as 
peroxides, via the so-called ‘peroxide shunt pathway’ (s1 and s2) [60]. This circumvents the use 
of the expensive electron donor NADPH, and is therefore particularly attractive for the use of 
P450s in biotechnology [66].
A potential problem for the use of P450s as biocatalysts is so-called uncoupling. In the catalytic 
cycle, three alternative pathways can occur that do not lead to product formation (Figure 7), 
but instead to formation of a superoxide anion (u1), hydrogen peroxide (u2) or water (u3). This 
has important implications for biotechnology. Firstly, the reactive oxygen species produced 
by uncoupling can damage the biocatalyst, and secondly, the expensive electron donating 
cofactor is used for futile redox cycling instead of product formation. The coupling efﬁciency 
of drug metabolising microsomal P450s is usually very low (<<50%) [67]. The coupling of 
bacterial P450s is generally much higher; the coupling of P450 cam for example, is nearly 
100% for its natural substrate, camphor. However, when other substrates than camphor are 
used, or when mutants of P450 cam are used to metabolise camphor, the coupling efﬁciency 
decreases drastically [68]. Several studies have shown that the coupling efﬁciency of P450s 
could be manipulated by mutagenesis [69].
Potential of P450s as biocatalysts
The number of different chemical reactions that can be performed by P450s is vast (Table 4) 
[60, 61]. Additionally, the P450s from mammalian liver exhibit a wide substrate speciﬁcity, 
which is a prerequisite for their ability to metabolise xenobiotics [70]. This makes them 
extremely versatile enzymes. It is for these reasons that this class of enzymes has been 
attracting attention with respect to their use as biocatalysts in industrial processes [7, 37, 44, 
55, 70-72], and P450s are currently subject to many mechanistic investigations aimed at their 
structural and mechanistic elucidation.
P450s can be used as biocatalysts in the synthesis of ﬁne chemicals and pharmaceuticals that 
are difﬁcult or expensive to synthesise through organic chemistry. An advantage of P450s over 
other oxygenases used as biocatalysts is that they are able to hydroxylate unactivated carbon 
atoms, often with high stereospeciﬁcity [70]. Additionally, P450s could be useful in drug 
discovery, where they can be employed to functionalise existing drugs or lead compounds 
[71]. Especially the development of new antibiotics is an important ﬁeld where P450s could 
make a valuable contribution, since they are involved in the biosynthesis of antibiotics in 
bacteria and fungi [71]. They could also play a role in bioremediation of chemical deposits in 
the environment, for example in the oxidation of halogenated benzenes [69, 73].
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explored. Two P450s in particular have been used for the studies described in this thesis. 
P450 2D6 is one of the most important drug metabolising P450s in human liver, while P450 
BM3 is one of the most studied bacterial P450s. These two enzymes will be introduced in the 
following paragraphs.
Reaction catalysed Example
aliphatic hydroxylation
CH C OH
epoxidation R R
O
aromatic hydroxylation R R
OH
N-, O- and S-
dealkylation
N
H
N
N-hydroxylation C NH2 C
H
N OH
N- and S-oxidation
N
RO
OR'
N+
RO
OR'
O-
oxidative deamination
C
H
NH2
R C
O
R
dehalogenation
C
H
R'
R C
R'
R OCl
dehydrogenation
OH
HN
O
O
N
O
dehydration C
H
N OH C N
C-C bond cleavage
OH OH
O
isomerisation prostaglandin H2 → prostaglandin I2
reduction NO N2O H2O+
esterase
R1
O
O R2 R1
O
OH R2
O
H
+
Table 4: List of different reactions catalysed by P450s [60, 61].
28
Mammalian P450 2D6
Of the microsomal Class II P450s, the human P450 2D6 is one of the most extensively studied. 
Although P450 2D6 constitutes only 2-3% of the total hepatic P450 content, it is responsible 
for least 16% of the phase I metabolism of drugs (Figure 5). P450 2D6 is involved in the 
metabolism of approximately 30% of the drugs currently on the market [74]. Furthermore, 
P450 2D6 receives a lot of attention because this enzyme displays genetic polymorphisms. 
2 to 21% Of the caucasian population is classiﬁed as a ‘poor metaboliser’, while another 1 
to 5% has the ‘ultrarapid metaboliser’ phenotype [75]. This can result in adverse drug 
reactions or ineffective drug therapies. As ‘negative selection criterion’, all new clinical 
candidates are screened for P450 2D6 binding and/or metabolism in an early stage of drug 
development. Development of a reliable three dimensional protein model of P450 2D6 would 
enable this screening to take place in silico. Considerable effort has been made to construct 
pharmacophore models and homology models. The homology models were initially based on 
the crystal structure of the bacterial P450 cam and P450 BM3 in the ‘90s [76, 77], and later, in 
2003, on rabbit P450 2C5 [78]. In late 2002, when the research project described in this thesis 
started, only several homology models were available that were based on the available crystal 
structures of bacterial P450s. For the pharmaceutical industry it is very important to have a 
reliable computer model of P450 2D6 that can be used to predict substrate afﬁnities or sites of 
metabolism of clinical candidates [79, 80]. Therefore, part of this project has been dedicated 
to the validation of a P450 2D6 homology model developed in our lab [78]. This model was 
based on the crystal structure of P450 2C5 which became available in 2003. Pharmacophore 
modeling has revealed that most typical P450 2D6 substrates contain a basic nitrogen at 
5-7 Å from the site of oxidation, and an adjacent aromatic moiety [78, 81]. Homology models 
have suggested several active site residues to be involved in substrate binding by interaction 
with the basic nitrogen and the aromatic moiety. Site-directed mutagenesis studies have 
been used to validate these predictions, and to experimentally elucidate the role of several 
Residue Postulated role Reference
F120 aromatic interaction with substrates [28, 82], this thesis
E216 ionic interaction with basic N of substrates [30, 83]
E222 ionic interaction with basic N of substrates [82]
D301 stabilises B-C loop containing F120 [84, 85]
T309 involved in oxygen activation [86]
M/V374 inﬂuences regioselectivity metoprolol [87]
F481 involved in ligand binding; substrate dependent [88]
F483 inﬂuences orientation of substrates by steric interactions [89], this thesis
Table 5: Key residues for P450 2D6 activity, determined by mutagenesis studies.
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of two aromatic residues, F120 and F483, in binding and metabolism of several typical P450 
2D6 substrates (Figure 8).
Bacterial P450 BM3
Bacterial P450s in general are easier to study than mammalian P450s. They are generally 
more stable, and easier to express and to isolate. Because they are soluble, no enzyme 
reconstitution in an artiﬁcial membrane is required for activity [90]. Their solubility also 
makes them more suitable for many types of biophysical studies than their membrane-
bound counterparts [56]. For example, the ﬁrst X-ray crystal structure of a bacterial P450, 
P450 cam [91], was solved 14 years before the ﬁrst crystal structure of a mammalian P450, 
rabbit 2C5 [92], became available. Therefore, bacterial P450s have been studied extensively to 
increase our fundamental understanding of P450 properties. 
P450 BM3 is one of the most studied bacterial P450s. The natural substrates of P450 BM3 are 
long-chain fatty acids, which are hydroxylated at very high activity at subterminal positions 
[93]. P450 BM3 has the highest catalytic activity ever determined for a P450, i.e. 17100 min-1 
with arachidonic acid [94], which is attributed to the very efﬁcient electron transfer from the 
reductase domain to the heme domain [56]. The reaction rates of P450 BM3 are generally 
several thousand fold higher than those of mammalian P450s, and 10 to 100 fold higher than 
those of other bacterial P450s such as P450 cam and P450 eryF (Figure 9).
Figure 8: Structure of P450 2D6. The most important residues (Table 5) are labelled and depicted in light 
grey. The ball in the heme group represents the heme iron. For this picture, the recently solved X-ray structure 
of P450 2D6 was used.
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The crystal structure of P450 BM3 [105] has provided the basis for investigation of the roles of 
various residues in substrate binding and catalysis (Table 6). It was soon discovered that F87, 
located directly above the heme iron, plays a crucial role in the regio- and substrate speciﬁcity 
of P450 BM3 [106]. Mutagenesis of F87 to a smaller residue alters the regiospeciﬁcity of fatty 
acid hydroxylation, and allows metabolism of more bulky substrates (Figure 10) [29, 73, 107, 
108]. 
Figure 9: Difference in catalytic activities of wild-type human and bacterial P450s (1A2, MeIQ [95]; 2A6, 
coumarin [96]; 2B1, ethoxytriﬂuorocoumarin [97]; 2C8, amodiaquine [98]; 2C9, tolbutamide [99]; 2D6, 
dextromethorphan [99]; 2E1, chlorzoxazone [100]; 3A4, midazolam [101]; cam, camphor [102]; eryF, 6-
deoxyerythronolide [103]; BM3(1), arachidonic acid [94]; BM3(2), palmitic acid [104]).
Figure 10: Crystal structure of P450 BM3. Important residues (Table 6) are labelled and depicted in light 
grey. The ball in the heme group represents the heme iron.
GENERAL INTRODUCTION
31
C
H
A
PTER
1
Protein engineering of P450s
As described in the previous paragraphs, the use of P450s as biocatalysts has so far been 
limited because of several restrictions of these enzymes. During the past 15 years, many of 
the limitations of P450s have been addressed using protein engineering by site-directed 
mutagenesis and directed evolution. As mentioned previously, mammalian P450s are known 
to have a low catalytic activity. In an attempt to increase the activity of various mammalian 
P450s, several site-directed and random mutagenesis studies have been performed. Most of 
these studies are from very recent date, and so far, the results have been of moderate success. 
The increase in catalytic efﬁciency of P450 1A2, 2A6, 2C, 2B1 and 3A4 rarely exceeded a factor 
10; in most studies in increase of only a factor 2 to 6 was found (Figure 11) [37].
Compared to mammalian P450s, the catalytic activities of bacterial P450s toward their 
natural substrates are generally much higher (Figure 9). The major drawback of the natural 
bacterial P450s is that they generally have a narrow substrate speciﬁcity compared to the 
drug-metabolising mammalian P450s, which limits their use as biocatalysts. This narrow 
substrate speciﬁcity has also been addressed using site-directed and random mutagenesis. 
These approaches have resulted in several mutants of bacterial P450s that are able to convert 
non-natural compounds with high catalytic activity. For P450 eryF for example, which normally 
catalyses the hydroxylation of 6-deoxyerythronolide, a single amino acid substitution enabled 
the enzyme to convert alternative substrates like testosterone and 7-benzyloxyquinoline 
[118, 119]. Mutants of P450 cam have been described that are able to convert non-natural 
substrates such as polycyclic aromatic hydrocarbons [102], polychlorinated benzenes [69] and 
hexachloroethane [120]. For the long-chain fatty acid hydroxylating P450 BM3 the list of non-
natural substrates converted by random- or site-directed mutants is still rapidly growing 
(Table 7 and Figure 11). The non-natural substrates converted by P450 BM3 mutants range from 
compounds that resemble the natural substrates, such as short- and medium-chain fatty 
acids and alkanes, to compounds that bear no structural resemblance to fatty acids, such as 
polycyclic aromatic hydrocarbons and several drug-like molecules.
Residue Postulated role Reference
F42 hydrophobic lid over active site [32]
R47 substrate recognition [32]
Y51 substrate recognition [32]
F87 determines regio- and substrate speciﬁcity [29, 32]
W96 heme binding [109]
T268 oxygen binding, electron transport [31, 110]
F393 determines heme reduction potential [31, 111]
Table 6: Key residues for P450 BM3 activity, determined by mutagenesis studies.
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Screening assays for P450s
As mentioned before, screening is usually the bottleneck of the directed evolution approach. 
The number of high-throughput screening assays that have been used in directed evolution 
of P450s is still limited (Table 8). For directed evolution of P450 BM3, an assay involving the 
conversion of pseudosubstrates, p-nitrophenoxycarboxylic acids (p-NCAs), of varying length 
to the yellow p-nitrophenolate has been used. The advantage of this assay is that it is suitable 
for screening in whole cells, provided that a permeabilising agent is added [121]. Another 
colorimetric assay that can be performed in whole cells is the formation of the insoluble blue 
dye indigo from indole. This assay has been used for P450 2A6 and P450 BM3.
For directed evolution of P450 1A2, 2A6, 2B1 and BM3, several ﬂuorescent assays have been 
employed using resoruﬁn- and coumarin derivatives. These assays were all performed in 96-
wells plate format using whole or permeabilised cells [96, 97, 113]. For P450 1A2, also a colony-
based screening method has been used, similar to mutagenicity tests such as the Ames 
test [128]. For these tests, histidine-dependent cells are exposed to mutagenic chemicals. 
The mutations introduced by these chemicals can revert the histidine-dependence of the 
cells. The number of colonies emerging on histidine-deﬁcient growth medium is therefore 
GENERAL INTRODUCTION
Figure 11: Examples of mutagenesis results of mammalian cytochromes P450 (a-h) versus P450 BM3 (i-o). 
The activities of the wild-type (black bars) and most active mutant (white bars) are plotted. Substrates 
used were: aphenacetin [112]; b7-ethoxyresoruﬁn [112]; cMeIQ [95]; d7-methoxyresoruﬁn [113]; ecoumarin [114]; 
findoles [115]; gethoxytriﬂuorocoumarin [97]; htestosterone [97]; iindole [107]; jhexanoate [94]; koctane [116]; 
lnaphthalene [116]; macenaphthylene [73]; nﬂuoranthene [117]; ohexane [104]. The techniques used were 
directed evolution for a-i, k, l and o, and site-directed mutagenesis for j, m and n. The inset shows a zoom-in 
of studies a-h.
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a measure for the mutagenicity of the chemical. When P450s are expressed in these cells, 
it is possible to study the ability of these P450s to convert a compound into a mutagenic 
metabolite by counting the number of revertants.
Many examples are known of assays that involve two steps: the formation of a product, 
followed by the reaction of the product with a reagent that results in the formation of a 
coloured or ﬂuorescent compound. For example, hydroxylated aromatic compounds can be 
detected colorimetrically after reaction with 4-aminoantipyrine [40]. Similarly, hydroxylated 
aromatic compounds can be coupled by horse radish peroxidase to form ﬂuorescent dimers 
[66, 129].
What the characteristics of an ideal screening assay are depends on the desired outcome. At 
least, the assay should be sensitive, fast and easy to perform. The sensitivity of ﬂuorescent 
assays (resoruﬁns, coumarins) is generally much higher compared to colorimetric assays 
Substrate Reaction Reference (year)
p-NCAs O-dealkylation [121, 122] (2001, 1999) 
alkanes hydroxylation [104, 116, 123, 124] (2001, 2002, 
2005)
cycloalkanes hydroxylation [116] (2001) 
(hetero)arenes hydroxylation [116] (2001) 
indole hydroxylation [107, 125] (2000, 2005) 
PAHs hydroxylation [73, 117] (2001) 
propranolol hydroxylation [108] (2005) 
short-chain fatty acids hydroxylation [94] (2000) 
medium-chain fatty acids hydroxylation [126] (2001) 
C12-C16 alkyl trimethyl-ammonium 
compounds
hydroxylation [127] (1997) 
testosterone hydroxylation this thesis
paracetamol dehydrogenation this thesis
amodiaquine N-deethylation this thesis
dextromethorphan N-demethylation this thesis
alkoxyresoruﬁns O-dealkylation this thesis
3,4-methylenedioxy-
methylamphetamine
N-dealkylation
N-hydroxylation
O-demethylenation
this thesis
clozapine N-demethylation
N-oxidation
this thesis
diclofenac hydroxylation this thesis
Table 7: Non-natural substrates converted by mutants of P450 BM3.
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(pNCAs, indole). It is also important that the screening substrate is suitable to screen for the 
desired activity. For example, a screening substrate that resembles the natural substrate of 
the enzyme, such as pNCA for P450 BM3, is not suited to screen for mutants that are able to 
convert non-natural substrates. Screening assays that are based on the reaction between the 
desired product, or a reaction by-product, and an additional reagent have the advantage that 
they can be used for an entire class of substrates (e.g. detection of aromatic hydroxylation with 
4-aminoantipyrine or detection of formaldehyde formation using purpald). A disadvantage 
of such assays is that the reagent can often react with other medium components, resulting 
in false negative or false positive signals. Since it is often difﬁcult to develop an assay that 
enables screening for the desired properties, it can be useful to use a number of structurally 
different substrates in a tandem- or cocktail approach. Since no ﬂuorescent high-throughput 
assay currently exists for P450 BM3, part of the research described in this thesis was dedicated 
to the evaluation of novel, ﬂuorescent high-throughput screening substrates for P450 BM3 
that enabled screening for mutants that metabolise drug-like molecules.
GENERAL INTRODUCTION
Detection method Enzyme 
preparation
Substrate –> product Used for 
P450
Reference
colorimetric permeabilised 
cells / cell lysate
p-NCAs –> 
p-nitrophenolate
P450 BM3 [104, 121, 
123, 130]
colorimetric colony based indole –> indigo P450 BM3
P450 2A6
[73, 107, 
114, 115]
ﬂuorimetric permeabilised 
cells
alkoxyresoruﬁn -> 
resoruﬁn
P450 1A2 [113]
ﬂuorimetric permeabilised 
cells
alkoxycoumarin -> 
hydroxycoumarin
P450 2A6 
P450 2B1
[96]
[97]
ﬂuorimetric permeabilised 
cells
NADP+ formation P450 BM3 [131]
mutagenicity test colony based MeIQ ->
hydroxyMeIQ
P450 1A2 [95, 112]
colorimetric (2-step) cell lysate 4-aminoantipyrine 
(reagent for aromatic 
hydroxylation)
P450 BM3 [108]
colorimetric (2-step) cell lysate purpald (reagent for 
formaldehyde)
P450 BM3 [132]
ﬂuorimetric (2-step) colony based ﬂuorescent dimers of 
aromatic compounds
P450 cam [66, 129]
Table 8: Screening assays used in directed evolution of P450s.
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As explained in this introduction, P450s could make very valuable biocatalysts for the 
pharmaceutical industry. For the development of safe and effective drugs, it is important 
to investigate the toxicity and pharmacological activity of human metabolites of drugs. For 
example, for the antiestrogen tamoxifen it has been discovered several years after the drug 
had been introduced to the market, that two metabolites, 4-hydroxytamoxifen and endoxifen, 
both formed via P450 2D6, are mainly responsible for the therapeutic effect of the drug [133]. 
People that are deﬁcient in P450 2D6 therefore probably do not beneﬁt from the treatment. 
Also, reactive metabolites are sometimes formed by P450s that can form protein- or DNA 
adducts and result in adverse drug reactions, such as the activation of acetaminophen by 
P450 2E1, 1A2 and 3A4 to the electrophilic N-acetyl-p-benzoquinoneimine (NAPQI) [53].
Risk assessment studies and the pharmacological and toxicological characterisation of 
drug metabolites is often hampered by the fact that high amounts of pure compounds 
are required for such studies. It would therefore be very beneﬁcial for the area of drug 
development if high quantities of the drug metabolites could be formed by highly active 
drug metabolising enzymes. Another area where such enzymes could be applied is in 
drug discovery. A library of mutant enzymes with a broad regioselectivity could be used to 
produce many different metabolites with potential therapeutically interesting properties. It 
is known that biotransformation reactions by P450 enzymes can result in metabolites with 
a much higher pharmacological activity than the parent compound (Table 3), as described for 
tamoxifen in the previous paragraph. Another example is the antihistamine loratadine, that 
is metabolised into the 10-fold more potent desloratadine [134]. 
When the research described in this thesis started, P450s were enjoying attention for 
their potential use in biocatalysis. With the help of DNA mutagenesis techniques, it had 
become possible to generate enzymes customised for for example the biosynsthesis of 
pharmaceuticals. However, reports on successful application of mutagenesis to design P450s 
for biocatalysis were still very limited. Different opinions exist on which class of P450s is most 
promising for the biosynthesis of pharmaceuticals. Some focus mainly on mammalian P450s, 
with their ability to metabolise a wide variety of drugs [37, 135]. Mutagenesis techniques could 
be used to increase their low catalytic activity, which is the main bottleneck for industrial 
application of mammalian P450s. Others, however, feel that the bacterial P450s, that are 
soluble, stable, more easy to express and have a much higher catalytic activity, have better 
chances to be developed into useful biocatalysts [70]. Their main bottleneck, however, is their 
narrow substrate range [37], which could also be addressed using mutagenesis.
This research focuses on the use of mutagenesis techniques on P450 enzymes, with the 
ultimate goal to obtain mutants for use in the pharmaceutical industry. Two different lines 
of research will be explored in particular:
i The research on mammalian P450s is currently not as far advanced as is the case for 
bacterial P450s. P450 2D6 is one of the most important human P450s involved in drug 
metabolism, and in our laboratory, P450 2D6 has been an object of study for over 10 years [79, 
36
136-139]. At the beginning of the research described in this thesis, two new PhD projects had 
just been started with the aim to study P450 2D6 using computational and experimental 
techniques. To increase our understanding of P450 2D6, in this research project, we aimed to 
validate a novel P450 2D6 homology model that was built in our laboratory [139]. Mutagenesis 
techniques were used to elucidate the role of various active site residues that are predicted 
by the model to be involved in substrate binding. This can yield novel insights in the structure 
and mechanism of P450 2D6, and in the quality of the model.
ii Engineered P450 enzymes have great potential as biocatalysts in the pharmaceutical 
industry. Because of the intrinsic high activity of the bacterial P450 BM3 (Figure 9), and 
because it was already known that its narrow substrate speciﬁcity could be broadened 
using mutagenesis (Table 7), we set out to generate highly active drug metabolising enzymes 
using P450 BM3 as starting point. Such mutants would be very useful for drug discovery 
and synthesis, as described above. Additionally, since P450 BM3 shows high resemblance to 
mammalian P450s, it could function as a convenient model system for mammalian P450s. At 
the beginning of this project, drug metabolising mutants of P450 BM3 had not been described. 
A combination of structure-guided site-directed mutagenesis and random mutagenesis was 
used to develop mutants with a high activity towards drug substrates.
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When developing novel pharmaceutical compounds, it is crucial to involve P450s at an early 
stage in drug discovery and development. New chemical entities and drug candidates are 
usually screened for metabolism by P450s, sites of metabolism, and pharmacological and 
toxicological properties of these metabolites. With reliable computer models, it would be 
possible to perform part of this screening in silico. In part I of this thesis, a novel homology 
model of P450 2D6, based on the crystal structure of rabbit P450 2C5, that has been developed 
in our laboratory [78] is used to predict active site residues that are involved in substrate 
binding. Site-directed mutagenesis studies are used to experimentally elucidate the role of 
these active sites residues, F120 and F483, in substrate binding and catalysis (chapter 2 and 
chapter 3).
As described in this introduction, P450 BM3 is an enzyme with high potential for industrial 
use. Therefore, in part II of this thesis, attempts are made to develop P450 BM3 into a useful 
and efﬁcient biocatalyst for drug-like compounds. In chapter 4, novel screening substrates 
are evaluated that allow screening for mutants of P450 BM3 with afﬁnity for drug-like 
molecules. Additionally, site-directed mutagenesis is used to rationally design a drug 
metabolising mutant of P450 BM3. In chapter 5, this mutant is characterised with respect to 
drug metabolism and allosteric behaviour.
In chapter 6, the drug metabolising P450 BM3 mutant described in chapter 4 and chapter 
5 is subjected to several rounds random mutagenesis to obtain novel drug metabolising 
mutants with enhanced catalytic activities. To increase our understanding of the mechanism 
of P450 BM3, the role of the beneﬁcial mutations identiﬁed in chapter 6 is rationalised using a 
combination of experimental and computer modeling techniques in chapter 7. Subsequently, 
in chapter 8, the drug metabolising mutants discovered in chapter 6 are used to generate large 
amounts of reactive metabolites from drug molecules that are known to lead to adverse drug 
reactions in humans. The production of these metabolites in high quantities facilitates their 
isolation and identiﬁcation. Finally, in chapter 9, a summary of all the results described in 
this thesis is presented, followed by overall conclusions and perspectives for future research.
38
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Abstract
The polymorphic human debrisoquine hydroxylase, Cytochrome P450 2D6 (P450 2D6), is one 
of the most important phase I drug metabolising enzymes. It is responsible for metabolising 
a large number of compounds that mostly share similarity in having a basic N-atom and an 
aromatic moiety. In homology modeling studies it has been suggested that in ﬁxation of this 
aromatic moiety there may be an important role for phenylalanine 120 (F120). In this study 
the role of F120 in ligand binding and catalysis was experimentally examined by mutating 
it into an alanine. Strikingly, this substitution led to a completely abolished 7-methoxy-4-
(aminomethyl)-coumarin (MAMC) O-demethylating activity of P450 2D6. On the other hand, 
bufuralol metabolism was hardly affected (Km 1-hydroxylation mutant: 1.2 µM, wild-type: 2.9 
µM, 4-hydroxylation mutant: 1.5 µM, wild-type: 3.2 µM) and neither was dextromethorphan 
O-demethylation (Km mutant: 1.2 µM, wild-type: 2 µM, Vmax mutant: 4.5 min
-1, wild-type: 3.3 min-1). 
However, the F120A mutant also formed 3-hydroxymorphinan, the double demethylated 
form of dextromethorphan, which was not detected using wild-type P450 2D6. 3,4-methy-
lenedioxymethylamphetamine (MDMA) was demethylenated by both mutant and wild-type 
P450 2D6 to 3,4-dihydroxymethamphetamine (3,4-OH-MA, Km mutant: 55 µM, wild-type: 2 
µM). In addition the mutant formed two additional metabolites; 3,4-methylenedioxyam-
phetamine (MDA) and N-hydroxy-3,4-methylenedioxymethylamphetamine (N-OH-MDMA). 
Inhibition experiments of dextromethorphan O-demethylation showed a decreased afﬁnity 
of the F120A mutant for quinidine (IC50 mutant: 240 nM, wild-type: 40 nM), while IC50’s for 
quinine were equal (1 µM). These data indicate the importance of F120 in the selectivity and 
regiospeciﬁcity in substrate binding and catalysis by P450 2D6. 
Introduction
Cytochromes P450 (P450s) are heme containing enzymes capable of oxidizing and reducing 
a large variety of endogenous and exogenous substrates in virtually all living organisms [1, 
2]. In humans one of the most important hepatic phase I drug metabolising enzymes is P450 
2D6. It is involved in the metabolism of about 30% of the currently marketed drugs, including 
neuroleptics, antidepressants β-blockers, opioids and antiarrythmics [3, 4]. The enzyme is 
known for its genetic polymorphisms, even increasing its clinical relevance [5, 6]. Although 
some crystal structures of mammalian P450s have become available in recent years [7, 8], so 
far no crystal structure of P450 2D6 has been resolved. Structural information on this enzyme 
still depends on homology modeling and mutagenesis studies. 
Recently we have developed a new homology model of P450 2D6 based on the crystal 
structure of rabbit P450 2C5 [9]. This was the ﬁrst model of P450 2D6 based on a mammalian 
P450 template and is therefore considered an improvement over the existing models. This 
was indicated by the good correlation between experimental data and the modelled protein-
substrate interactions. The model identiﬁed some active site key residues. First of all E216 has 
been shown to be a key ligand binding residue involved in hydrogen bonding with a variety 
of substrates. This residue has been subjected to several mutagenesis studies [10, 11], that 
indicated involvement of this residue in ﬁxation of basic nitrogen atoms present in many 
P450 2D6 substrates. A second important active site residue in this and other homology 
models is F483 [12], interacting via van der Waals forces with substrates like codeine. Earlier 
mutagenesis of this residue to an isoleucine showed effects on testosterone metabolism 
[13]. However, the anchoring of aromatic moieties present in most P450 2D6 substrates, as 
predicted in pharmacophore models [14-16], cannot be completely ascribed to this residue. 
Therefore other phenylalanine residues contributing to aromatic interactions with substrates 
have to be present in the active site. Mutation of F481 to other non-aromatic residues led to 
decreased activities towards model substrates [17], although in the model of Venhorst et al. 
this residue is not considered to be in the active site of P450 2D6.
Even more interesting is the position of a third phenylalanine at position 120 in the active 
site of P450 2D6 homology models [9, 11, 12]. In these P450 2C5-based models F120 appears 
to be positioned directly above the porphyrin ring. From docking and molecular dynamics 
studies this residue seems to be the anchoring residue for the aromatic moiety of ligands 
like quinidine and sparteine via π-stacking [9]. In the present study the role of F120 in ligand 
binding and metabolism by P450 2D6 is studied experimentally by mutating this residue 
into an alanine. According to computational simulations this mutation will create not only 
ROLE OF PHENYLALANINE 120
53
C
H
A
PTER
2
54
ROLE OF PHENYLALANINE 120
more space in the active site, but also eliminates a potentially important aromatic anchoring 
point. By mutating F120 into an alanine we are aiming at the elucidation of the role of this 
residue in substrate binding and turnover by P450 2D6.
Materials and Methods
Materials
The pSP19T7LT_2D6 plasmid containing human P450 2D6 with a C- terminal His6-tag 
bicistronically co-expressed with human Cytochrome P450 NADPH reductase was kindly 
provided by Prof. Dr. Ingelman-Sundberg. 7-methoxy-4-(aminomethyl)-coumarin (MAMC), 
7-hydroxy-4-(aminomethyl)-coumarin (HAMC), 3,4-methylenedioxy-methyl-amphetamine 
(MDMA) and 3,4-methylenedioxyamphetamine (MDA) were synthesised as described [18, 19]. 
Bufuralol hydrochloride was obtained from Gentest. N-methylhydroxylamine hydrochloride, 
dextromethorphan hydrobromide and dextrorphan tartrate were obtained from Sigma. All 
other chemicals were of analytical grade and obtained from standard suppliers.
Synthesis of N-hydroxy-3,4-methylenedioxymethylamphetamine
N-hydroxy-3,4-methylenedioxymethylamphetamine (1-(3,4-methylenedioxyphenyl)-N-
methyl,2-hydroxylaminopropane) was prepared from piperonyl methyl ketone and N-
methylhydroxylamine by reductive amination with sodium cyanoborohydride [20]. A two-fold 
excess of N-methylhydroxylamine hydrochloride was stirred with piperonyl methyl ketone in 
methanol at room temperature and then sodium cyanoborohydride was added and stirred 
for additional 48 h. After adding water, neutralising the cyanoborohydride with 6 M HCl and 
neutralising the acid with 6 M NaOH, the product was extracted in dichloromethane.
1H NMR (400 Hz, CDCl3): δ 1.00 (d, 3H, CCH3), 2.38 (dd, 1H, H-1), 2.68 (s, 3H, NCH3), 2.91 (m, 1H,
CHN), 3.10 (dd, 1H, H-1), 5.90 (s, 2H, OCH2O), 6.63 (dd, 1H, H-6’), 6.70 (d, 1H, H-2’), 6.72 (d, 1H,
H-5’). 13C NMR (400 Hz, CDCl3): δ 14.20 (CH3), 38.82 (CH2), 43.95 (CH3N), 65.35 (CH), 72.82, 100.83
(OCH2O), 108.17 (C-5’), 109.70 (C-2’), 122.13 (C-6’), 133.29 (C-1’), 145.87 (C-4’), 147.59 (C-3’).
MS direct injection: m/z, M+˙ 210, MS/MS: 179 (3), 163 (100), 135 (3).
Site-directed mutagenesis
The phenylalanine 120 to alanine (F120A) mutation was introduced into pSP19T7LT_2D6 
using the QuickChange XL Site-Directed Mutagenesis kit (Stratagene). The sequences of the 
forward- and reverse oligonucleotides, respectively, with the mutated residue in bold italic, 
were as follows: 5’-CGT TCC CAA GGG GTG GCC CTG GCG CGC TAT-3’ and 5’-ATA GCG CGC CAG 
GGC CAC CCC TTG GGA ACG-3’. After mutagenesis, the presence of the desired F120A mutation 
was conﬁrmed by DNA sequencing.
Expression and membrane isolation
Both the P450 2D6[F120A] and the wild-type pSP19T7LT_2D6 plasmids were transformed into 
Escherichia coli strain JM109. Expression was carried out in 3L ﬂasks containing 300 ml TB 
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(Terriﬁc Broth) medium with additives (1 mM δ-aminolevulinic acid, 400 µl/L trace elements 
[21], 1 µg/ml thiamine, 100 µg/ml ampicillin). Cultures were inoculated with 3 ml frozen E. coli 
cells containing the desired plasmid, and induction was initiated by the addition of 2 mM 
isopropyl β-D-thiogalactoside. Cultures were grown for 48 h at 28 °C and 125 rpm, before they 
were harvested. P450 contents were determined by CO difference spectra [22]. 
Harvested cells were pelleted by centrifugation (15 min, 4000 g, 4 °C) and the resulting pellet 
was resuspended in TSE buffer (50 mM Tris-acetate pH 7.6, 250 mM sucrose, 0.25 mM EDTA), 
35 mg wet weight cells/ml. Spheroblasts were prepared by adding 0.1 mg/ml lysozyme and 
gently shaking the cells for 30 min on ice. Spheroblasts were pelleted by centrifugation (15 
min, 4000 g, 4 °C), and resuspended in KPi-glycerol buffer (100 mM potassium phosphate 
buffer, pH 7.4, 20% glycerol, 0.1 mM DTT), 0.5 g/ml. The spheroblasts were lysed by passage 
through a French press followed by sonication (Branson Soniﬁer 250, 10 x 20 sec, 70% full 
power), and the membrane fraction was isolated by ultracentrifugation (45 min, 120,000 g, 4 
°C). Membranes were resuspended in 0.4% of the original culture volume of TSE buffer and 
P450 contents were determined with CO difference spectra.
Metabolism and inhibition assays
MAMC O-demethylation [23]: Reactions were carried out in duplicate in a 96 wells plate, in 
a total volume of 200 µl. The reaction mixture consisted of 50 mM potassium phosphate 
buffer (KPi) pH 7.4, 5 mM MgCl2, 0-500 µM MAMC (10 concentrations) and E. coli membranes 
(40 nM wild-type 2D6 or 2D6[F120A]). The reactions were initiated by addition of an NADPH 
regenerating system, resulting in ﬁnal concentrations of 0.1 mM NADPH, 0.3 mM glucose-
6-phosphate, and 0.4 units/ml glucose-6-phosphate dehydrogenase. The reaction was 
monitored for 40 minutes at 37 °C on a Victor2 1420 multilabel counter (Wallac) (λex= 405 
nm, λem= 460 nm). The metabolite of MAMC, i.e. HAMC, was identiﬁed and quantiﬁed using 
the synthetic reference compound. HPLC analysis of MAMC metabolism was performed as 
described [18], using a C18 column (Chrompack Chromspher 5, 250 x 4.6 mm) with a ﬂow rate 
of 0.4 ml/minute.
Dextromethorphan O-demethylation [10]: Reactions were carried out in 300 µl 50 mM KPi pH 
7.4, 5 mM MgCl2, 0-40 µM dextromethorphan (10 concentrations) and E. coli membranes (50 
nM wild-type 2D6 or 25 nM 2D6[F120A]). After 5 min of pre-incubation at 37 °C, the reactions 
were initiated with an NADPH regenerating system as described above. The reaction was 
allowed to proceed for 5 minutes before it was stopped by the addition of 15 µl 70% HClO4. 
After centrifugation (10 min, 6800 g), 30 µl aliquots of the supernatant were analysed by 
HPLC. Metabolites were separated using a C18 column (Chrompack Chromspher 5, 250 x 4.6 
mm) with a ﬂow rate of 1 ml/minute. The mobile phase consisted of 30% acetonitril and 
1% triethylamine, set to pH 3 with 70% HClO4. Metabolites were detected by ﬂuorescence 
(λex= 280 nm, λem= 311 nm) and identiﬁed by LC-MS. Inhibition of O-demethylation by various 
concentrations of quinidine and quinine was measured under the same conditions using a 
concentration of 8 µM dextromethorphan.
Bufuralol hydroxylation [10, 24]: Reactions were carried out as described above with 0-100 
µM bufuralol (9 concentrations) and E. coli membranes (50 nM wild-type 2D6 or 25 nM 
2D6[F120A]). Metabolites were separated using a C18 column (Chrompack Chromspher 5, 250 x 
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4.6 mm) with a ﬂow rate of 0.6 ml/minute. The mobile phase consisted of 30% acetonitril and 
0.1% triethylamine, set to pH 3 with 70% HClO4. Metabolites were detected by ﬂuorescence 
(λex= 252 nm, λem= 302 nm). Metabolites of bufuralol were identiﬁed by comparison with other 
studies [24].
MDMA metabolism: Reactions were carried out as described above with 0-200 µM MDMA (9 
concentrations) and E. coli membranes (50 nM wild-type 2D6 or 25 nM 2D6[F120A]). Metabolites 
were separated using a C18 column (Phenomenex Inertsil ODS 150 x 4.6 mm) with a ﬂow rate 
of 0.4 ml/minute. The mobile phase consisted of 23% acetonitril and 0.1% triethylamine, set 
to pH 3 with 70% HClO4. Metabolites were detected by ﬂuorescence (λex= 280 nm, λem= 320 
nm) and identiﬁed electrochemically (ECD, oxidation mode 0.8 V, for detection of 3,4-OH-
MA), by LC-MS (3,4-OH-MA, MDA, N-OH-MDMA) and using synthesised reference compounds 
(MDA, N-OH-MDMA). 
Peak areas of all metabolites were quantiﬁed by Shimadzu Class VP 4.3 and analysed using 
GraphPad Prism 4.0.
LC-MS
To identify the metabolites of MDMA, dextromethorphan and dextrorphan, incubations were 
carried out for 10 min as described above with 100 µM MDMA, 100 µM dextrorphan or 25 µM 
dextromethorphan and E. coli membranes (50 nM wild-type 2D6 or 2D6[F120A]). Volumes of 
100 µl supernatant were injected and separated using a phenyl column (Waters Novapak 
Phenyl 150 x 4.6 mm) with a ﬂow rate of 0.4 ml/minute. The metabolites were eluted using 
a gradient starting with a 1% acetonitril eluens, supplemented with 10 mM ammonium 
acetate, increasing linearly to 95% acetonitril with 10 mM ammoniumacetate in 30 minutes 
and analysed by MS. APCI positive ionisation was used on a LCQ Deca mass spectrometer 
(Thermo Finnigan), vaporizer temperature 450 ˚C, N2 as sheath (40 psi) and auxiliary gas (10 
psi), needle voltage 6000 V, heated capillary 150 ˚C.
Homology Modeling
A protein homology model of P450 2D6 was constructed based on the crystal structures 
of dimethylsulphophenazole and diclofenac bound rabbit P450 2C5, PDB codes 1N6B and 
1NR6 respectively [7, 25]. Homology modeling, model reﬁnement and model validation was 
performed as described [9]. The ﬁnal model of wild-type P450 2D6 was used as a template for 
modeling of the F120A mutant. The F120 residue was mutated to alanine using the homology 
module of InsightII (Biosym), after which an energy minimisation and a one picosecond 
position restrained molecular dynamics simulation was carried out. 
Results
Expression of wild-type P450 2D6 and P450 2D6[F120A]
P450 2D6[F120A] had consistently signiﬁcantly lower expression levels compared to wild-
type P450 2D6. An average culture contained about 70 nM of P450 for the mutant versus 200 
nM for wild-type after 48 hours induction. In the difference spectrum taken from the culture 
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of the mutant enzyme a high absorbance was measured at 420 nm, showing the presence of 
large amounts of P420, the inactive form of P450, indicating that the mutation decreases the 
stability of the enzyme to some extent.
Metabolism of model compounds
O-demethylation of the P450 2D6 marker substrate MAMC (Figure 1) showed to be linear for 
over 40 minutes using E. coli membranes containing 40 nM of wild-type P450 2D6. Enzyme 
kinetics analysis revealed a Km of 49 µM and a Vmax of 3.7 min
-1 (Table 1). Using P450 2D6[F120A] 
under the same conditions did not lead to detectable HAMC formation. HPLC analysis of these 
incubations gave the same results and did not show any additional metabolites.
Dextromethorphan was selectively O-demethylated to dextrorphan by wild-type P450 2D6 
(Km 2 µM, Vmax 3.3 min
-1). P450 2D6[F120A] also formed dextrorphan, be it with a slightly lower 
Km and higher Vmax than the wild-type. The formation of dextrorphan showed to be linear for 
at least 20 minutes, indicating the mutant to be stable enough for studying the metabolism. 
Dextrorphan and other metabolites were identiﬁed by LC-MS. The N-demethylated metabolite 
of dextromethorphan, i.e. 3-methoxymorphinan (m/z 258, MS/MS: m/z 215), was detected for 
both the wild-type and the F120A mutant with a tr of 36 min. Because of overlap with the peak 
of dextromethorphan (m/z 272, MS/MS: m/z 215) at tr= 37 minutes, N-demethylation could 
Figure 1: Structures of the substrates (A: MAMC, B: MDMA, C: bufuralol, D: dextromethorphan) and 
ligands (E: quinidine (8R, 9S) and quinine (8S, 9R)) used, showing sites of oxidation by wild-type P450 2D6 
(arrows) and chiral carbon atoms (*).
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not be quantiﬁed. Interestingly, also a metabolite with m/z 244 (tr= 31.1 minutes, MS/MS: 
m/z 147) was detected for the F120A mutant, apparently the double O- and N-demethylated 
metabolite of dextromethorphan, i.e. 3-hydroxymorphinan. 
The 3-hydroxymorphinan formation could also not be quantiﬁed under the conditions 
used because it is a secondary metabolite. When the F120A mutant was incubated with 
dextrorphan, again 3-hydroxymorphinan was formed and two other metabolites with m/z 
274 were detected (tr= 27.5 minutes, MS/MS: m/z 199 and tr= 30.3 minutes MS/MS: m/z 257 and 
201), indicating hydroxylation of dextrorphan. With the wild-type P450 2D6 no metabolites 
of dextrorphan were detected.
Upon incubation of bufuralol both with wild-type P450 2D6 and P450 2D6[F120A] four 
metabolites were detected; 6-OH bufuralol, 1’-OH bufuralol, 4-OH bufuralol and ∆1’,2’ 
bufuralol, as identiﬁed before by others [24]. Under the conditions used only peak areas 
of the metabolites 1’-OH bufuralol and 4-OH bufuralol could be quantiﬁed. For both these 
metabolites the F120A mutant showed a two times lower Km than wild-type P450 2D6 with a 
comparable turnover (Table 1).
Another known P450 2D6 substrate that was subjected to incubations with wild-type and 
the F120A mutant was MDMA [26]. In the case of wild-type P450 2D6 only demethylenation 
of MDMA to the catechol 3,4-dihydroxymethylamphetamine (3,4-OH-MA) was observed 
with a Km of 2 µM and a Vmax of 3.4 x 10
5 ﬂuorescence units/min/nmol/P450. This metabolite 
was identiﬁed by ECD, LC-MS (measured as the quinone, tr= 21.2 minutes, m/z 180) and it 
was described before by others [26]. The mutant enzyme also formed this catechol with a 
similar Vmax, but with a 30-fold higher Km. In addition to demethylenenation, MDMA was 
Table 1: Metabolism of model compounds by wild-type P450 2D6 and P450 2D6[F120A].
P450 2D6 P450 2D6[F120A]
Substrate Metabolites Km Vmax Km Vmax
MAMC HAMC 49 ± 2 3.7 ± 0.6 a - b - b
dextromethorphan dextrorphan
3-OH-morphinan
2.0 ± 0.2
- b
3.3 ± 0.4 a
- b
1.2 ± 0.4
+ c
4.5 ± 0.3 a
+ c
dextrorphan 3-OH-morphinan - b - b + c + c
bufuralol 1’-OH
4-OH
2.9 ± 0.4
3.2 ± 0.5
54 ± 17 d
2.7 ± 0.8 d
1.2 ± 0.2
1.5 ± 0.3
51 ± 11 d
2.7 ± 0.6 d
MDMA 3,4-OH-MA
MDA
N-OH-MDMA
1.9 ± 0.7
- b
- b
3.4 ± 1.0 d
- b
- b
55.4 ± 16
9.0 ± 2.5
11.0 ± 2.8
4.6 ± 1.1 d
6.0 ± 3.3 d
10.9 ± 3.8 d
All values are the means of at least three independent experiments ± S.D. Km expressed in µM, 
a Vmax 
expressed in min-1, b not detectable, c present but not quantiﬁable, d Vmax expressed in 1 x 10
5 ﬂuorescence 
units/min/nmol P450.
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also N-demethylated to MDA by the mutant enzyme, with a Km of 9 µM and a Vmax of 6 x 10
5 
ﬂuorescence units/min/nmol/P450, as identiﬁed by LC-MS (tr= 21.4 minutes, m/z 180) and co-
elution with the synthetic reference (Figure 2). Furthermore, a third metabolite was formed by 
the F120A mutant with a Km of 11 µM, and a Vmax of 11 x 10
5 ﬂuorescence units/min/nmol/P450. 
This metabolite was also identiﬁed by LC-MS. A m/z of 210 was observed for this metabolite 
(tr= 21.9 minutes), indicating hydroxylation of MDMA (m/z 194). MS/MS data showed a mass 
over charge of 163, suggesting that hydroxylation took place on the nitrogen, as the m/z of 
163 is the propyl-methylenedioxyphenyl fragment, which is also a common fragment of both 
MDA and MDMA. In order to conﬁrm the identity of this new metabolite of MDMA, N-OH-
MDMA was synthesised and showed identical mass spectroscopic behaviour. Direct injection 
of this compound in the MS gave a m/z 210, with as the major MS/MS fragment m/z 163. In 
addition, the N-OH-MDMA also co-eluted with the new metabolite on both the C18 as the 
phenyl reversed phase columns, when spiked in an incubation sample, verifying it to have 
the same molecular structure.
Figure 2: Chromatograms of 100 µM MDMA incubations with membranes of E. coli cells expressing wild-
type P450 2D6 (1) and P450 2D6[F120A] (2) in the presence (grey) and absence (black) of 20 µM quinidine (A). 
Metabolites are indicated by arrows and reference chromatograms of synthesised MDA (3) and synthesised 
N-OH-MDMA (4) are also shown. (B): Scheme of MDMA metabolism by wild-type P450 2D6 and P450 
2D6[F120A] into 3,4-OH-MA (a), MDA (b), and N-OH-MDMA (c).
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Inhibition of dextromethorphan metabolism
Inhibition of dextromethorphan O-demethylation by quinidine and quinine was determined 
for both wild-type P450 2D6 and P450 2D6[F120A] (Figure 3). In case of both the enzymes 
quinine inhibited dextrorphan formation with an IC50 of about 1 µM (Table 2), whereas 
quinidine was about six-fold less potent in inhibiting the F120A mutant (IC50 240 nM) than 
the wild-type enzyme (IC50 40 nM). 
Modeling
In a reﬁned homology model of P450 2D6 used in this study, F120, E216 and F483 are positioned 
at approximately the same location as in the previously reported homology model [9]. D301 
however, does not point into the active site, but is oriented such that it stabilises the B/C-
Figure 3: Inhibition of dextromethorphan metabolism by quinine (A) and quinidine (B).  Data are presented 
for the F120A mutant (triangles) and wild-type P450 2D6 (squares). Plotted values are the means of at least 
two independent experiments.
Ligand P450 2D6 
IC50 (µM)
P450 2D6[F120A]
IC50 (µM)
quinidine 0.04 ± 0.01 0.24 ± 0.04
quinine 0.76 ± 0.17 1.3 ± 0.27
Table 2: IC50 values of the ligands quinine and quinidine for P450 2D6 and P450 2D6[F120A]. 8 µM 
dextromethorphan was used as substrate. All values are the means of at least two independent 
experiments.
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loop by hydrogen bonding to the backbone N-atoms of residues V199 and F120. D301 however 
may also play an electrostatic role in the binding of basic substrates by increasing the net 
negative charge within the active site [12]. Furthermore, the constructed homology model 
used in this study has a more ‘closed’ binding pocket as a result of the fact that the substrate-
free P450 2C5 crystal structure template used for the old homology model is lacking the F/G-
loop (unpublished data).
Discussion
Recently computer homology modeling studies suggested F120 to be a P450 2D6 active site 
residue involved in the binding of substrates via aromatic interactions [9, 11, 12]. The primary 
aim of this study was to evaluate the role of this residue in the P450 2D6 active site. The 
results presented in this study show that F120 is very relevant in P450 2D6 ligand binding, 
substrate selectivity and regiospeciﬁcity in catalysis. 
The expression levels of the F120A mutant in E. coli were found to be lower than the wild-type 
enzyme, indicating that F120 may have a role in the stability of the enzyme. High levels of P420 
were seen in the difference spectra, showing that the expression itself was not hampered, 
but that a large amount of enzyme formed was not functional as was reported before for 
several other P450 2D6 mutants [10, 27]. 
Four typical P450 2D6 substrates were selected to characterise the F120A mutant. Compared 
to wild-type P450 2D6 large substrate-dependent differences in metabolism were found 
after introducing a single mutation, not reported before for other P450 2D6 mutants. MAMC 
was not metabolised by the F120A mutant while bufuralol metabolism by the F120A mutant 
was similar to the metabolism by the wild-type enzyme. For both dextromethorphan and 
MDMA there were changes in regiospeciﬁcity after mutating F120 into an alanine. So despite 
the fact that all four substrates show structural similarity in having a basic N-atom at about 
7 Å of the site of oxidation and in having an adjacent aromatic moiety [14], still the inﬂuence 
of the mutation differed between these substrates. The only time large substrate dependent 
differences were described for a P450 2D6 mutant was with a E216Q mutant, using the 
substrate spirosulfonamide [11] that lacks a basic N-atom and therefore does not ﬁt into the 
classical pharmacophore model [14-16].
 
Neither HAMC nor other metabolites were detected after incubating MAMC with the F120A 
mutant so apparently F120 inﬂuences either the afﬁnity, or the orientation of this substrate 
with respect to the heme. More experiments with other coumarin derivatives could give 
more information about the underlying mechanisms [28].
Bufuralol metabolism by P450 2D6 was studied previously using a series of D301 mutants 
[24] and also mutants of E216 to non-acidic residues were studied using this model substrate 
[10, 11]. Large effects were found on afﬁnity and turnover of the mutants for this compound, 
showing that these acidic residues are more important for bufuralol metabolism than F120 as 
can be concluded from this study. The role of D301 was postulated also to be ﬁxation of the B-C 
loop containing residue F120 [10-12] however the present results do not seem to support this 
role as the F120A mutation hardly shows an effect on bufuralol metabolism. Consequently, 
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the role of D301 does not seem to be merely the ﬁxation of F120 into the active site [29], but 
creation of the net negative charge together with E216 may be of bigger importance. 
N-dealkylation of substrates is a possible route in P450 2D6 metabolism and F481 was 
predicted previously to be an important binding residue for these substrates [15]. However 
mutating the F481 residue into a glycine did not have a large inﬂuence on N-deisopropylation 
of metoprolol [17]. Both MDMA and dextrorphan were N-demethylated by the F120A mutant 
implicating a more promiscuous way of orientation of these two substrates in the active 
site of P450 2D6 and the involvement of the F120 residue in binding substrates undergoing 
N-dealkylation. 
Besides N-dealkylation of MDMA, also N-hydroxylation occurred when MDMA was incubated 
with the F120A mutant. N-OH-MDMA has been described before as an MDMA metabolite in 
horse urine [30], however from this study it remained unclear what enzymes were playing 
a role in this reaction. Furthermore aliphatic N-hydroxylation has not been described before 
as a metabolic reaction catalysed by P450 2D6 wild-type or mutants for any substrate. The 
co-occurrence of both N-dealkylation and N-hydroxylation of a single substrate has been 
reported once before for N-methylbenzamidine by rabbit P450 2C3 [31]. Additional work 
should give more insights in the mechanism of these transformations by P450 2D6[F120A]. 
The role of F120 in the active site of P450 2D6 seems to be at least two-fold; ﬁrstly, the 
phenyl ring ﬁlls the active site cavity causing a reduction of its size and secondly, it may 
have a function as an aromatic interaction site. The metabolite 3-hydroxymorphinan is 
Figure 4: Binding orientation of dextromethorphan automatically docked in the active site of the homology 
models of P450 2D6 using Autodock with standard conditions [32]. In wild-type P450 2D6 the orientation of 
dextromethorphan (in light grey) with its O-methyl pointing towards the heme is favoured (A), in the F120A 
mutant two distinct orientations, supporting both N-demethylation (in dark grey) as O-demethylation (in 
light grey) were found (B).
a b
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detected exclusively in dextromethorphan incubations with the F120A mutant. In Figure 4 it 
is demonstrated how the mutation of the bulky phenylalanine into a smaller alanine residue 
allows the dextromethorphan N-demethylation binding mode to be accommodated more 
easily by creating more space in the P450 2D6 active site. As indicated earlier, F120 is considered 
important for interacting with quinidine via π-stacking [9]. The six-fold increase in IC50-value 
as determined for the F120A mutant validates the speciﬁc anchoring role of this residue. This 
role was conﬁrmed by the inability of the F120A mutant to metabolise MAMC. The two roles, 
i.e. space ﬁlling and aromatic anchoring, however, only partly explain the substrate speciﬁc 
inﬂuence, as bufuralol, MDMA and MAMC are structurally similar substrates but showed 
different changes in metabolism when incubated with the F120A mutant.
In the rat isoforms of the P450 2D family, no homologous aromatic residues are present in the 
B-C loop so F120 is a human P450 2D6 active site speciﬁc residue [9]. The data presented here 
introduce F120 as the fourth important residue in the binding of ligands to and catalysis by 
P450 2D6, next to E216, D301 and F483. The effects of removing the F120 phenyl-moiety are on 
the afﬁnity, turnover and orientation of substrates, but the effects were quite different for 
structurally similar substrates. To rationalise the large differences found with the four chosen 
substrates advanced molecular modeling is needed. Combined with molecular dynamics it 
can give insights where space is a limiting factor or where speciﬁc interactions play a role in 
the P450 2D6 active site.
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Abstract
The polymorphic Cytochrome P450 2D6 (P450 2D6) is involved in the metabolism of 30% of 
the drugs currently prescribed, and is thus clinically relevant. Typical P450 2D6 substrates 
generally contain a basic nitrogen atom and an aromatic moiety adjacent to the site of 
metabolism. Recently, we demonstrated the importance of active site residue F120 in 
substrate binding and catalysis in P450 2D6. On the basis of protein homology models, it 
is claimed that another active site phenylalanine, F483, may play an important role in 
the interaction with the aromatic moiety of P450 2D6 substrates. Experimental data to 
support this hypothesis, however, is not yet available. In fact, in the only study performed, 
mutation of F483 to isoleucine or tryptophan did not affect the 1’-hydroxylation of bufuralol 
at all [1]. In the present study, the role of F483 in ligand binding and metabolism by P450 
2D6 was examined experimentally using site-directed mutagenesis. Replacement of F483 
by alanine resulted in a 30-fold lower Vmax for bufuralol 1’-hydroxylation, while the Km was 
hardly affected. The Vmax for 3,4-methylenedioxy-methylamphetamine O-demethylenation 
on the other hand decreased only two-fold, whereas the effect on the Km was much larger. For 
dextromethorphan, in addition to dextrorphan (O-demethylation) and 3-methoxymorphinan 
(N-demethylation), two other metabolites were formed that could not be detected for the 
wild-type. The substrate 7-methoxy-4-(aminomethyl)-coumarin was not metabolised at all by 
P450 2D6[F483A], a phenomenon that was reported also for P450 2D6[F120A]. The presented 
data show that next to F120, residue F483 plays a very important role in the metabolism of 
typical P450 2D6 substrates. The inﬂuence of F483 on metabolism was found to be strongly 
substrate dependent.
Introduction
The Cytochrome P450 superfamily constitutes a large group of oxido-reductases that are 
responsible for the oxidation and reduction of many endogenous compounds as well as a 
wide variety of xenobiotics [2-4]. In humans, cytochrome P450 2D6 (P450 2D6) is one of the 
most important enzymes of this family [5]. Despite its low abundance –P450 2D6 represents 
only 4-8% of the total cytochrome P450 in human liver – it metabolises ~30% of the drugs 
currently on the market [6, 7]. Its clinical relevance is even increased by the fact that P450 2D6 
is highly polymorphic; 6% of the European population is classiﬁed as a ‘poor metaboliser’, 
while another 3% has the ‘ultrarapid metaboliser’ phenotype [7-10], thus contributing to 
large interindividual differences in drug metabolism. 
The development of accurate models of the active site of P450 2D6 is very useful to identify 
potential drug candidates that interact with the enzyme. Because no crystal structure is 
yet available for P450 2D6, the structural information required for such models has to be 
obtained from homology modeling [11, 12] and experimental mutagenesis studies.
Most substrates of P450 2D6 contain a basic nitrogen at a distance of approximately 5 - 7 Å from 
the site of oxidation, and an adjacent aromatic moiety [13]. The negatively charged active site 
residues E216 and D301 have been shown to play a role in ﬁxation of the basic nitrogen atom 
[14-16]. Pharmacophore and homology models suggest a role for aromatic residues in the 
active site to undergo VanderWaals interactions with aromatic moieties of the ligands [17]. 
Three aromatic phenylalanine residues have been proposed as active-site residues, F120, F481 
and F483. Recently, it was experimentally underlined that F120 is indeed one of the aromatic 
active site residues that plays an important role in substrate binding and metabolism [18, 19]. 
In earlier P450 2D6 homology models based on bacterial cytochrome P450 crystal structure 
templates it was suggested that another aromatic residue associated with ligand binding is 
F481 [17, 20, 21]. Substitution of F481 by non-aromatic residues reduced the afﬁnity of several 
typical P450 2D6 substrates [17]. In more recent homology models based on rabbit P450 2C5, 
however, F481 is positioned outside the binding pocket, but in close contact with active site 
residue F483 [1, 15, 22, 23].
Our model (Figure 1) [22] and several others [1, 15, 23, 24] suggest that this aromatic active 
site residue, i.e. F483, is also a potential ligand-contact residue. In a modeling study by Kemp 
et al. phenylalanines 120 and 483 are referred to as very important residues in the active 
site of P450 2D6, which are involved in the binding of various NCI compounds [24]. However, 
experimental data supporting a role for F483 in binding known P450 2D6 substrates is 
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not yet available. In fact, in the only experimental study on this residue, it was shown that 
substitution of F483 by isoleucine or tryptophan did not affect the 1’-hydroxylation of the 
typical P450 2D6 substrate bufuralol [1]. Interestingly, the F483I mutant was able to catalyse 
the 15α-hydroxylation of testosterone, which is not a substrate for wild-type P450 2D6 [23]. 
Therefore, it is not yet clear whether this residue plays a role in the binding of typical P450 
2D6 substrates. Recently, we demonstrated that the role of another active-site phenylalanine-
residue, F120, is very substrate dependent [18, 19]. The F120A mutant completely lost the ability 
to metabolise 7-methoxy-4-(aminomethyl)-coumarin (MAMC), while no signiﬁcant effect on 
bufuralol metabolism was observed. 3,4-Methylenedioxymethylamphetamine (MDMA) and 
dextromethorphan were still metabolised by F120A, but the regiospeciﬁcity of metabolism 
had changed signiﬁcantly.
The goal of the present study is to investigate whether the role of phenylalanine F483 in 
the metabolism of typical P450 2D6 substrates is substrate dependent. Using site-directed 
mutagenesis, this phenylalanine residue was substituted by an alanine (F483A), and the 
effect of this mutation on the binding and metabolism of four typical P450 2D6 substrates, 
dextromethorphan, bufuralol, MDMA and MAMC (Figure 2), was studied.
Materials and Methods
Materials
7-methoxy-4-(aminomethyl)-coumarin (MAMC), 7-hydroxy-4-(aminomethyl)-coumarin (HAMC),
3,4-methylenedioxymethylamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA)
were synthesised as described [25, 26]. Bufuralol hydrochloride was obtained from Gentest. N-
Figure 1: The active site of the homology model of P450 2D6 [18], showing the active site residues F120, E216, 
D301 and F483. The ball at the bottom represents the heme iron atom. The substrate dextromethorphan is 
represented in the active site.
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methylhydroxylamine hydrochloride, dextromethorphan hydrobromide and dextrorphan 
tartrate were obtained from Sigma. All other chemicals were of analytical grade and obtained 
from standard suppliers.
Plasmid and site-directed mutagenesis
The pSP19T7LT_2D6 plasmid containing human P450 2D6 with a C-terminal His6-tag 
bicistronically co-expressed with human Cytochrome P450 NADPH reductase (CPR) was 
constructed as follows: the CPR was generated by reverse transcription of human genomic 
DNA using a reverse transcription kit with oligo dT primers (Clontech Inc., USA). After reverse 
transcription, the cDNA was ampliﬁed with primers creating restriction enzyme cut sites. 
Human P450 2D6 was ampliﬁed from a cDNA. During ampliﬁcation additional C-terminal 
histidines as well as sites for restriction enzyme cleavage were introduced. The ampliﬁed 
and digested P450 2D6 and CPR were subsequently ligated into the expression plasmids 
pSP19T7LT [27] in tandem, with a short linker region in between the two genes. The correct 
gene sequence was veriﬁed by sequencing.
The phenylalanine 483 to alanine (F483A) mutation was introduced into pSP19T7LT_2D6 
using the QuikChange XL Site-Directed Mutagenesis kit (Stratagene). The sequences of the 
forward- and reverse oligonucleotides, respectively, with the altered nucleotides in bold 
italic, were as follows: 5’-AT-GGT-GTC-TTT-GCT-GCC-CTG-GTG-AGC-CC-3’ and 5’-GG-GCT-CAC-
CAG-GGC-AGC-AAA-GAC-ACC-AT-3’. After mutagenesis, the presence of the desired F483A 
mutation was conﬁrmed by DNA sequencing.
Figure  2: Structures of four typical P450 2D6 substrates.
A: bufuralol, B: MDMA, C: MAMC, D: dextromethorphan.
Sites of oxidation by wild-type P450 2D6 are indicated by arrows.
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Expression and membrane isolation
The plasmids pSP19T7LT_2D6 and pSP19T7LT_2D6[F483A] were transformed into Escherichia 
coli strain JM109. Expression was carried out in 3L ﬂasks containing 300 ml TB (Terriﬁc Broth) 
medium with additives (1 mM δ-aminolevulinic acid, 400 µl/L trace elements [28], 1 µg/
ml thiamine, 100 µg/ml ampicillin). Cultures were inoculated with 3 ml frozen E. coli cells 
containing the desired plasmid, and expression of P450 2D6 and CPR was initiated by the 
addition of 2 mM IPTG. Cultures were grown for 48 h at 28 °C and 125 rpm, before they were 
harvested. P450 contents were determined by CO difference spectra [29]. 
Harvested cells were pelleted by centrifugation (15 minutes, 4000 g, 4 °C) and the resulting 
pellet was resuspended in 15 ml TSE buffer (50 mM Tris-acetate pH 7.6, 250 mM sucrose, 0.25 
mM EDTA, 0.1 mM DTT). After the addition of 0.1 mg/ml lysozyme, the cells were disrupted 
using a French Press (1000 psi, 3 repeats). To remove remaining undisrupted cells, the lysate 
was centrifuged (15 minutes, 4000 g, 4 °C) and the resulting pellet was discarded. The 
cytosolic fraction was separated from the membranous fraction by ultracentrifugation in a 
Beckmann 50.2Ti rotor (45 minutes, 120,000 g, 4 °C). The membrane pellet was resuspended 
in 4 ml of TSE buffer and P450 contents were determined using CO difference spectra. CPR 
activity was measured using cytocrome c reduction as described previously [30, 31]. The CPR 
concentrations were calculated from the CPR activities based on a speciﬁc activity of 3200 
nmol cytochrome c/min/nmol reductase, as described previously [30, 31].
For determination of dissociation constants of ligands, the P450 was puriﬁed from the 
membranes. Enzymes were solubilised by stirring for 2 h at 4°C in KPi-glycerol buffer (50 mM 
potassium phosphate buffer pH 7.4, 10% glycerol, 0.25 mM EDTA, 0.1 mM DTT), supplemented 
with 0.5% Emulgen 911. Insoluble parts were removed by centrifugation (60 minutes, 120,000 
g, 4 °C). Supernatant was incubated, gently rocking, with Ni-NTA agarose for 30 minutes at 4 
°C. The column material was retained in a polypropylene tube with porous disc (Pierce), and 
washed with KPi-glycerol buffer containing 2 mM histidine. P450 2D6 was eluted with 0.2 M 
histidine. After overnight dialysis in KPi-glycerol buffer the sample was concentrated on a 
Vivaspin 20 ﬁltration tube (10.000 MWCO PES, Sartorius).
Metabolism of model compounds
Before the enzyme kinetic parameters of the four substrates were determined, a series 
of experiments was performed to determine the linearity of the reactions with time and 
enzyme concentration. Based on these experiments (data not shown), incubation times and 
enzyme concentrations were chosen that are within the linear range.
To determine MAMC metabolism [25, 32], reactions were carried out in triplicate in a black 
Costar 96 wells plate, in a total volume of 200 µl. The reaction mixture consisted of 100 
mM potassium phosphate buffer (KPi) pH 7.4 with 5 mM MgCl2 and 2 mM EDTA, and E. coli 
membranes containing 40 nM P450 2D6 (wild-type or P450 2D6[F483A]), and CPR. Nine 
different concentrations of MAMC were used ranging from 0 to 320 µM. The reaction was 
initiated by addition of an NADPH regenerating system, resulting in ﬁnal concentrations 
of 0.1 mM NADPH, 0.3 mM glucose-6-phosphate, and 0.4 units/ml glucose-6-phosphate 
dehydrogenase. The reaction was monitored for 30 minutes at 37 °C on a Victor2 1420 
multilabel counter (Wallac) (λex= 405 nm, λem= 460 nm). The metabolite of MAMC, i.e. HAMC, 
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was identiﬁed and quantiﬁed using the synthetic reference compound. Samples were also 
analysed on HPLC as described previously [25] to determine if other metabolites were formed 
that could not be detected on the ﬂuorescence microplate reader.
For dextromethorphan metabolism [16], the reaction mixture was composed as described for 
MAMC, with E. coli membranes containing 25 nM P450 2D6 (wild-type or P450 2D6[F483A]) 
and CPR. Ten different concentrations of dextromethorphan were used ranging from 0 to 80 
µM.  After 5 minutes of preincubation at 37 °C, the reaction was initiated by addition of an 
NADPH regenerating system as described above. The reaction was allowed to take place for 10 
minutes at 37 °C before it was stopped with 1/20 volume of 70% HClO4. Precipitated proteins 
were removed by centrifugation (10 minutes, 6800 g), and the supernatant was analysed by 
HPLC (injection volume 25 µl). Metabolites were separated using a C18 column (Phenomenex 
Luna 5µ, 150 x 4.6 mm) with a ﬂow rate of 0.6 ml/minute. The mobile phase consisted of 
30% acetonitril and 0.1% triethylamine, set to pH 3 with HClO4. Metabolites were detected by 
ﬂuorescence (λex= 280 nm, λem= 311 nm). The metabolite dextrorphan was identiﬁed using co-
elution with the reference compound; other metabolites were identiﬁed by LC-MS.
For bufuralol metabolism [16, 33], reactions were carried out as described above for 
dextromethorphan, with nine concentrations of bufuralol ranging from 0 to 80 µM. 
Metabolites were separated using a C18 column (Phenomenex Luna 5µ, 150 x 4.6 mm) 
with a ﬂow rate of 0.6 ml/minute. The mobile phase consisted of 30% acetonitril and 0.1% 
triethylamine, set to pH 3 with HClO4. Metabolites were detected by ﬂuorescence (λex= 252 
nm, λem= 302 nm). Metabolites of bufuralol were identiﬁed by comparing retention times 
and relative peak areas with those described in previous studies [33]; 1’-OH bufuralol was 
identiﬁed using co-elution with a reference compound. LC-MS was used to identify ∆1’,2’ 
bufuralol (data not shown).
MDMA metabolism [34] was determined as described above with nine concentrations of MDMA 
ranging from 0 to 220 µM. Metabolites were separated using a C18 column (Phenomenex 
Luna 5µ, 150 x 4.6 mm) with a ﬂow rate of 0.6 ml/minute. The mobile phase consisted of 
22% acetonitril and 0.1% triethylamine, set to pH 3 with HClO4. Metabolites were detected by 
ﬂuorescence (λex= 280 nm, λem= 320 nm). MDA was identiﬁed using the synthesised reference 
compound, and the catechol, 3,4-OH-MA, was identiﬁed previously using electrochemical 
detection [18]. 
Peak areas of all metabolites were quantiﬁed by the Shimadzu Class VP 4.3 software package. 
Reaction rates were calculated and plotted against the substrate concentrations to obtain 
Michaelis Menten curves, and the ‘one site binding hyperbola’ ﬁtting module of GraphPad 
Prism 4.0 was used to estimate Km and Vmax values.
Identification of metabolites using LC-MS
To identify the unknown metabolites of dextromethorphan, LC-MS was used. For LC-
MS measurements, incubations were carried out as described above with 40 µM 
dextromethorphan, and E. coli membranes containing 25 nM P450 2D6 (wild-type or P450 
2D6[F483A]), and CPR. Volumes of 50 µl supernatant were injected and separated using a 
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phenyl column (Phenomenex Phenyl 150 x 4.6 mm) with a ﬂow rate of 0.6 ml/minute. 
The metabolites were eluted using a gradient starting with an 5% acetonitril eluens, 
supplemented with 20 mM ammonium acetate, increasing linearly to 90% acetonitril with 
20 mM ammoniumacetate in 14 min and analysed by MS. APCI positive ionisation was used 
on a LCQ Deca mass spectrometer (Thermo Finnigan), vaporizer temperature 450 ˚C, N2 as 
sheath (40 psi) and as auxiliary gas (10 psi), needle voltage 6000 V, heated capillary 150 ˚C. 
MS/MS was performed with an activation energy of 30%.
Determination of dissociation constants
Dissociation constants were determined for dextromethorphan, bufuralol and MDMA in 
disposable 1 ml cuvettes. Two cuvettes were prepared containing 1 µM of puriﬁed P450 2D6 
(wild-type or P450 2D6[F483A]) in a ﬁnal volume of 500 µl 100 mM potassium phosphate 
buffer (KPi) pH 7.4. Aliquots of 5 µl of a 1 mM ligand solution in KPi buffer were added to the 
sample cuvette, while the same amount of KPi buffer was added to the reference cuvette. 
Difference spectra from 350 to 450 nm were taken after every addition. In total, 11 aliquots 
were added, which corresponds to a ligand concentration ranging from 10 µM (addition 1) to 
104 µM (addition 11). Upon type 1 binding of the substrates, a peak at 390 nm and a trough 
Table 1: P450 and CPR concentrations in membrane fractions.
Figure 3: CO-difference spectra of E. coli JM109 cells expressing P450 2D6 and P450 2D6[F483A]. The cell 
samples, taken after 48h of expression, were diluted two-fold before the spectra were recorded.
Solid line: wild-type P450 2D6; dashed line: P450 2D6[F483A]. Both spectra correspond to approximately 
200 nM P450 protein.
P450 2D6 P450 2D6[F483A]
[P450] membranes (µM) 8.1 ± 0.8 7.9 ± 0.7
[CPR] membranes (µM) 4.7 ± 0.5 4.0 ± 0.5 
Ratio [P450]/[CPR] 1.7 ± 0.3 2.0 ± 0.3
CPR concentrations were calculated from CPR activities of 15 mM Cyt c/min for P450 2D6 membranes and 
12.9 mM Cyt c/min for P450 2D6[F483A] membranes by dividing by 3200 mM Cyt c/min/nmol CPR.
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at 420 nm appeared. The ∆Abs (390 nm-420 nm) values were plotted against the ligand 
concentration, and the ‘one site binding hyperbola’ ﬁtting module of GraphPad Prism 4.0 
was used to estimate the spectral dissociation constants (Ks). 
Results
Expression of P450 2D6 and P450 2D6[F483A]
P450 2D6 and P450 2D6[F483A] were successfully expressed in E. coli. A typical cell culture 
yielded approximately 400 nM P450, and the expression levels were not affected by the 
presence of the F483A mutation (Figure 3). The P450 and CPR concentrations in the membranes 
were similar for wild-type P450 2D6 and P450 2D6[F483A], as summarised in Table 1. The 
puriﬁed fractions contained 50 ± 5 µM of P450 for wild-type and mutant. The P450 content of 
the membranes or puriﬁed fractions did not decrease signiﬁcantly after storage for up to six 
months at –80 °C and repeated cycles of freeze-thawing, indicating that the stability of the 
Figure 4: HPLC chromatograms of dextromethorphan metabolism by wild-type P450 2D6 (A) or P450 
2D6[F483A]  (B). Metabolites indicated by arrows are 1: hydroxydextrorphan; 2: 3-hydroxymorphinan; 3: 
dextrorphan and 4: 3-methoxymorphinan. The substrate dextromethorphan has a retention time of 24 
minutes. and is not displayed in these chromatograms.
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enzyme was not signiﬁcantly inﬂuenced by the mutation. A substantial amount of P420, the 
inactive form of P450, could also be detected in the whole cell fractions and in the membrane 
fractions. The amount of P420 in wild-type P450 2D6 and P450 2D6[F483A] was similar (Figure 3). 
In the puriﬁed fractions, no P420 could be detected.
Metabolism of model compounds
The P450 2D6 marker substrate MAMC was O-demethylated by wild-type P450 2D6 with a 
Km of 42 µM and a Vmax of 2.0 min
-1 (Table 2). In contrast, the P450 2D6[F483A] mutant did not 
form any detectable HAMC; re-analysis of the samples using HPLC also showed no detectable 
metabolites of MAMC.
The main metabolite formed upon dextromethorphan metabolism by wild-type P450 2D6 
was the O-demethylated form dextrorphan (Table 2) (m/z 258 and MS/MS m/z 201). In addition, 
trace amounts of the N-demethylated compound, 3-methoxymorphinan (m/z 258 and MS/
MS m/z 215), were detected, but the amounts were too low to determine accurate enzyme 
kinetic parameters (Figure 4). P450 2D6[F483A] also formed dextrorphan, with a 15-fold 
higher Km  and a two-fold higher Vmax than the wild-type resulting in a 7.5-fold lower Vmax/Km. 
3-Methoxymorphinan was formed by P450 2D6[F483A] with higher activity than wild-type 
P450 2D6, and Vmax and Km values could be determined (Table 2). In addition, trace amounts of 
two other metabolites were observed (Figure 4). LC-MS analysis showed that these were the 
double (O- and N-) demethylated 3-hydroxymorphinan (m/z 244 and MS/MS m/z 201), and 
the monohydroxylated, O-demethylated hydroxydextrorphan (m/z 274 and MS/MS m/z 217), 
respectively. 
Bufuralol was metabolised by wild-type P450 2D6 into three detectable metabolites, 1’-OH 
bufuralol, 4-OH bufuralol and ∆1’,2’ bufuralol, as described before [18] (Table 2). Although the Km 
values of P450 2D6 and P450 2D6[F483A] for bufuralol 1’-hydroxylation were very similar, the 
Vmax of P450 2D6[F483A] was 32-fold lower. Under the conditions applied, only 1’-OH bufuralol 
and trace amounts of 4-OH bufuralol could be detected for P450 2D6[F483A] (Table 2).
MDMA was converted by wild-type P450 2D6 mainly to the catechol 3,4-dihydroxy-
methylamphetamine (3,4-OH-MA) with a Km of 2.2 µM and a Vmax of 1.7 x 10
5 ﬂuorescence units/
min/nmol P450. Only trace amounts of MDA [34] were detected. P450 2D6[F483A] formed 3,4-
OH-MA with a 13-fold higher Km and a 2-fold lower Vmax, resulting in a 26-fold lower Vmax/Km 
value (Table 2). Like for wild-type P450 2D6, trace amounts of MDA were also observed for P450 
2D6[F483A]. In contrast to the F120A mutant, no detectable N-hydroxylation of MDMA was 
performed by P450 2D6[F483A] [18].
Determination of dissociation constants
The Ks values of dextromethorphan, bufuralol and MDMA were determined for wild-type 
P450 2D6 and for P450 2D6[F483A] (Table 3). For MAMC, no Ks values could be determined 
because this ligand has a very high absorbtion at 350-450 nm that interfered with the binding 
spectra. Dextromethorphan, bufuralol and MDMA all showed type 1 spectra for P450 2D6 and 
P450 2D6[F483A], indicating that the ligands bind at the substrate binding site. No large 
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differences were found between Ks values for P450 2D6 and P450 2D6[F483A]. Ks Values of 
dextromethorphan and bufuralol were in both in the range of 20 – 30 µM for wild-type P450 
2D6 and P450 2D6[F483A], while the Ks values of MDMA were higher for both enzymes (50 
– 60 µM).
Discussion
The aim of this study was to investigate the role of P450 2D6 active site residue F483 in ligand 
binding and metabolism. Aromatic residues in the P450 2D6 active site cavity are thought 
to be particularly important, because of their ability to interact with aromatic moieties 
present in many P450 2D6 substrates [13]. Recently, it has been described that substitution 
of active site F120 by an alanine has large substrate dependent effects on the binding and 
metabolism of typical P450 2D6 substrates [18, 19]. Homology modeling studies have also 
suggested an important role for residue F483 [1, 15, 22, 23], but to date experimental evidence 
supporting this suggestion was not available. The results presented in this study clearly 
show that substitution of the phenylalanine moiety at position 483 by an alanine (F483A) has 
marked effects on substrate selectivity and regiospeciﬁcity when using four typical P450 2D6 
substrates (Figure 2). The observed effects of the F483A mutation were found to be strongly 
substrate-dependent, as was seen recently for F120A. 
P450 2D6[F483A] did not metabolise MAMC, in contrast to wild-type P450 2D6. Apparently, 
both residue F483 (this study) and residue F120 [18] are both required for metabolism of 
this substrate. These residues could either provide steric constraints to keep the substrate 
in the orientation required for metabolism, or they could function as aromatic anchoring 
points. A possible explanation is that MAMC is kept into position by both phenylalanines in 
a ‘sandwich’ conﬁguration.
Dextromethorphan is believed to bind by electrostatic interactions between its basic nitrogen 
atom and the acidic residues E216 and D301 [16]. Recently, it has been shown that aromatic 
residue F120 also plays a role in dextromethorphan metabolism, since substitution of this 
residue resulted in the formation of two novel metabolites [18, 19]. The present study shows 
that residue F483 is also involved in metabolism of dextromethorphan. Wild-type P450 2D6 
performs mainly O-demethylation of dextromethorphan while P450 2D6[F483A] also formed 
substantial amounts of N-demethylated product. In addition, two novel metabolites were 
formed (Figure 4) that could not be detected in wild-type P450 2D6 incubations, but have 
been described previously for P450 2D6[F120A] [18, 19]. The Ks values of dextromethorphan 
were similar for wild-type P450 2D6 and P450 2D6[F483A], indicating that the binding afﬁnity 
of dextromethorphan is not greatly affected by the mutation. The observed effects on the 
metabolic ratio may therefore result from the different orientations that can be adopted by 
the large, non-ﬂat substrate dextromethorphan in the active site of P450 2D6[F483A], as a 
consequence of the increased available space.
For bufuralol metabolism, the acidic residues E216 and D301 have been shown to be very 
important because they are involved in the ﬁxation of the basic nitrogen of bufuralol [15, 16, 
33]. Mutagenesis of aromatic residue F120 to alanine, on the other hand, did not signiﬁcantly 
affect the metabolism of this substrate [18]. In a previous mutagenesis study, it was found 
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that the substitution of F483 by tryptophan or isoleucine did not inﬂuence bufuralol 1’-
hydroxylation [1]. In the present study, however, a signiﬁcant effect on bufuralol metabolism 
was observed when F483 was replaced by the smaller alanine. This mutation resulted in a 
32-fold lower Vmax for bufuralol 1’-hydroxylation, while the Km value was hardly affected. The 
binding afﬁnity of bufuralol was not signiﬁcantly inﬂuenced by the F483A mutation (Table 3). 
The fact that the more conservative substitutions of F483 by tryptophan and isoleucine have 
no effect on bufuralol metabolism suggests that these amino acid residues can compensate 
for the loss of the phenylalanine-residue, by aromatic, hydrophobic, and/or steric interaction 
with bufuralol.
Previous studies with P450 2D6[F120A] showed that for this mutant, regioselectivity of 
MDMA metabolism had changed signiﬁcantly. The amount of MDA produced by this mutant 
was greatly increased compared to wild-type P450 2D6. In addition, a novel metabolite was 
formed which could be identiﬁed as N-OH-MDMA [18]. In the present study, it was shown 
that the F483A substitution did not inﬂuence the metabolic ratio of MDMA metabolism, but 
only the kinetic parameters of 3,4-OH-MA formation (Table 2). For the formation of the major 
metabolite 3,4-OH-MA, the Km value of P450 2D6[F483A] was 13-fold higher than the wild-
type value, while the Vmax value decreased only 2-fold (Table 2). The Ks value of MDMA was 
very similar for wild-type P450 2D6 and P450 2D6[F483A] (Table 3). The fact that the changes 
in Km value and Ks value do not follow the same trend may be explained by the fact that the 
Km and Ks values actually represent qualitatively different processes. The Ks value, which is 
determined by difference spectroscopy, is describing the ability of a ligand to induce a spin 
shift of the heme-iron in the absence of NADPH. The parameter Km is related to the enzyme 
reaction and its value is determined by both binding afﬁnity and rate limiting steps of the 
catalytic reaction [35].
Residue F120 was shown to be important for MDMA metabolism, but not for bufuralol 
metabolism, while for F483 bufuralol metabolism and MDMA metabolism are both affected 
by the mutation. For bufuralol, only the Vmax was altered, while for MDMA mainly the Km was 
inﬂuenced by the mutation. These results suggest that these two compounds have different 
modes of binding, despite their high degree of structural similarity.
In conclusion, the data presented in this study prove that F483 plays an important role in P450 
2D6 selectivity and activity. Together with acidic residues E216 and D301 and aromatic residue 
F120, it deﬁnes the ligand binding properties and the regiospeciﬁcity of metabolism. However, 
of the at least 25 residues postulated to form the active site of P450 2D6, as yet only eight 
have been subjected to experimental studies [36]. Therefore, involvement of other residues 
in binding and metabolism of P450 2D6 substrates remains to be established. For E216 and 
D301, it has been shown that they are important for the ﬁxation of the basic nitrogen atom 
in ligands [14-16]. The strongly substrate dependent effects observed after mutagenesis of 
the aromatic residues F120 and F483 can be attributed either to the change in the active site 
topology upon removal of the phenylalanines, or can be due to loss of aromatic interaction 
points. The fact that the Ks values of wild-type P450 2D6 and P450 2D6[F483A] were very 
similar for the substrates tested suggests that the role of F483 in binding and metabolism 
of these compounds is mainly by inﬂuencing the statistics of possible orientations. However, 
advanced molecular dynamics simulations can give further insight in these mechanisms.
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Abstract
In this study, the ﬁrst ﬂuorescent assay for bacterial cytochrome P450 BM3 (P450 BM3) and 
mutants is described. P450 BM3 mutants are potentially very versatile biocatalysts for the 
production of ﬁne chemicals. A ﬂuorescent assay would be very useful for the identiﬁcation 
of non-natural ligands in high throughput inhibition assays. Because of the ease and 
sensitivity of alkoxyresoruﬁn O-dealkylation assays, four different alkoxyresoruﬁnes were 
evaluated as substrates. Wild-type P450 BM3 showed extremely low activity towards all 
four alkoxyresoruﬁns tested. Five different P450 BM3 mutants were constructed carrying 
different combinations of mutations R47L, F87V and L188Q, which were previously shown to 
increase activity towards non-natural substrates. For all mutants, a high benzyloxyresoruﬁn 
O-dealkylation (BROD) activity was found. The triple mutant P450 BM3 R47L/F87V/L188Q 
showed highest activity, being 900-fold increased compared to wild-type P450 BM3. The 
BROD assay could also be applied in whole E. coli cells; permeabilisation by LPS-deﬁciency 
strongly increased the activity. To demonstrate the applicability of the BROD assay to screen 
for novel ligands of P450 BM3 R47L/F87V/L188Q, a library of 45 drug-like compounds was 
tested for inhibition. Eight compounds showed strong inhibition of the BROD-activity, 
demonstrating for the ﬁrst time that also drug-like molecules can bind with high afﬁnity to 
P450 BM3 mutants.
Introduction
Cytochromes P450 (P450s) constitute a family of monooxygenases involved in the oxidation 
and reduction of a large variety of endogenous and exogenous compounds [1-3]. Because 
of their catalytic diversity and broad substrate range, there is an increasing interest to use 
P450s as biocatalysts in the production of ﬁne chemicals, including pharmaceuticals [4-
6]. Biocatalysis could be used for the discovery of new drugs, or the optimisation of lead 
compounds and existing drugs. Because of their low stability and catalytic activity, mammalian 
P450s are not very suitable as biocatalysts [7-9]. Bacterial P450s are often much more stable 
and exhibit higher catalytic activities, which make them more promising candidates for 
biocatalysis. The soluble Cytochrome P450 BM3 (P450 BM3) from Bacillus megaterium [10] 
has the highest catalytic activity ever detected for a P450 monooxygenase [7]. This can be 
explained by the fact that P450 BM3 is a fusion protein, consisting of a catalytic heme-
containing domain fused to an FAD and FMN containing reductase domain, which results 
in very efﬁcient electron transport. Wild-type P450 BM3 catalyses the hydroxylation of long-
chain fatty acids at subterminal positions (ω-1 to ω-3) [10]. However, it has been shown that 
by mutagenesis of the active site the substrate speciﬁcity of P450 BM3 can be engineered to 
include alkanes [11-13], indole [14], short- and medium chain fatty acids [15, 16] and polycyclic 
aromatic hydrocarbons (PAHs) [17, 18] as substrates. 
For the use of P450 BM3 as a biocatalyst in the pharmaceutical industry, mutants of P450 
BM3 are required that are able to bind and metabolise drug-like molecules. At present, such 
mutants have not been described. The search for such variants is only feasible when fast, 
sensitive assays are available that allow screening for P450 BM3 mutants that are able to 
bind drug-like compounds. At present, the only continuous activity assay for P450 BM3 is a 
colorimetric assay using p-nitrophenoxy-derivatives of long-chain fatty acids as substrates 
(p-nitrophenoxycarboxylic acids, pNCAs), which are converted by P450 BM3 into the yellow p-
nitrophenolate [19]. A disadvantage of colorimetric assays, however, is that they are generally 
much less sensitive than ﬂuorescent assays, and more prone to interference by assay 
components. Therefore, the aim of this study is to develop a ﬂuorescent high-throughput 
assay for P450 BM3. 
As potential substrates, a series of alkoxyresoruﬁns was chosen. Several 7-alkoxyresoruﬁns are 
known to be ﬂuorescent substrates for mammalian drug metabolising P450s [20-22]. They can 
be O-dealkylated to yield resoruﬁn, which has an extremely strong ﬂuorescence at very high 
wavelengths [23] (Figure 1). Because of the high sensitivity and the ease of the alkoxyresoruﬁn 
O-dealkylation assay, these substrates are often used as marker substrates to determine the 
P450 activity in tissues [20, 24, 25]. Recently, reports have been published on alkoxyresoruﬁns 
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that are used for high-throughput P450 screening purposes [26, 27]. In addition to their 
favourable ﬂuorescence properties, another advantage is that alkoxyresoruﬁns can be 
considered drug-like molecules. pNCAs, on the other hand, bear more structural resemblance 
to the natural substrates of P450 BM3, i.e. fatty acids. This makes alkoxyresoruﬁns more 
suitable to screen for P450 BM3 mutants that are able to bind drug-like molecules.
In this study, we tested four different alkoxyresoruﬁns for metabolism by P450 BM3 and 
several site-directed mutants. Based on literature data, three amino acid residues were 
chosen for mutagenesis in order to construct mutants with increased activity towards non-
natural substrates. The selected mutations have been shown to enable P450 BM3 to convert 
PAHs and indole [14, 17, 18], compounds that share some structural characteristics with 
alkoxyresoruﬁns. The bulky aromatic residue F87, which is positioned above the porphyrin 
plane [28], prevents the binding of large substrates near the catalytic centre. This residue 
was therefore replaced by valine. Residue R47 that is located in the entrance channel of P450 
BM3 and is known to be involved in substrate recognition was converted to a hydrophobic 
leucine, to improve the recognition of hydrophobic substrates and to avoid repulsion of basic 
compounds. Furthermore, the hydrophobic L188, also located in the entrance channel, was 
replaced by a glutamine. Five different P450 BM3 mutants were constructed containing one, 
two or all of these mutations. The alkoxyresoruﬁn showing highest activity in cell lysates was 
also tested in whole E. coli cells expressing the triple mutant of P450 BM3, R47L/F87V/L188Q.
Materials and Methods
Materials
The alkoxyresoruﬁns were purchased from Sigma-Aldrich. The plasmid pT1-P450BM3 
containing the P450 BM3 cDNA under control of the temperature-inducible PRPL promoter 
was a kind gift from R.D. Schmid (Institut für Technische Biochemie, Universität Stuttgart). 
The bacteriophage U3 was a kind gift from M. Kranendonk (Department of Genetics, Faculty 
of Medical Sciences, Universidade Nova de Lisboa). All other chemicals were of analytical 
grade and obtained from standard suppliers.
Site-directed mutagenesis
Five different site-directed mutants of P450 BM3 were constructed: R47L, R47L/F87V, R47L/
L188Q, F87V/L188Q and R47L/F87V/L188Q. The mutations were introduced into pT1-P450BM3 
Figure 1: Alkoxyresoruﬁn O-dealkylation reaction scheme. Methoxyresoruﬁn: R= H; ethoxyresoruﬁn: R= 
CH3; pentoxyresoruﬁn: R= C4H9; benzyloxyresoruﬁn: R=C6H5.
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using the QuikChange XL Site-Directed mutagenesis kit (Stratagene). The sequences of the 
forward primers, with the altered residue in bold italic, were as follows: 
R47L 5’-C GAG GCG CCT GGT TTA GTA ACG CGC TAC TTA TC-3’
F87V 5’-GCA GGA GAC GGG TTA GTA ACA AGC TGG ACG-3’
L188Q 5’-GAA GCA ATG AAC AAG CAG CAG CGA GCA AAT CCA G-3’
After mutagenesis, the presence of the desired mutations was conﬁrmed by DNA sequencing 
(Baseclear, Leiden, The Netherlands).
Expression and isolation of P450 BM3
The plasmids of the wild-type (pT1-P450BM3) and mutants were transformed into 
Escherichia coli strain DH5α using standard procedures. Expression was carried out in 3 L 
ﬂasks containing 300 ml Terriﬁc Broth (TB) medium (24 g/L Yeast Extract, 12 g/L Tryptone, 
4 ml/L Glycerol) with additives (1 mM δ-aminolevulinic acid, 400 µl/L trace elements [29], 
0.5 mM thiamine, 100 µg/ml ampicillin). Cultures were inoculated with 1/50 volume of an 
overnight culture in LB medium (5 g/L Yeast Extract, 10 g/L Tryptone, 5 g/L NaCl). Cultures 
were grown for approximately 3 h at 37 °C and 175 rpm. When the OD600 had reached 0.8, 
expression was induced by increasing the temperature to 42 °C. Expression was allowed to 
continue for 5 h before the cells were harvested. P450 contents of the cells were determined 
with a CO difference spectrum to determine the expression level [30]. Cells were pelleted 
by centrifugation (15 minutes, 4000 g, 4 °C), and the pellet was resuspended in 15 ml of KPi-
Glycerol buffer (100 mM potassium phosphate (KPi) buffer pH 7.4, 10% glycerol, 0.25 mM EDTA, 
0.1 mM DTT). Cells were disrupted using a French Press (1000 psi, 3 repeats). The cytosolic 
fraction was separated from the membrane fraction by ultracentrifugation in a Beckmann 
50.2Ti rotor (45 minutes, 120,000 g, 4 °C). The P450 BM3 containing supernatant was stored at 
–20 °C, after the P450 contents were determined with a CO difference spectrum.
Isolation of a lipopolysaccharide defective (LPSd) mutant of E. coli DH5α 
To determine the inﬂuence of cell wall permeability on the applicability of the BROD assay 
in whole bacterial cells, permeable mutants of E. coli DH5α were isolated. An LPSd mutant of 
E. coli DH5α was isolated by the bacteriophage U3r selection method as described previously 
[31]. 3 ml of LB medium was inoculated with 30 µl of an overnight culture of DH5α cells. Cells 
were placed at 37 °C and 200 rpm until the OD600 reached 0.1. At that point, 100 µl of cells 
were mixed with 100 µl bacteriophage U3 phagic suspension. The cells were incubated for 
20 minutes at 37 °C with mild agitation. Subsequently, the infected cells were mixed with 
2.5 ml of LB top-agar and spread on an LB agar plate. Several colonies were dissolved in a 
sterile solution 0.85% NaCl and a droplet was plated on a MacConkey agar plate. Colonies 
that repeatedly (three times) did not grow on MacConkey agar were identiﬁed as stable LPSd 
mutants. The plasmid carrying the P450 BM3 R47L/F87V/L188Q gene was transformed into an 
LPSd mutant of E. coli DH5α using standard procedures but leaving out the heat-shock step in 
the transformation protocol. Expression was performed as described above, with exception 
of the temperature of induction, which was lowered from 42 °C to 40 °C.
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Determination of alkoxyresorufin O-dealkylation
The enzyme activity of P450 BM3 wild-type and the mutants toward a series of alkoxy-
resoruﬁns was determined in a microtiter plate assay in which formation of resoruﬁn 
is followed continuously. Reactions were carried out in black Costar 96-well plates in a 
ﬁnal volume of 200 µl. The assay buffer consisted of 100 mM potassium phosphate (KPi), 
pH 7.6, supplemented with 5 mM MgCl2. Various amounts of cytosolic fraction resulting 
in enzyme concentrations of 100, 50 and 10 nM were incubated with 10 µM of methoxy-, 
ethoxy-, pentoxy- or benzyloxyresoruﬁn for wild-type P450 BM3 and ﬁve site-directed 
mutants. Reactions were initiated by the addition of an NADPH regenerating system 
resulting in ﬁnal concentrations of 0.1 mM NADPH, 0.3 mM glucose-6-phosphate and 0.4 
units/ml glucose-6-phosphate dehydrogenase. The reaction was monitored for 15 minutes 
at 24 °C on a Victor2 1420 multilabel counter (Wallac) (λex= 530 nm, λem= 580 nm). The product 
of the reaction,resoruﬁn, was quantiﬁed using a standard curve of the reference compound 
(5 nM to 500 nM).
 
Characterisation of BROD activity
Because screening of the alkoxyresoruﬁns showed that benzyloxyresoruﬁn was a good 
substrate for the triple mutant R47L/F87V/L188Q, the enzyme characteristics of this reaction 
were investigated in more detail. The assay was characterised by end point measurements 
that were performed in Eppendorf tubes at 24 °C. The assay buffer consisted of 100 mM 
potassium phosphate (KPi), pH 7.6, supplemented with 5 mM MgCl2. To determine the 
linearity of product formation in time and the enzyme concentration dependency, 2 µM 
benzyloxyresoruﬁn was incubated for various amounts of time with varying enzyme 
concentrations (1.25 – 15 nM) in a ﬁnal volume of 200 µl. For the determination of enzyme 
kinetics, 2.5 nM of enzyme was incubated with benzyloxyresoruﬁn concentrations ranging 
from 0 to 6.75 µM (11 concentrations). Reactions were always initiated by the addition of an 
NADPH regenerating system as described above, and were allowed to proceed for 4 minutes. 
The reaction was stopped by the addition of 16 µl of 2.5 M trichloro acetic acid (TCA), and 
subsequently the samples were neutralised by the addition of 200 µl of 2 M Tris. 50 µl Aliquots 
were analysed using ﬂow-injection using a Gilson 234 autoinjector coupled to a ﬂuorescence 
detector (λex= 530 nm, λem= 586 nm). The mobile phase consisted of 50% methanol and had a 
ﬂow rate of 0.4 ml/minute. 
High-throughput inhibition screening
After optimising the BROD assay conditions, its applicability to identify new ligands was 
tested with a selection of 45 known drug-like ligands for mammalian P450s. The screening 
assay was performed in black Costar 96-well plates in a ﬁnal volume of 200 µl. The reaction 
mixture was composed as described above for the batch assay. 2.5 nM of P450 BM3 R47L/F87V/
L188Q and 2 µM of benzyloxyresoruﬁn were incubated with 50 and 250 µM of each library 
compound. The reaction was monitored for 15 minutes at 24 °C on a Victor2 1420 multilabel 
counter (Wallac) (λex=530 nm, λem =580 nm).
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BROD assay in whole cells
To determine if BROD activity could also be measured in whole E. coli cells, a test was 
performed in a microtiter plate in a ﬁnal volume of 200 µl. After culturing as described 
above, E. coli DH5α cells expressing P450 BM3 R47L/F87V/L188Q were pelleted (15 minutes, 
4000 g, 4 °C) and resuspended in one volume of assay buffer. 20 µl of these cells was added 
to the sample well. An NADPH regenerating system as described above was added. Reactions 
were initiated by the addition of benzyloxyresoruﬁn resulting in a ﬁnal concentration of 5 
µM. The reaction was monitored for 15 minutes at 24 °C on a Victor2 1420 multilabel counter 
(Wallac) (λex= 530 nm, λem= 580 nm). In addition, the same experiment was performed with 
a lipopolysaccharide defective (LPSd) mutant of E. coli DH5α expressing P450 BM3 R47L/F87V/
L188Q that was isolated and cultured as described above.
Results
Expression of  P450 BM3
All ﬁve mutants were successfully expressed in E. coli DH5α cells, and the triple mutant was 
also expressed in DH5α LPSd cells. All expression levels were comparable to those of wild-type 
P450 BM3. For all the expressed enzymes a typical culture yielded 300-400 nM of enzyme, and 
no P420, the inactive form of P450, could be detected (Figure 2). This shows that the presence 
Figure 2: CO difference spectra of wild-type P450 BM3 and site-directed mutants. Spectra were taken 
on whole E. coli DH5α cells and E.coli DH5α LPSd cells as described previously [30]. Spectra represent from 
bottom to top: wild-type P450 BM3; R47L; R47L/L188Q; R47L/F87V; F87V/L188Q; R47L/F87V/L188Q; R47L/F87V/
L188Q in LPSd cells.
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of the mutations did not inﬂuence the enzyme expression levels or the stability. After the 
isolation procedure, the cytosolic fractions contained approximately 6-8 µM of P450 BM3, 
which indicates that the yield of the isolation procedure was 75-100%.
Determination of alkoxyresorufin O-dealkylation
First, the four selected alkoxyresoruﬁns (methoxy-, ethoxy-, pentoxy- and benzyloxyresoruﬁn) 
were incubated at a concentration of 10 µM with wild-type P450 BM3 and the ﬁve mutants. As 
can be seen in Table 1, methoxyresoruﬁn was not metabolised by any of the enzymes studied, 
while ethoxyresoruﬁn was metabolised only at a very low rate by the triple mutant (R47L/
F87V/L188Q). With pentoxyresoruﬁn, very low activity was observed for the triple mutant and 
for double mutant R47L/F87V. Interestingly, benzyloxyresoruﬁn appeared to be a substrate 
for all six enzymes tested (Table 1) although for wild-type P450 BM3 and mutant R47L the rate 
of metabolism was extremely low (0.005 nmol resoruﬁn/min/nmol enzyme). An extremely 
high BROD activity of 4.5 nmol resoruﬁn/min/nmol enzyme was found for the triple mutant, 
corresponding to a 900-fold increase compared to wild-type P450 BM3.
Characterisation of BROD activity
The triple mutant R47L/F87V/L188Q was characterised further with respect to BROD activity. 
Because sample mixing and reaction temperature in the microplate reader cannot be 
controlled as accurately as in Eppendorf tubes, the BROD assay was characterised using 
standard batch incubations. First, the ranges were determined where the BROD activity 
was linear with enzyme concentration and incubation time. The product formation was 
almost linear with time for up to 4.5 minutes before the activity started to level off (Figure 
3A). Product formation was almost linear with enzyme concentration up to 5 nM (Figure 3B); 
at higher enzyme concentrations the product formation leveled off. Based on these data, 
Table 1: Alkoxyresoruﬁn O-dealkylation activity of P450 BM3 and ﬁve mutants.
V  MROD V  EROD V  PROD V  BROD
Wild-type - - - 0.005
R47L - - - 0.005
R47L/L188Q - - - 0.20 
R47L/F87V - - 0.20 0.71
F87V/L188Q - - - 1.44
R47L/F87V/L188Q - 0.012 0.22 4.48
V is expressed in nmol resoruﬁn/min/nmol enzyme. Substrate concentrations were 10 µM. Enzyme 
concentrations were 100 nM for wild-type P450 BM3 and R47L, and 10 nM for the other mutants. M-, E-, 
P- and BROD: methoxy, ethoxy, pentoxy and benzyloxyresoruﬁn O-dealkyaltion.
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enzyme kinetics analysis of BROD was performed at an enzyme concentration of 2.5 nM of 
enzyme and with 4 minutes incubation time. Under these conditions Km and Vmax values of 1.9 
µM and 8.6 nmol resoruﬁn/min/nmol enzyme, respectively, were found (Table 2).
High-throughput inhibition screening
To demonstrate the applicability of the BROD assay to serve as a high-throughput inhibition 
assay to identify drug-like compounds with afﬁnity for P450 BM3, a library of 45 drug-like 
compounds (see legend Table 3) was tested. Compounds were considered hits when more 
than 10% inhibition was observed at an inhibitor concentration of 50 µM.  As listed in Table 
3, eight hits were found. Ketoconazole, tranylcypromine, tamoxifen and hydroxyellipticine 
were found to be very strong inhibitors. At 50 µM, ketoconazole inhibited BROD activity 
completely, so for this compound lower concentrations were tested (0.23 nM – 1500 nM). 
With these data, an IC50 value of 21.3 nM was found (Figure 5). Orphenadrine, proadifen and 
quinidine inhibited BROD activity for approximately 50% under the conditions used, and 
carbamazepine displayed a low inhibitory potency of 25%.
Figure 3: Time- and enzyme concentration dependence of benzyloxyresoruﬁn metabolism. A: time 
dependence of BROD by 2.5 nM P450 BM3 triple mutant. B: enzyme concentration dependence of BROD 
with incubation times of 4 minutes.
Table 2: Kinetic parameters of the P450 BM3 triple mutant for BROD activity.
Km (µM) Vmax Vmax/Km
R47L/F87V/L188Q 1.9 ± 0.1 8.6 ± 1.7 4.5 ± 0.9
Human P450 3A4a 6.1 0.13 0.021
Vmax values are expressed in nmol resoruﬁn/min/nmol enzyme. All values are the means ± SD of at least 
three independent measurements. aFor comparison, literature values of human P450 3A4, for which 
benzyloxyresoruﬁn is a substrate, are also included [27].
98
ALKOXYRESORUFINS AS FLUORESCENT SUBSTRATES FOR P450 BM3
BROD assay in whole cells
To investigate whether the BROD assay could also be performed in whole cells, E. coli DH5α 
cells expressing P450 BM3 R47L/F87V/L188Q were incubated with benzyloxyresoruﬁn. The 
results show that under the conditions used, BROD activity in whole cells is very low (Figure 4). 
Incubation of a lipopolysaccharide defective (LPSd) mutant E. coli DH5α cells showed a 7-fold 
increased BROD activity. This may be explained by the fact that LPSd mutants miss a major 
component of the outer membrane, and thus have an increased permeability for many 
compounds. The IC50 value of ketoconazole in LPS
d cells was determined by adding 0.23-1500 
nM of ketoconazole to the assay. This resulted in an IC50 value of 4.3 nM, which is in the same 
range as the IC50 value found using cytosolic fraction (Figure 5).
Discussion
The aim of this study was to develop a ﬂuorescent high-throughput screening method for P450 
BM3 that can be used for inhibition screening. Such an assay would be of great value to identify 
novel ligands that are able to bind P450 BM3 or P450 BM3 mutants. Because of their favourable 
ﬂuorescence properties and their structural similarity to drug-like molecules, alkoxyresoruﬁns 
were selected as potential substrates for P450 BM3. Of the four alkoxyresoruﬁns that were 
tested on wild-type and mutant forms P450 BM3, benzyloxyresoruﬁn appeared to be the best 
substrate. It was metabolised by all six enzymes to a certain extent. The highest BROD activity 
Compound % Inhibition at 50 µM
Ketoconazole 100
Tranylcypromine 93
Tamoxifen 92
Hydroxyellipticine 91
Orphenadrine 59
Proadifen 57
Quinidine 40
Carbamazepine 25
A hit is deﬁned as a compound that inhibits BROD activity of the P450 BM3 triple mutant at an inhibitor 
concentration of 50 µM for >10%. The percentage of inhibition at this concentration is indicated in 
the table. The compounds in the library that were not picked up as hits were: α-naphtoﬂavon, 3-
acetamidofenol, adriamycine, aminopyrine, amodiaquine, arterenol, barbital, caffeine, chlorzoxazone, 
cloxacillin, clozapine, codeine, dacarbazine, debrisoquine, dexamethasone, dextromethorphan, 
diclofenac, dicoumarol, disulﬁram, ﬂucoxacilline, furosemide, indomethacine, ketamine, metyrapone, 
mianserine, phenobarbital, raloxifen, sparteine, sulfaphenazole, tacrine, theophylline, troleandomycine, 
xylocaine, nortriptyline, indol.
Table 3: Hits found in a library of 45 drug-like compounds.
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was found for the triple mutant, R47L/F87V/L188Q (Table 1). This enzyme displayed a Vmax/Km 
value over 200-fold higher than that of human P450 3A4, for which benzyloxyresoruﬁn is a 
substrate (Table 2). This suggested that benzyloxyresoruﬁn could be a promising diagnostic 
substrate for P450 BM3.  
The ﬂuorescent high-throughput BROD assay described in this study has various advantages 
compared to the assays currently available for P450 BM3. One technique frequently used 
to determine P450 BM3 activity is the measurement of NADPH consumption [32]. The main 
disadvantages of this assay are that monitoring of cofactor depletion is far less sensitive 
than product formation, and that uncoupling of the enzyme can occur which results in false 
positive signals [1]. Other techniques, based on product identiﬁcation and quantiﬁcation with 
GC-MS, NMR or HPLC, are not suitable for high-throughput purposes because of long analysis 
Figure 4: BROD activity in whole E. coli cells. Rates of benzyloxyresoruﬁn 
metabolism (nM resoruﬁn formed per minute) by the P450 BM3 triple 
mutant in normal E. coli DH5α cells (black bar) and E. coli DH5α LPSd cells 
(grey bar). Enzyme contents of normal cells and LPSd cells were similar.
Figure 5: Dose-response curves of ketoconazole in cytosol and whole cells. Data were obtained by incubation 
of 0.23 – 1500 nM ketoconazole and 5 µM benzyloxyresoruﬁn with 2.5 nM P450 BM3 triple mutant in cytosol 
(closed triangles) or with 20 µl whole LPSd DH5α cells expressing P450 BM3 triple mutant (open triangles). 
IC50 values were 21.3 nM in cytosol and 4.3 nM in whole LPS
d DH5α  cells.
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times and/or laborious sample preparations [11, 18]. The only continuous activity assay for 
P450 BM3, that has already been used to identify P450 BM3 mutants with altered activity, 
is the p-nitrophenoxycarboxylic acid (pNCA) assay [13, 15, 33]. The product of the reaction is 
p-nitrophenolate, which can be detected at 410 nm. Although the Vmax/Km value for 10-pNCA 
conversion by P450 BM3 F87A is approximately 10-fold higher than that of benzyloxyresoruﬁn 
metabolism by the triple mutant [15], the detection limit of p-nitrophenolate is approximately 
200-fold higher than the detection limit of resoruﬁn used in this study. This makes the 
spectrophotometric assay much less sensitive than the ﬂuorescent BROD assay. In addition, 
the high excitation and emission wavelengths of resoruﬁn make the assay less sensitive to 
interference by other assay components. This is especially important when the assay is used 
with whole cells instead of crude lysates or puriﬁed enzymes.
For applications of the BROD assay for screening of libraries of random P450 BM3 mutants, 
it is very valuable that the assay can also be performed in whole E. coli cells because this 
makes laborious enzyme isolation procedures obsolete. Recently, it has been shown that 
methoxyresoruﬁn can be used in whole cell screening assays with E. coli cells expressing human 
P450 1A2 mutants [26]. In the present study, benzyloxyresoruﬁn is efﬁciently metabolised in 
whole DH5α cells. The use of an LPSd bacterial host leads to a strong increase in BROD-activity 
(Figure 4), which can be explained by a higher permeability for benzyloxyresoruﬁn. The 
increased permeability of LPSd cells toward chemicals has previously been used to increase 
the sensitivity of various mutagenicity tester strains [34, 35].
Data in Table 1 suggest that for benzyloxyresoruﬁn metabolism the F87V mutation is most 
important: the double mutant R47L/L188Q that lacks the F87V mutation has a 23-fold lower 
BROD activity compared to the triple mutant. This conﬁrms the crucial role of F87 in controlling 
substrate speciﬁcity of P450 BM3. The R47L/F87V mutant that lacks the L188Q mutation has 
a 6-fold lower BROD activity compared to the triple mutant. The effect of the R47L mutation 
was least pronounced; the double mutant F87V/L188Q lacking this mutation showed only 
2-fold decreased BROD activity compared to the triple mutant. Apparently, this residue plays 
a minor role in binding of benzyloxyresoruﬁn. The F87V/L188Q mutant has already been 
described in literature; this mutant was shown to metabolise indole [14] and PAHs [17]. 
Benzyloxyresoruﬁn is a well-established substrate for several human drug metabolising 
P450s, including P450 3A4. The active sites of P450 BM3 and human P450 3A4 appear to have 
several features in common. Both human P450 3A4 and P450 BM3 can apparently bind two 
substrates in the active site simultaneously [36, 37]. Also, both enzymes have a relatively 
large active site composed of mainly hydrophobic residues [28, 38, 39]. Therefore, it is not 
surprising that of the four alkoxyresoruﬁns used in this study, the large and hydrophobic 
benzyloxyresoruﬁn was found to be the best substrate for P450 BM3. 
The BROD assay was subsequently used as a high-throughput inhibition screening method. In 
a library of 45 drug-like compounds, several ligands for P450 BM3 R47L/F87V/L188Q were found 
(Table 3). Three of these compounds can be classiﬁed as general P450 inhibitors (ketoconazole, 
proadifen and tranylcypromine), and four of the eight hits are known substrates of human 
P450 3A4 (carbamazepine, hydroxyellipticine, quinidine and tamoxifen). 
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This is the ﬁrst report where drug-like molecules have been identiﬁed as ligands for P450 
BM3. Together with the other favourable characteristics of P450 BM3 with respect to stability 
and catalytic activity, this makes P450 BM3 a very good candidate to be used as a biocatalyst 
for the discovery and synthesis of drugs [4]. It still needs to be investigated, however, 
whether the drug-like compounds identiﬁed as hits in this study are also metabolised by 
P450 BM3. In addition, alternative P450 BM3 mutants could be constructed that still possess 
the ability to perform BROD, but have altered activities toward drugs. This could lead to a 
series of P450 BM3 mutants that can convert different classes of drug-like compounds into 
novel metabolites, resulting in libraries of structurally related molecules with potentially 
therapeutically interesting properties.
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ATYPICAL KINETICS IN A P450 BM3 MUTANT
Abstract
Recently we described a triple mutant of the bacterial cytochrome P450 BM3 as the ﬁrst 
mutant with afﬁnity for drug-like compounds. In this paper we show that this mutant, but not 
wild-type P450 BM3, is able to metabolise testosterone and several drug-like molecules such 
as amodiaquine, dextromethorphan, acetaminophen and 3,4-methylenedioxymethylam-
phetamine that are known substrates of human P450s. Interestingly, the metabolism of 3,4-
methylenedioxymethylamphetamine and acetaminophen could be stimulated up to 70-fold 
by the addition of caffeine, a known activator of rat P450 3A2.  With testosterone metabolism, 
homotropic cooperativity was observed. This shows that heterotropic and homotropic 
cooperativity, known to occur in the P450 3A family, can also take place in P450 BM3. P450 
BM3 therefore can be used as a model system to study atypical kinetics in mammalian P450s. 
Secondly, this study shows that P450 BM3 can be engineered to a drug metabolising enzyme, 
making it a promising candidate to use as biocatalyst in drug discovery and synthesis.
Introduction
Cytochromes P450 (P450s) constitute a large superfamily of monooxygenases that are involved 
in the oxidation and reduction of a wide variety of compounds [1]. Next to their important 
endogenous functions, they are well known for their role in the metabolism of xenobiotics 
such as drugs, food components and environmental contaminants [2, 3]. Drug metabolising 
P450s generally have a broad substrate selectivity and are able to perform a wide variety of 
reactions. Because of this catalytic diversity, the application of P450s in biotechnology, for 
example as biocatalysts in the production of ﬁne chemicals such as pharmaceuticals, may 
have good perspectives [4-6]. Bacterial P450s are especially interesting as biocatalysts because 
they are soluble, and, compared to their membrane-bound mammalian counterparts, are 
more stable and catalytically more active. One of the most extensively studied bacterial 
P450s is cytochrome P450 BM3 (P450 BM3) from Bacillus megaterium [4, 7]. P450 BM3 has the 
highest catalytic activity ever detected for a P450 monooxygenase [7, 8]. Its natural substrates 
are long-chain fatty acids. Very recently it was stated that the limited substrate diversity of 
bacterial P450s is a major disadvantage for industrial purposes [9]. Several reports, however, 
have demonstrated that by site-directed and random mutagenesis the substrate speciﬁcity 
of P450 BM3 can be altered strongly to include a wide variety of compounds, such as indole, 
polycyclic aromatic hydrocarbons and alkanes [10-12]. Very recently it was shown that a 
mutant of the P450 BM3 heme domain is able to metabolise the beta-blocker propranolol 
using a peroxide shunt pathway [13].
Recently, we demonstrated that a rationally designed triple mutant of P450 BM3, R47L/F87V/
L188Q, has afﬁnity for several drug-like compounds [14]. This mutant of P450 BM3 seems to 
share some characteristics with P450 3A4: it converts benzyloxyresoruﬁn, which is a well-
established substrate for P450 3A4, whereas ketoconazole, a potent inhibitor of P450 3A4, 
was identiﬁed as the most potent inhibitor when screening inhibition of dealkylation 
of benzyloxyresoruﬁn by a library of 45 drug-like compounds. Comparison of the crystal 
structures of P450 3A4 and wild-type P450 BM3 reveals that both enzymes contain a relatively 
large active site composed of mainly hydrophobic residues [15, 16], and seem to be able to 
accommodate two substrate molecules in the active site simultaneously [17, 18]. The presence 
of two substrate binding sites in the active site may explain the non-Michaelis Menten 
kinetic behaviour of P450 3A4 [19]. For human P450s, the occurrence of atypical kinetics is 
clinically relevant because non-Michaelis-Menten kinetics complicate the extrapolation of in 
vitro data to in vivo in drug discovery and development [22]. Cytochrome P450 eryF was the 
ﬁrst bacterial P450 to display both heterotropic and homotropic cooperativity, and therefore 
was proposed as a convenient model protein to investigate the fundamental mechanisms 
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underlying atypical enzyme kinetics of P450s [20]. The availability of crystal structures, the 
higher stability and the ease of overexpression in E. coli are big advantages that bacterial 
P450s have over mammalian P450s. However, bacterial P450 eryF belongs to the class I P450s 
which have different redox partner systems than the class II P450s to which the human drug 
metabolising P450s belong. For this reason, bacterial P450 BM3, which has a class II-type 
redox system, may be considered a more appropriate model for the mammalian P450s [8]. 
In contrast to its closely related homologues CYP102A2 and CYP102A3 from Bacillus subtilis, 
nonhyperbolic enzyme kinetics has not yet been reported for the well-studied P450 BM3 
[21].
In this study, we characterised the P450 BM3 triple mutant R47L/F87V/L188Q with respect to 
metabolism of testosterone and the drugs acetaminophen, dextromethorphan, amodiaquine 
and 3,4-methylenedioxymethylamphetamine (MDMA) (Figure 1). Because these substrates 
are known to be metabolised by mammalian P450s to multiple metabolites these compounds 
are very suitable as diagnostic substrates, because the metabolite proﬁles obtained give 
valuable information on the differences in substrate orientation between mutants [21, 22]. To 
investigate whether heterotropic cooperativity in the presence of an effector molecule could 
be observed for the P450 BM3 triple mutant, similar to what has been described for the P450 
Figure 1: Chemical structures of the compounds used in this study. A: amodiaquine; B: dextromethorphan; 
C: MDMA; D: acetaminophen; E: testosterone. Known sites of metabolism are indicated by arrows, and for 
acetaminophen, the structure of the metabolite NAPQI is also displayed.
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3A family, two compounds that are known activators of the P450 3A family, α-naphtoﬂavone 
(α-NF) and caffeine [23], were tested for their ability to inﬂuence the reaction rates and 
product distribution.
Materials and Methods
Chemicals
The plasmid pT1-P450BM3 containing the wild-type P450 BM3 cDNA under control of the 
temperature-inducible PRPL promoter was a kind gift from R. D. Schmid (Institut für Technische 
Biochemie, Universität Stuttgart). The construction of the triple mutant of P450 BM3 was 
described earlier [14]. Expression and isolation of P450 BM3 and P450 BM3 R47L/F87V/L188Q 
was performed as described previously [14]. BD Supersomes, containing P450 1A1 with human 
NADPH P450 reductase, and P450 2C8 with human NADPH P450 reductase and cytochrome 
b5, were obtained from BD Gentest. The plasmids pCWh3A4 and pLCMhOR containing P450 
3A4 and human NADPH P450 reductase, respectively, were a kind gift from M. Kranendonk 
(Department of Genetics, Faculty of Medical Sciences, Universidade Nova de Lisboa, Portugal) 
and were expressed as described earlier [24]. All chemicals were of analytical grade and 
obtained from standard suppliers.
Metabolism of drug-like compounds by P450 BM3 and P450 BM3 R47L/F87V/L188Q
Although it was reported previously that 50 µM amodiaquine did not signiﬁcantly inhibit 
benzyloxyresoruﬁn O-dealkylation (BROD) activity of the P450 BM3 triple mutant [14], 
at 500 µM signiﬁcant inhibition (40%; data not shown) was observed. Therefore, in this 
paper metabolism was studied at a substrate concentration of 500 µM. The amodiaquine 
incubations were performed in 100 mM potassium phosphate (KPi) buffer pH 7.4, with E. 
coli cytosolic fraction containing 500 nM P450 BM3 wild-type or R47L/F87V/L188Q. The ﬁnal 
volume of the incubation was 250 µl.
The reaction was initiated by addition of an NADPH regenerating system resulting in ﬁnal 
concentrations of 0.2 mM NADPH, 0.3 mM glucose-6-phosphate and 0.4 units/ml glucose-6-
phosphate dehydrogenase. The reaction was allowed to proceed for 45 minutes at 24 °C before 
it was terminated by the addition of 25 µl of a 10% (v/v) HClO4 solution. Precipitated protein 
was removed by centrifugation (15 minutes, 4000 g), and the supernatant was analysed 
by HPLC. Metabolites were separated using a C18 column (Phenomenex Luna 5µ, 150 × 4.6 
mm), using the following gradient: 0-2 minutes 0% B; 2-24 minutes increase to 15% B; 24-27 
minutes 15% B; 27-28 minutes decrease to 0% B; 28-35 minutes 0% B. Eluens A consisted of 
5% acetonitril, 10 mM ammonium acetate and 0.3% (v/v) formic acid, and eluens B consisted 
of 90% acetonitril, 10 mM ammonium acetate and 0.3% (v/v) formic acid. The ﬂow rate was 
0.6 ml/minute. Metabolites were detected with a UV detector at 254 nm and with MS. An 
LCQ Deca mass spectrometer (Thermo Finnigan) was used, with positive ion Electro Spray 
Ionisation (ESI). The vaporiser temperature was 450 °C, N2 was used as sheath gas (60 psi) and 
auxiliary gas (20 psi), the needle voltage was 5000 V and the heated capillary was at 200 °C.
The dextromethorphan incubations were performed as described for amodiaquine. 
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Metabolites were separated using a C18 column (Phenomenex Luna 5µ, 150 × 4.6 mm) 
with a ﬂow rate of 0.6 ml/minute. The mobile phase consisted of 30% acetonitril with 0.1% 
triethylamine, set to pH 3.0 with HClO4. Metabolites were detected with a ﬂuorescence 
detector (λexcitation= 280 nm and λemission= 311 nm), and also with LC-MS as described in [22].
The testosterone incubations were performed as described for amodiaquine. The ﬁnal volume 
of the incubation was 500 µl. After 45 minutes of incubation, the sample was extracted with 
3 ml CH2Cl2. The organic layer was evaporated under nitrogen gas, and the metabolites were 
taken up in 250 µl 42% methanol. Metabolites were analysed by HPLC using a C18 column 
(100 x 3 mm, 5µ, Chromspher Chrompack). Metabolites were eluted using the following 
gradient: 0-5 minutes 20% B; 5-25 minutes increase to 50% B; 25-27 minutes 50% B; 27-28 
minutes decrease to 20% B; 28-35 minutes 20% B. Eluens A consisted of 15% methanol and 
500 mM ammonium acetate, and eluens B consisted of 99% methanol. The ﬂow rate was 
0.6 ml/minute. Metabolites were detected with a UV detector at 254 nm and with MS. An 
LCQ Deca mass spectrometer (Thermo Finnigan) was used, with positive ion Atmospheric 
Pressure Chemical Ionisation (APCI). The vaporiser temperature was 450 °C, N2 was used as 
sheath gas (20 psi) and auxiliary gas (20 psi), the needle voltage was 6000 V and the heated 
capillary was at 200 °C.
For MDMA, incubations were performed as described for amodiaquine, but with 2 mM NADPH 
instead of an NADPH regenerating system. Metabolites were separated using a C18 column 
(Phenomenex Luna 5µ, 150 × 4.6 mm) with a ﬂow rate of 0.6 ml/minute. The mobile phase 
consisted of 20% acetonitril and 0.1% triethylamine, set to pH 3.0 using HClO. Metabolites 
were detected with a ﬂuorescence detector (λexcitation= 280 nm and λemission= 320 nm). 
For acetaminophen, incubations were performed as described for MDMA. Because the 
metabolite N-acetyl-p-benzoquinoneimine (NAPQI) is very reactive, 5 mM reduced glutathione 
(GSH) was added to form a stable NAPQI-SG conjugate. The acetaminophen incubation was 
separated using a C18 column (Phenomenex Luna 5µ, 150 × 4.6 mm) with a ﬂow rate of 0.5 ml/
minute. The gradient used was as follows: 0-5 minutes 0% B; 5-32 minutes increase to 68% B; 
32-33 minutes increase to 100% B; 33-34 minutes 100% B; 34-35 minutes decrease to 0% B; 35-
40 minutes 0% B. Eluens A consisted of 20 mM ammonium acetate, set to pH 6.0 with acetic 
acid. Eluens B was composed of 20 mM ammonium acetate and 50% acetonitril, set to pH 6.0 
with acetic acid. Metabolites were detected with a UV detector at 254 nm. 
To test if all three mutations in the triple mutant are required for activity, the incubations 
with testosterone and MDMA were also performed with the single mutants R47L, F87V 
and L188Q, and the double mutants R47L/F87V, R47L/L188Q and F87V/L188Q. For metabolite 
identiﬁcation and comparison, incubations with various human P450s were performed for 
all substrates as described above, with 50 nM P450, 500 µM substrate, and an incubation 
time of 20 minutes at 37 °C. The human P450s used were heterologously expressed P450 2D6 
and P450 2D6[F120A], cultured as described previously [22], and heterologously expressed 
P450 3A4 as described in [24], and P450 1A1 and 2C8 in BD Supersomes (Gentest). The BD 
Supersomes contained P450 and human NADPH P450 reductase, and in the case of P450 
2C8 also Cytochrome b5. P450 2D6, P450 2D6[F120A] and P450 3A4 were all co-expressed with 
human NADPH P450 reductase.
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Determination of kinetic parameters
First, the ranges were determined where the enzyme activity is linear with enzyme 
concentration and incubation time. Based on these experiments (data not shown), the 
suitable conditions were chosen for determination of the kinetic parameters. For MDMA, 
the enzyme concentration was 200 nM and the incubation time was 45 minutes, and 9 
substrate concentrations were used in the range of 0-4 mM. For acetaminophen, the enzyme 
concentration was 200 nM and the incubation time was 45 minutes, and 9 substrate 
concentrations were used in the range of 0-6 mM. For testosterone the enzyme concentration 
was 240 nM and the incubation time was 45 minutes, and 11 substrate concentrations were 
used in the range of 0-600 μM. Additionally, enzyme kinetic parameters were determined 
for the three steroids progesterone, androstenedione and nandrolone. For progesterone the 
incubations were carried out as described for testosterone, with the following modiﬁcations: 
480 nM P450 BM3 R47L/F87V/L188Q was used; progesterone concentrations were in the range 
of 0-500 μM (11 concentrations); incubation times were 30 minutes. The HPLC gradient was as 
follows: 0-5 minutes 0% B; 5-29 minutes increase to 80% B; 29-30 minutes decrease to 0% B; 
30-35 minutes 0% B. For nandrolone and androstenedione the incubations were carried out 
as described for testosterone, with the following modiﬁcations: 200 nM P450 BM3 R47L/F87V/
L188Q was used; substrate concentrations were in the range of 0-500 μM (11 concentrations); 
incubation times were 20 minutes. The HPLC gradient was as follows: 0-2 minutes 5% B; 2-22 
minutes increase to 50% B; 22-23 minutes increase to 100% B; 23-25 minutes 100% B; 25-26 
minutes decrease to 5% B; 26-30 minutes 5% B.
Peak areas of all the metabolites were determined using the Shimadzu Class VP 4.3 software 
package. Formation of the MDMA metabolite 3,4-methylenedioxyamphetamine (MDA) was 
quantiﬁed using a synthesised reference compound [22]. N-hydroxy-3,4-methylenedioxy-
methylamphetamine (N-OH-MDMA) was quantiﬁed using the MDA standard curve, 
assuming that the ﬂuorescence of MDA and N-OH-MDMA are comparable. NAPQI-SG 
was quantiﬁed using a standard curve of acetaminophen, assuming that the extinction 
coefﬁcients of acetaminophen and NAPQI-SG are comparable. The steroid metabolites were 
quantiﬁed using a standard curve of the parent compounds, assuming that the extinction 
coefﬁcients of the parent compounds and their metabolites are comparable. Reaction rates 
were calculated and plotted against the substrate concentrations. The data of MDMA and 
acetaminophen were ﬁtted with the Michaelis Menten equation in GraphPad Prism 4.0 to 
obtain the kinetic parameters Km and Vmax. For the steroids, the V/[S] curves were sigmoidal 
rather than hyperbolic, therefore the data were ﬁtted with the Hill equation: V= Vmax × Sn / 
(K0.5
n + Sn) where V is the reaction rate, S is the substrate concentration, K0.5 is the substrate 
concentration that gives a velocity of 0.5 × Vmax, and n is the Hill coefﬁcient.
Activation of P450 BM3 R47L/F87V/L188Q activity by caffeine and α-naphtoflavone
To study heterotropic cooperativity, the known P450 3A activators caffeine (5 mM) or α-NF 
(50 µM) were added to various incubations with wild-type P450 BM3 and P450 BM3 R47L/
F87V/L188Q. The incubations were performed as described above. For acetaminophen and 
MDMA, 1 mM substrate was used, for testosterone, 100 µM substrate was used, and for 
dextromethorphan and amodiaquine, 500 µM substrate was used.
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For MDMA and acetaminophen, the caffeine concentration dependence of the activation was 
studied by varying the caffeine concentration from 0 to 10 mM (6 concentrations). Enzyme 
kinetic parameters were subsequently determined in the presence of caffeine. For MDMA, 5 
mM caffeine was used, and for acetaminophen 9 mM caffeine.
Results
Metabolism of drug-like compounds by P450 BM3 and P450 BM3 R47L/F87V/L188Q
Wild-type P450 BM3 did not metabolise any of the drug-like compounds tested. In contrast, 
the triple mutant metabolised all compounds studied. P450 BM3 R47L/F87V/L188Q converted 
amodiaquine into two metabolites (Figure 2A). The ﬁrst metabolite had a retention time (tr) of 
10.1 minutes, and the second metabolite had a tr of 12.5 minutes To identify these metabolites, 
incubations with P450 1A1, 2C8 and 2D6 were performed, which are known to N-desethylate 
amodiaquine [25]. The metabolite of tr= 12.5 minutes was formed by P450 1A1, P450 2C8 and 
P450 2D6 and could thus be identiﬁed as N-desethylamodiaquine. This was conﬁrmed by 
MS (m/z 328; MS/MS m/z 283). N-desethylamodiaquine was formed with the highest speciﬁc 
activity by P450 2C8, which was 125 times higher than that of P450 BM3 R47L/F87V/L188Q 
(Table 1). The metabolite of tr= 10.1 minutes was not formed by P450 1A1, P450 2C8 and P450 
2D6; it was identiﬁed by MS as a mono-hydroxylated metabolite (m/z 372; MS/MS m/z 299).
Figure 2: HPLC chromatograms of P450 BM3 wild-type (black line) and P450 BM3 R47L/F87V/L188Q (grey 
line) incubations with amodiaquine (A), dextromethorphan (B), testosterone (C) and MDMA (D). For all 
substrates, the chromatograms of the incubations with P450 BM3 wild-type were identical to those of the 
t=0 minutes control incubations (not shown), indicating that no metabolism took place. In the incubations 
with P450 BM3 R47L/F87V/L188Q, several metabolites were formed for all substrates (indicated by their 
names and by retention times).
tr= 12.5
OH-amodiaquine
tr= 10.1
tr= 16.5
OH-testosterone
  tr= 10.0
OH-testosterone
tr= 16.1
OH-testosterone
tr= 19.1
tr= 3.8
tr= 8.8
tr= 17.2
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Dextromethorphan was N-demethylated by the P450 BM3 triple mutant to form 3-
methoxymorphinan (Figure 2B). This metabolite was identiﬁed by LC-MS as described previously 
(m/z 258; MS/MS m/z 215) [22]. The speciﬁc activity of dextromethorphan N-demethylation by 
the P450 BM3 triple mutant was 12.5-fold lower than that of P450 2D6 (Table 1).
Testosterone was metabolised by P450 BM3 R47L/F87V/L188Q to three metabolites (Figure 
2C). The major metabolite had a tr of 10.0 minutes, the second highest metabolite had a tr 
of 16.1 minutes and the third metabolite had a tr of 19.1 minutes. All three metabolites were 
identiﬁed by LC-MS as monohydroxylated metabolites (m/z 305). In addition, trace amounts 
of a dihydroxylated metabolite (m/z 321) at tr= 2.6 minutes were observed with MS. The 
metabolite at tr= 16.1 minutes co-eluted with a reference standard of 16β-hydroxytestosterone. 
Of the double and single mutants, only the two double mutants F87V/L188Q and R47L/F87V 
showed metabolism of testosterone. The same metabolites were formed as by the triple 
mutant, but the amounts were 4- and 10-fold lower, respectively (data not shown). P450 
3A4 is known to form mainly 6β-hydroxytestosterone. Comparison of incubations with P450 
3A4 and P450 BM3 R47L/F87V/L188Q showed that the P450 BM3 triple mutant does not form 
6β-hydroxytestosterone. The speciﬁc activity of the formation of the metabolite tr= 10.0 by 
P450 BM3 R47L/F87V/L188Q was approximately 2-fold higher than the speciﬁc activity of 
testosterone 6β-hydroxylation by P450 3A4, assuming that the extinction coefﬁcient of both 
metabolites is similar (Table 1). 
MDMA was metabolised by P450 BM3 R47L/F87V/L188Q to three metabolites (Figure 2D). The 
major metabolite had a tr of 8.8 minutes and was identiﬁed as MDA by coinjection with a 
reference standard. The second metabolite, with tr= 17.2 minutes, was identiﬁed as N-OH- 
MDMA by coinjection with a reference standard [22]. The minor metabolite with tr= 3.8 
Substrate 
(metabolite)
P450 BM3
R47L/F87V/L188Q
P450 2D6 P450 3A4 P450 1A1 P450 2C8
Amodiaquine 
(desethyl)
100% 2631% 1953% 12752%
Dextromethorphan 
(N-demethyl)
100% 1250%
Testosterone (tr 10.0) 100% 45%
MDMA (3,4-OH-MA) 100% 3682%
acetaminophen 
(NAPQI)
100% 1500%
Values are in % product formation/min/nmol enzyme relative to incubations with P450 BM3 R47L/
F87V/L188Q. For amodiaquine, N-desethylamodiaquine was compared with N-desethylamodiaquine 
formed by P450 1A1, 2C8 and 2D6. For dextromethorphan, 3-methoxymorphinan was compared with 3-
methoxymorphinan formed by P450 2D6. For testosterone, the major metabolite was compared with 6β-
hydroxytestosterone formed by P450 3A4. For MDMA, 3,4-OH-MA was compared with 3,4-OH-MA formed 
by P450 2D6. For acetaminophen, NAPQI formation was compared with P450 3A4.
Table 1: Activity of P450 BM3 R47L/F87V/L188Q compared to several human P450s.
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minutes was identiﬁed previously as 3,4-dihydroxy-methylamphetamine (3,4-OH-MA) using 
electrochemical detection [22]. Comparison with an incubation with P450 2D6 showed that 
the speciﬁc activity of 3,4-OH-MA formation by P450 BM3 R47L/F87V/L188Q was 35-fold lower 
than that of P450 2D6 (Table 1). Of the double and single mutants, only the double mutant 
F87V/L188Q was able to metabolise MDMA. The amount of metabolite formed was so low 
that only MDA was detectable (data not shown).
Acetaminophen was metabolised by P450 BM3 R47L/F87V/L188Q to one metabolite with a tr 
of 17.5 minutes (Figure 3). This peak was identiﬁed as the NAPQI-SG conjugate by coinjection 
with a reference standard synthesised as described [26, 27]. The speciﬁc activity of NAPQI 
formation by P450 BM3 R47L/F87V/L188Q was approximately 15-fold lower than that of P450 
3A4 (Table 1).
Figure 3: HPLC chromatograms of P450 BM3 wild-type and P450 BM3 R47L/F87V/L188Q incubations with 
acetaminophen. Black line: wild-type P450 BM3. Dark grey line: P450 BM3 R47L/F87V/L188Q. Light grey line: 
P450 BM3 R47L/F87V/L188Q with 5 mM caffeine. The NAPQI-SG peak is indicated in the chromatogram.
15 20
without caffeine with caffeine
substrate (product) Vmax Km Vmax/Km Vmax Km Vmax/Km
MDMA (MDA) - - 0.35 ± 0.01 1.3 ± 0.3 0.85 ± 0.13 1.5 ± 0.4
MDMA (N-OH) - - 0.14 ± 0.02 0.46 ± 0.05 0.71 ± 0.1 0.65 ± 0.1
acetaminophen (NAPQI) - - 0.05 ± 0.01 7.3 ± 0.1 2.1 ± 0.1 3.5 ± 0.2
Data are for MDA and N-OH-MDMA formation from MDMA, and NAPQI formation from acetaminophen. 
All values are the means of at least 3 independent experiments performed on separate days ± S.D. Because 
in the absence of caffeine no saturation of enzyme activity was observed, Km and Vmax values could not be 
determined; instead, the slope of the V/[S] curve was used to determine the catalytic efﬁciency Vmax/Km. 
Vmax values are expressed in nmol product/minute/nmol enzyme; Km values are expressed in mM.
Table 2: Kinetic parameters of MDMA and acetaminophen metabolism by P450 BM3 R47L/F87V/L188Q in 
the presence and absence of caffeine.
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Determination of kinetic parameters
For MDMA metabolism, the 3,4-OH-MA peak was too small to determine accurate kinetic 
parameters. No saturated V/[S] curve could be obtained for MDA- and N-OH-MDMA formation 
with the substrate concentration range used for this experiment (Figure 4). Therefore, the 
slope of the linear part of the V/[S] plot was used to determine the catalytic efﬁciency Vmax/Km 
(Table 2). Compared to MDA formation by P450 2D6[F120A], the catalytic efﬁciency of P450 
BM3 R47L/F87V/L188Q was approximately 700-fold lower [28].
For acetaminophen metabolism, also no saturated V/[S] curve could be obtained for NAPQI 
formation with the substrate concentration range used for this experiment (Figure 4). The 
catalytic efﬁciency Vmax/Km was determined using the slope of the linear part of the V/[S] plot 
(Table 2). From Figure 4 it can be concluded that the Km value is >> 2 mM. In literature, Km values 
of 300 µM have been described for P450 3A4, and of 1 mM and 3 mM for P450 2E1 and P450 1A2, 
respectively [29]. Vmax values could not be compared, because in reference [29] the amount of 
P450 in the incubations was not quantiﬁed.
For testosterone, V/[S] curves were constructed for all three mono-hydroxylated metabolites. 
All curves were sigmoidal, which suggests the occurrence of positive homotropic cooperativity. 
This was conﬁrmed by the Hill coefﬁcients (Table 3). If the Hill coefﬁcient n= 1, Michaelis 
Menten kinetics apply, whereas with n > 1 or n < 1 positive or negative cooperativity applies, 
respectively. For all the mono-hydroxylated testosterone metabolites formed by P450 BM3 
R47L/F87V/L188Q, a Hill coefﬁcient of 1.7 was found, indicating that positive cooperativity 
occurs. This has also been observed previously for testosterone 6β-hydroxylation by human 
P450 3A4 [30]. In addition to testosterone, the three steroids androstenedione, nandrolone 
and progesterone were also investigated. The kinetic parameters and the retention times of 
the metabolites of all four steroids are summarised in Table 3, and a V/[S] curve of the major 
metabolite is shown in Figure 5. Homotropic cooperativity was observed for all steroids. 
Figure 4: V/[S] curves of MDMA and acetaminophen metabolism by P450 BM3 R47L/F87V/L188Q. For MDA 
formation from MDMA (left) and NAPQI formation from acetaminophen (right), V/[S] curves obtained in 
the absence (squares) and presence (triangles) of caffeine are ﬁtted with the Michaelis Menten equation. A 
zoom-in of the acetaminophen graph is displayed in the inset.
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Substrate (retention time 
of metabolite)
K0.5 (µM) Vmax 
(nmol/min/nmol)
Vmax/Km
(x 103)
n LC-MS
androstenedione (tr 19.7) 136.0 ± 31.7 40.5 ± 6.2 297.8 ± 83.0 1.4 ± 0.2 mono-OH
androstenedione (tr 21.9) 216.0 ± 68.5 2.0 ± 0.3 9.3 ± 3.2 1.6 ± 0.1 mono-OH
androstenedione (tr 15.3) 139.5 ± 29.1 0.6 ± 0.1 4.3 ± 1.1 2.2 ± 0.6 di-OH
androstenedione (tr 17.7) 224.7 ± 56.6 0.13 ± 0.01 0.6 ± 0.2 1.5 ± 0.2 mono-OH
nandrolone (tr 16.4) 252.0 ± 18.1 25.6 ± 0.6 101.6 ± 7.7 1.7 ± 0.2 mono-OH
nandrolone (tr 20.2) 253.0 ± 8.7 10.9 ± 1.0 43.1 ± 4.2 1.6 ± 0.3 mono-OH
nandrolone (tr 21.8) 270.3 ± 23.4 2.1 ± 0.1 7.8 ± 0.8 1.8 ± 0.2 mono-OH
progesterone (tr 27.6) 43.9 ± 12.8 4.6 ± 0.5 104.8 ± 32.6 1.9 ± 0.3 mono-OH
progesterone (tr 29.6) 51.9 ± 11.6 1.0 ± 0.2 19.3 ± 5.8 2.1 ± 0.3 mono-OH
progesterone (tr 18.9) -
a -a -a -a di-OH
testosterone (tr 10.0) 85.9 ± 15.2 4.5 ± 1.2 52.4 ± 17.2 1.7 ± 0.3 mono-OH
testosterone (tr 16.1) 103.6 ± 11 1.4 ± 0.4 13.5 ± 4.1 1.7 ± 0.2 mono-OH
testosterone (tr 19.1) 92.0 ± 5.2 0.4 ± 0.1 4.3 ± 1.1 1.7 ± 0.2 mono-OH
testosterone (tr 2.6) -
a -a -a -a di-OH
All values are the means of at least 3 independent experiments performed on separate days ± S.D. All 
data were ﬁtted with the Hill equation. K0.5 values are in µM. Vmax values are nmol product/minute/nmol 
enzyme. –a: metabolite only present in trace amounts, no kinetic parameters could be determined.
Table 3: Kinetic parameters of steroid metabolism by P450 BM3 R47L/F87V/L188Q.
Table 4: Effect of α-NF and caffeine on the metabolism of drug-like compounds by P450 BM3.  
Substrate (concentration) control + α-NF (50 µM) + caffeine (5 mM)
Amodiaquine (500 µM) 100% 65% 104%
Testosterone (100 µM) 100% 40% 55%
Dextromethorphan (500 µM) 100% 70% 250%
MDMA (1 mM) 100% 102% 213%
acetaminophen P450 BM3 (1 mM) 100% 104% 2039%
acetaminophen P450 3A4 (1 mM) 100% 150% 280%
Values are in % product formation relative to incubations without activator. Only the data for the major 
metabolites are displayed. The other metabolites were similarly affected. 
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Three monohydroxylated and one dihydroxylated metabolites were formed from 
androstenedione, three monohydroxylated metabolites were observed for nandrolone, and 
two monohydroxylated and one dihydroxylated metabolites were identiﬁed for progesterone. 
Androstenedione was converted with the highest activity, approximately 10-fold higher than 
testosterone.
Activation of P450 BM3 R47L/F87V/L188Q activity by caffeine and α-naphtoflavone
To investigate whether heterotropic cooperativity occurs in P450 BM3, two known activators 
of P450 3A, α-naphtoﬂavone (α-NF) and caffeine, were tested. Single concentrations of these 
activators (derived from reference [23]) were added to incubations with amodiaquine, 
dextromethorphan, testosterone, acetaminophen and MDMA. Wild-type P450 BM3 did not 
metabolise any of the substrates in the absence or presence of activator. For P450 BM3 R47L/
F87V/L188Q, amodiaquine metabolism was not inﬂuenced by the presence of caffeine, but 
α-NF inhibited the product formation to 65% (Table 4). Dextromethorphan metabolism was 
slightly inhibited by α-NF, whereas caffeine stimulated 3-methoxymorphinan formation 2.5–
fold. Testosterone metabolism was inhibited to approximately 50% by both caffeine and α-
NF; all peaks were inhibited to the same extent. For acetaminophen and MDMA metabolism, 
α-NF did not have a signiﬁcant effect on the amount of product formed. However, in the 
Figure 5: V/[S] curves of the major metabolites of androstenedione (A), nandrolone (B), progesterone (C) 
and testosterone (D) formed by P450 BM3 R47L/F87V/L188Q. The sigmoidal V/[S] curves were ﬁtted with the 
Hill equation. In the insets, a Hill plot is displayed (Log[V/(Vmax-V)] vs Log[S]).
A B
C D
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presence of caffeine a signiﬁcant increase in speciﬁc activity was observed. For MDMA, the 
speciﬁc activity increased 2-fold for all three metabolites, and for acetaminophen a dramatic 
increase of a factor 20 was observed (Figure 3). Acetaminophen metabolism by hP450 3A4 was 
activated to 150% by α-NF, and to 280% by caffeine (Table 4).
The activation of acetaminophen and MDMA metabolism by P450 BM3 R47L/F87V/L188Q in the 
presence of caffeine was investigated further. Varying the caffeine concentration showed that 
maximal activation occurred at 5 mM for MDMA and at 9 mM for acetaminophen (data not 
shown). To determine the effect of this activator on Km and Vmax values, the kinetic parameters 
for acetaminophen and MDMA metabolism were determined in the presence of 9 or 5 mM 
caffeine, respectively. In the presence of caffeine, enzyme saturation did take place for both 
substrates within the substrate range used (Figure 4), and the data could be ﬁtted with the 
Michaelis Menten equation. Kinetic parameters Km and Vmax could be determined (Table 2). For 
MDMA, the presence of caffeine increased the catalytic efﬁciency Vmax/Km approximately 4-
fold for MDA- and N-OH-MDMA formation. The Vmax value for MDA formation was only 2.7-fold 
lower than that of MDA formation by P450 2D6[F120A] [28]. For acetaminophen, the presence 
of caffeine dramatically increased the catalytic efﬁciency Vmax/Km of NAPQI formation 70-fold. 
In comparison, a 2- to 10-fold increase in catalytic efﬁciency is usually observed for activation 
of P450 3A by α-NF or caffeine [23, 31].
Caffeine itself was not metabolised by P450 BM3 R47L/F87V/L188Q in either the absence or 
presence of acetaminophen or MDMA (data not shown).
Discussion
Although the limited substrate diversity of bacterial P450s has been mentioned previously as 
a major disadvantage for its use as a biocatalyst for the production of pharmaceuticals [9], the 
present study demonstrates that several drug-like compounds were readily metabolised by 
P450 BM3 R47L/F87V/188Q. Enzyme kinetics analysis of this drug metabolising triple mutant 
of P450 BM3 revealed positive homotropic cooperativity with testosterone as substrate, with 
a Hill coefﬁcient of 1.7. With three other steroids, similar behaviour was observed. For the 
other substrates tested hyperbolic kinetic curves were observed. Similar behaviour has been 
described for P450 3A4 [30]. In addition, strong heterotropic cooperativity was shown to occur 
in the presence of caffeine. The speciﬁc activity of acetaminophen metabolism increased 70-
fold, which is much higher than the 2- to 10-fold activation described in literature for P450 
3A. Furthermore, addition of caffeine strongly increased afﬁnity towards MDMA. In contrast, 
the P450 3A activator α–NF does not act as an activator for P450 BM3 R47L/F87V/L188Q. α–NF 
does not inﬂuence acetaminophen and MDMA metabolism, while it inhibits the metabolism 
of the other substrates (Table 4). The latter implies that α–NF is able to bind to P450 BM3 R47L/
F87V/L188Q, and it remains to be investigated whether it can also be metabolised. 
A possible explanation for the stimulation of P450 BM3 R47L/F87V/L188Q activity by caffeine 
could be that caffeine binds in the active site and forces the substrates into an orientation 
that results in increased metabolism by reducing the substrate mobility. However, for MDMA 
metabolism, the metabolite ratio is not inﬂuenced by the addition of caffeine. This implies 
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that all the orientations required for the formation of the three metabolites are still possible 
and the substrate is still mobile. Alternatively, it is possible that caffeine binds to an allosteric 
site of the protein, resulting in a conformational change in the active site with an increased 
binding afﬁnity for the substrate [32, 33]. The observed activation is substrate dependent, 
caffeine did not increase the metabolism of some of the substrates tested. Activation of P450 
3A4 is also known to be substrate dependent: some compounds activate the metabolism of 
one substrate, but inhibit the metabolism of another substrate [34]. 
The fact that the P450 BM3 triple mutant displays homotropic and heterotropic cooperativity 
suggests that multiple substrate molecules can bind to this triple mutant simultaneously, 
possibly to multiple binding sites with distinct characteristics. P450 BM3 is easier to study 
than mammalian P450s, because it is a soluble protein with higher stability and activity. It 
can be used as a model to increase our understanding of the mechanisms of atypical kinetics 
in mammalian P450s. We also propose a perspective for the use of heterotropic cooperativity 
in biotechnology: instead of mutagenesis of the enzyme, the presence of a second ligand 
could be used to increase the reaction rate or alter the product distribution of an enzymatic 
reaction to make it more suitable for biocatalysis. Cases have been reported where the 
presence of a second ligand in the active site of a P450 not only enhanced the amount of 
metabolite produced by increasing the reaction rate and binding afﬁnity, but also altered the 
product distribution of the reaction [17, 35]. Together with mutagenesis techniques, this type 
of allosteric kinetics can be employed as a novel tool in the further development of P450 BM3 
as a fast and clean catalyst for biotechnology.
P450 BM3 has a high potential for the use in biotechnology, because it is a highly active, stable, 
single-component enzyme that can be easily engineered to convert a wide variety of substrates 
into (therapeutically) useful products. In this study it was shown that a mutant of P450 BM3 
can be used to produce various metabolites from several different drug-like compounds. In 
addition to C-hydroxylation (steroids), also N-hydroxylation (MDMA), N-dealkylation (MDMA, 
dextromethorphan, amodiaquine), O-demethylenation (MDMA) and dehydrogenation 
(acetaminophen) were observed. The rate of testosterone hydroxylation, and acetaminophen 
dehydrogenation in the presence of caffeine, by the P450 BM3 triple mutant is similar to 
the reaction rate of P450 3A4. However, the activity of the P450 BM3 triple mutant towards 
MDMA, amodiaquine and dextromethorphan is still 20 to 125-fold lower than the activity of 
mammalian P450s, which leaves room for improvement. This triple mutant will be used as the 
starting point for random mutagenesis, to obtain series of P450 BM3 mutants with further 
improved ability to convert a wide variety of drug-like compounds with higher activities. Such 
mutants can prove very useful in drug-discovery and drug synthesis.
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Abstract
Previously, we’ve described a site-directed triple mutant of cytochrome P450 BM3 (P450 BM3) 
that is able to convert various drugs [1]. In the present study random mutagenesis was used 
to improve the activity of this mutant. With three generations of error-prone PCR, mutants 
were obtained with 200-fold increased turnover towards drug substrates dextromethorphan 
and 3,4-methylenedioxymethylamphetamine. The initial activities of these mutants were up 
to 90-fold higher than of human P450 2D6. These highly active drug metabolising enzymes 
have great potential for biotechnology. Using sequencing analysis, the mutations responsible 
for the increase in activity were determined. The mutations that had the greatest effects 
on the activity were F81I, E267V and particularly L86I, which is not located in the active site. 
Computer modeling studies were used to rationalise the effects of the mutations. This 
study shows that random mutagenesis can be used to identify novel critical residues, and to 
increase our insight in P450s.
Introduction
Cytochromes P450 (P450s) are involved in the metabolism of most drugs currently on the 
market [2]. Because of their broad substrate range and catalytic diversity, there is an increasing 
interest to use P450s in biotechnology, for example for the production of pharmaceuticals or 
the optimisation of lead compounds and existing drugs [3, 4]. Some disadvantages of the 
use of the membrane-bound human drug metabolising P450s are their low expression levels 
and stability, the requirement of a redox partner, and their generally low catalytic activities 
[5, 6]. The soluble Cytochrome P450 BM3 (P450 BM3) from Bacillus megaterium [7] would 
be a good candidate for use as a biocatalyst in pharmaceutical industry. In P450 BM3, the 
reductase domain is fused to its catalytic heme domain, so no co-expression of a separate 
redox partner is required. Furthermore, this enzyme has the highest catalytic activity ever 
recorded for a P450, is easily overexpressed in E. coli, and has a high stability [5]. Although the 
natural substrates of P450 BM3 are fatty acids, it can be easily manipulated by mutagenesis 
to obtain enzymes that are able to convert a wide variety of non-natural substrates such as 
indol, alkanes and propranolol [8-10]. Recently, we described a site-directed triple mutant 
of P450 BM3, R47L/F87V/L188Q, that is able to convert various drug-like compounds [1]. The 
catalytic activity of this mutant, however, was still up to 125-fold lower than that of human 
P450s. In the present study we used random mutagenesis to improve the catalytic activity of 
the triple mutant. Libraries of random mutants were generated using error-prone PCR, and 
mutants with improved activity were selected using a whole-cell ﬂuorescent screening assay 
with various alkoxyresoruﬁns [11]. In addition, an LC-MS based whole-cell screening assay 
to measure dextromethorphan metabolism was developed. Computer modeling studies 
were used to rationalise the strongly increased enzyme activities observed with some of the 
obtained mutants.
Materials and Methods
Random mutagenesis
The triple mutant of P450 BM3 was constructed in the plasmid pT1-P450BM3 and transformed 
into E. coli DH5α cells as described earlier [11]. Libraries of random mutants were constructed 
using error-prone PCR. To enable cloning of the heme domain, a SacI restriction site was 
constructed 130 bp upstream of C-terminus of the heme domain by introducing a silent 
mutation in residue L431, as described in [12]. The PCR was carried out in a 50 µl reaction mixture 
containing template plasmid (5 ng), forward primer (5’-CACAGGAACCGGATCCCATGACAATTAA
AGAA-3’, N-terminal BamHI site bold italic) and reverse primer (5’-GTGAAGGAATACCGCCAA-
3’) (20 pmol each), dATP and dGTP (0.2 mM each), dCTP and dTTP (1 mM each), MgCl2 (7 mM), 
NOVEL DRUG METABOLISING MUTANTS OF P450 BM3
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10x Taq polymerase buffer (5 µl) and Taq polymerase (5 units). The PCR was performed in a 
thermocycler for 30 cycles (95 °C, 45 s; 50 °C, 30 s; 72 °C, 60 s). The PCR product was digested with 
BamHI and SacI, and ligated into the pT1 expression vector digested with the same restriction 
enzymes. The resulting plasmid was transformed into lipopolysaccharide defective (LPSd) E. 
coli DH5α cells as described previously [11].
The QuikChange Site-Directed mutagenesis kit (Stratagene) was used to introduce the 
mutations L86I, E267V and N319T into the triple mutant R47L/F87V/L188Q. Sequences of 
the forward primers, with the altered residues in bold italic, were as follows: L86I 5’-GCAG
GAGACGGGATAGTAACAAGCTGGACG-3’; E267V 5-’TAATTGCGGGACACGTAACAACAAGTGGT-3’; 
N319T 5’-ATGTCGGCATGGTCTTAACCGAAGCGCTGC-3’. The reverse primers used were the exact 
complements of the forward primers. DNA sequencing was performed to conﬁrm the 
presence of the desired mutations.
Expression of P450 BM3 mutants
Colonies with random mutants of P450 BM3 were picked from agar plates and transferred 
to 96-wells plates containing 200 µl/well of LB medium supplemented with 50 µg/ml 
ampicillin. As a control, four wells were inoculated with cells containing the plasmid with 
the non-mutated parent DNA. Cells were grown overnight at 37 °C and 650 rpm in a wells 
plate shaking incubator (Denley Vortemp, Thermo Electron). After overnight growth, 20 µl of 
cell suspension were transferred to a 96-wells plate containing 180 µl/well TB medium (24 g/
L yeast extract, 12 g/L tryptone, 4 ml/L glycerol) with additives (1 mM δ-aminolevulinic acid, 
400 µl/L trace elements [13], 0.5 mM thiamine, 50 µg/ml ampicillin). Cells were grown for 3 
h at 37 °C and 650 rpm before expression was induced by increasing the temperature to 40 
°C. Expression was allowed to continue for approximately 5 h before the cells were harvested. 
The plates were centrifuged (3000 g, 15 minutes, 4 °C) and the medium was discarded. Cell 
pellets were stored at –20 °C until use.
Screening on alkoxyresorufin O-dealkylation activity
96-Wells plates with cells were thawed and resuspended in 200 µl/well cold 100 mM 
potassium phosphate (KPi) buffer, pH 7.4. 20 µl of cell suspension was transferred to three 
black 96-wells plates containing 160 µl/well 100 mM KPi buffer pH 7.4 with 12.5 µM substrate 
(benzyloxyresoruﬁn, pentoxyresoruﬁn, or a mixture of methoxy- and ethoxyresoruﬁn). The 
reaction was initiated by the addition of 20 µl of an NADPH regenerating system resulting in 
ﬁnal concentrations of 0.2 mM NADPH, 0.3 mM glucose-6-phosphate and 0.4 units/ml glucose-
6-phosphate dehydrogenase. Formation of the ﬂuorescent product resoruﬁn was monitored 
for 15 minutes at 24 °C on a Victor2 1420 multilabel counter (Wallac, λex= 530 nm, λem= 580 nm). 
Mutants with increased activity and/or altered selectivity towards different alkoxyresoruﬁns 
compared to the non-mutated parent enzyme were cultured on a 300 ml scale as described 
previously [11], and were subsequently characterised using dextromethorphan and 3,4-methy- 
lenedioxymethylamphetamine (MDMA) as substrates.
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Screening on dextromethorphan N-demethylation activity
To identify P450 BM3 mutants that can convert drugs with high activity, a high throughput 
screening assay was developed for dextromethorphan metabolism. For this assay, the 96-
wells plates with frozen cell pellets were thawed and resuspended in 180 μl/well cold 100 
mM potassium phosphate (KPi) buffer, pH 7.4, containing 1 mM dextromethorphan and 0.1% 
Triton X-100. The reaction was initiated by the addition of 20 μl of an NADPH regenerating 
system as described above. The reaction was allowed to proceed for 3 hours at 24 °C, and was 
terminated by the addition of 20 μl of a 10 % (v/v) HClO4 solution. The plates were centrifuged 
(3000 g, 15 minutes, 4 °C) and the supernatant was analysed by LC-MS. LC separation was 
carried out using a C18 column (Phenomenex Luna 5 μ, 150 × 4.6 mm). The mobile phase 
consisted of 80% acetonitril with 0.1% formic acid, and the ﬂow rate was 0.5 ml/minute. Every 
three minutes, 10 μl of a sample was injected. The MS system used was an LCQ Deca mass 
spectrometer (Thermo Finnigan). Atmospheric Pressure Chemical Ionisation (APCI) was used, 
with a vaporiser temperature of 450 °C, N2 as sheath gas (40 psi) and auxiliary gas (10 psi), a 
needle voltage of 6000 V, and the heated capillary was 150 °C. The system was used in scan-
mode, and the intensities of the MS signal at m/z 258 (demethylated dextromethorphan) of 
the mutants were compared to those of the non-mutated parent enzymes, and mutants with 
improved activity were cultured and characterised using dextromethorphan and MDMA as 
substrates.
 
Characterisation of P450 BM3 mutants using dextromethorphan and MDMA
First, the linearity of product formation in time and the enzyme concentration dependence 
were determined. Incubations were performed for dextromethorphan and MDMA as described 
below, with a ﬁxed substrate concentration of 250 µM, and various enzyme concentrations 
(25-200 nM), or with a ﬁxed substrate concentration of 2 mM dextromethorphan or 3 mM 
MDMA and various incubation times (0-60 minutes). Based on these experiments (data not 
shown), the following conditions were chosen for further studies:
The dextromethorphan incubations were performed in 100 mM KPi buffer pH 7.4, with E. 
coli cytosolic fraction containing 200 nM P450 BM3 triple mutant or 100 nM of the random 
mutants. Substrate concentrations were used ranging from 0 to 4 mM (11 concentrations). 
The ﬁnal volume of the incubations was 200 µl. The reactions were initiated by addition of 20 
µl of an NADPH regenerating system as described above. The reaction was allowed to proceed 
for 20 minutes at 24 °C and terminated by the addition of 20 µl of a 10% (v/v) HClO4 solution. 
Precipitated protein was removed by centrifugation (15 minutes, 4000 g), and the supernatant 
was analysed by HPLC. Metabolites were separated using a C18 column (Phenomenex Luna 
5 µ, 150 × 4.6 mm) with a ﬂow rate of 0.6 ml/minute. The mobile phase consisted of 30% 
acetonitril with 0.1% triethylamine, set to pH 3.0 with HClO4. Metabolites were detected with a 
ﬂuorescence detector (λexcitation= 280 nm and λemission= 311 nm), and also with LC-MS as described 
in [14]. The dextromethorphan metabolite 3-methoxymorphinan (3-MM, N-demethylated 
dextromethorphan) was quantiﬁed using a standard curve of dextromethorphan, assuming 
that the ﬂuorescence of dextromethorphan and 3-MM are comparable. Product formation 
was plotted against substrate concentration in GraphPad Prism 4.0.
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For MDMA, incubations were performed as described for dextromethorphan. Substrate 
concentrations were used ranging from 0 to 3 mM (9 concentrations), and the incubation 
time was 30 minutes. The mobile phase consisted of 20% acetonitril and 0.1% triethylamine, 
set to pH 3.0 using HClO. Metabolites were detected with a ﬂuorescence detector (λexcitation= 
280 nm and λemission= 320 nm). Peak areas were determined using the Shimadzu Class VP 
4.3 software package. The MDMA metabolite 3,4-methylenedioxyamphetamine (MDA) was 
quantiﬁed using a synthesised reference compound. Product formation was plotted against 
substrate concentration in GraphPad Prism 4.0.
Investigation of non-linear behaviour using stopped-flow
To further investigate the observed non-linear time course of product formation by some 
of the mutants, benzyloxyresoruﬁn O-dealkylation (BROD) activity was measured using a 
stopped-ﬂow setup consisting of two syringes, a mixing chamber and a cuvette (KinTek 
Corporation, Austin, Texas, USA). One syringe was ﬁlled with enzyme and substrate (enzymes: 
10 nM ﬁnal concentration; substrate: 10 µM ﬁnal concentration). The second syringe was ﬁlled 
with an NADPH regenerating system as described. The system was at 24 °C. The reaction was 
initiated by mixing the contents of both syringes in a mixing chamber, immediately followed 
by a cuvette. The cuvette was positioned in a ﬂuorometer (λexcitation= 530 nm and λemission= 580 
nm) and the reaction was monitored for 10 minutes. The sampling frequency was 10 s-1. Data 
was plotted in GraphPad Prism 4.0.
Computer modeling of the random mutants
The highly active mutants obtained were modeled based on the heme-binding domain, 
residues 1-455, of the substrate-free crystal structure, PDB code 1BU7 [15]. The substrate-free 
structure was selected because the structure of the bulky, rigid substrate dextromethorphan 
strongly differs from the highly ﬂexible palmitoyl-derivates present in the ligand-bound 
structures. Energy minimisation of the mutant structures was performed using the MOE 
(Molecular Operating Environment) program [16]. Based on superimposition of the minimised 
mutant structures and the wild-type structure, preliminary suggestions on the function 
and effect of the mutated residues could be made. Because the effects of the mutations on 
the activity were much bigger for dextromethorphan than for MDMA, automated docking 
calculations were performed for dextromethorphan using GOLD [17]. To further study the 
effects of the mutations on the enzyme conformation, molecular dynamics simulations 
were performed on the resulting docked complexes using GROMOS05 [18] and GROMACS [19, 
20], using the GROMOS forceﬁeld set 45A3 [21, 22]. The minimised protein-ligand complexes 
were centered in a periodic solvated box containing approximately 14,000 molecules. This 
system is gradually heated up to 300 K, and equilibrated for 40 ps. Subsequently, 1 ns of free 
simulation was performed.
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Results
Selection of random mutants of P450 BM3
As template for random mutagenesis, the triple mutant P450 BM3 R47L/F87V/L188Q was used. 
After the ﬁrst round of mutagenesis, 400 colonies were screened. The benzyloxyresoruﬁn-
O-dealkylation (BROD) activities were plotted against the pentoxyresoruﬁn-O-dealkylation 
(PROD) and methoxy/ethoxyresoruﬁn-O-dealkylation (MROD/EROD) activities in a scatter 
plot, in order to visualise the range of activities and the variation in substrate selectivity of 
the random mutants (Figure 1A and 1B). Compared to the triple mutant controls, mutant M01 
showed no increased BROD activity, and a decreased PROD activity, but a signiﬁcantly higher 
MROD/EROD  activity. The triple mutant and most other mutants did not show any MROD/
EROD activity in the screening procedure (Figure 1B). Mutant M02 showed a higher activity 
toward all substrates. Mutants M03 and M04 both showed increased BROD activity.
In a second round, M01 and M02 were selected as a template for further mutagenesis, based 
on their increased MROD/EROD activity (M01 and M02) and PROD activity (M02) (Figure 1A 
and 1B). To be able to screen for mutants with improved activity towards dextromethorphan, 
an LC-MS screening assay was used. To improve the permeability of the cells, the known 
permeabilising agents Triton X-100 and EDTA were added to the assay. The presence of 10 
or 25 mM EDTA did not increase the amount of product formed, but with 0.1% Triton X-100, 
Figure 1: Screening assays with alkoxyresoruﬁns. Random mutants in PROD vs BROD scatter plots (A, C, 
D) or MROD/EROD vs BROD scatter plots (B). A and B: First generation mutants with P450 BM3 R47L/F87V/
L188Q as mutagenesis template. C: second generation mutants with M01 as mutagenesis template. D: 
second generation mutants with M02 as mutagenesis template. Data were obtained from 96-wells plate 
screening assays. Each dot represents one mutant. Mutants that showed no activity have not been included. 
‘×’ represents non-mutated controls (A/B: triple mutant. C: M01. D: M02). Open squares represent mutants 
that have been selected for further investigation.
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product formation was 2.5-fold higher than in the absence of permeabilising agent (data not 
shown). The mutants originating from error-prone PCR on M01 and M02 were screened both 
with the alkoxyresoruﬁn screening assay and the dextromethorphan screening assay. With 
M01 as template, 350 colonies were screened, resulting in the identiﬁcation of mutant M05, 
that had a 6-fold increased BROD activity and PROD activity (Figure 1C), and 3.7-fold increased 
dextromethorphan demethylation activity compared to M01. 600 Colonies were screened 
that had M02 as a starting point. Based on the BROD/PROD scatter plot, ﬁve mutants were 
selected for further studies (colonies M06, M07, M08, M09 and M10, Figure 1D).
In a third round of error-prone PCR, M05 was used as a template, and only the dextro-
methorphan screening assay was used. 50 Colonies were screened, and mutant M11 with 1.5-
fold improved activity was selected for further characterisation (data not shown).
Characterisation of the random mutants
MDMA was metabolised into three metabolites by all the random mutants tested. The main 
metabolite was 3,4-methylenedioxyamphetamine (MDA), the second most abundant meta-
bolite was N-hydroxy-3,4-methylenedioxymethylamphetamine, and the minor metabolite 
was 3,4-dihydroxymethylamphetamine. This metabolic proﬁle was also observed for the 
triple mutant in a previous study [1]. Dextromethorphan was N-demethylated to 3-methoxy-
morphinan (3-MM) by all mutants. Additionally, with LC-MS, trace amounts of two mono-
hydroxylated metabolites were observed for M02 that could not be detected with ﬂuorescence 
detection. In this study, data is presented only for the major metabolites MDA and 3-MM. 
Some of the mutants that were selected from the screening assays did not show increased 
metabolism towards the substrates tested. These mutants, M03, M04 and M06-M10, were 
therefore not investigated further. The mutants further analysed in this study are M01, M02, 
M05 and M11.
Analysis of the time dependence of the enzyme activity of the random mutants showed 
that these enzymes all have a very high initial activity during the ﬁrst 50 seconds of the 
reaction, followed by decrease to a slower rate of metabolism (Figure 2) which was linear 
for at least 60 minutes (data not shown). Product formation by the triple mutant was too 
low to be determined accurately in the ﬁrst 10 minutes of the reaction. To study the initial 
enzyme activity in more detail, stopped-ﬂow experiments were performed with the four 
random mutants and the triple mutant using the substrate benzyloxyresoruﬁn. This setup 
allowed a much higher sampling frequency (10 s-1), resulting in more accurate data. Because 
benzyloxyresoruﬁn is a better substrate for the triple mutant than dextromethorphan and 
MDMA, the time course of this mutant could also be studied using this setup.
As was observed for dextromethorphan and MDMA, the stopped-ﬂow data showed a high 
initial activity followed by a slower phase. The rates for the slow phase, the exponential decay 
and the fast phase have been estimated by ﬁtting the data in Figure 2 to the empirical function 
used previously by Noble et al. [23]. Results are given in Table 1. For comparison, the rates of 
metabolism for the human P450 2D6 mutant 2D6[F120A] are also given. P450 2D6[F120A] is 
chosen for comparison rather than wild-type P450 2D6, because 2D6[F120A] is also able to 
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Figure 2: Time dependence of dextromethorphan (A) and MDMA (B) N-demethylation, and benzyloxyresoruﬁn 
O-dealkylation (C) by mutants M11 (open circles), M05 (open squares), M01 (closed squares) and M02 (open 
triangles). For benzyloxyresoruﬁn, the activity of the triple mutant was also measured.
Product formation from dextromethorphan and MDMA by the triple mutant was too low to be detected 
accurately under the conditions used. Curves were ﬁtted to the following equation, derived from [23, 24]: 
product = [P1(1-e
-P2t)]/P2 + P3t.
Triple
Mutant
Mutant
M01
Mutant
M02
Mutant 
M05
Mutant
M11
hP450 
2D6[F120A]b
Dex P1 nd
a 41.8 47.7 91.2 212.9 4.5 ± 0.3 [25]
Dex P2 nd
a 1.2 2.0 1.1 1.0
Dex P3 nd
a 6.2 3.0 16.4 51.0
MDMA P1 nd
a 97.8 216.8 158.9 313.9 3.5 ± 0.1 [26]
MDMA P2 nd
a 5.7 20.4 10.5 8.9
MDMA P3 nd
a 1.0 0.6 1.8 2.7
BROD P1 6.1 2.3 18.5 13.9 13.3
BROD P2 0.5 0.2 0.6 0.4 0.5
BROD P3 1.7 0.3 3.7 1.8 1.3
Data was obtained for dextromethorphan (Dex) and 3,4-methylenedioxy-methylamphetamine 
(MDMA) N-demethylation, and for benzyloxyresoruﬁn O-dealkylation (BROD). Values were obtained 
by ﬁtting the curves to the following equation, derived from [23, 24]: product = [P1(1-e
-P2t)]/P2 + P3t 
[27]. The ﬁrst derivative of this equation, P1(e
-P2t) + P3, shows that this term describes an initial ‘fast’ 
rate (P1) followed by a deactivation process (exponential rate: P2) to a ‘slow’ rate (P3). P1 and P3 are in 
nmol product/min/nmol enzyme, and P2 is in min
-1. aFor the triple mutant, product formation from 
dextromethorphan and MDMA was too low to be detected accurately under the conditions used (nd). 
bFor comparison, literature Vmax values for hP4502D6[F120A] are included (for dextromethorphan: O-
demethylation. For MDMA: N-demethylation).
Table 1: Initial, fast enzyme rates and slow enzyme rates as determined from the product formation/time 
curves in Figure 2.
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form MDA at appreciable rates, while wild-type P450 2D6 forms mainly 3,4-dihydroxymethyl-
amphetamine. The dextromethorphan O-demethylation activities are very similar for wild-
type 2D6 and 2D6[F120A] [25]. 
At a substrate concentration of 2 mM, the initial reaction rate of dextromethorphan N-
demethylation by the P450 BM3 random mutants was up to 47-fold higher than the Vmax of 
dextromethorphan O-demethylation by P450 2D6[F120A], and the slow rates were up to 11-
fold higher (Table 1). At a substrate concentration of 3 mM, the initial rate of MDA formation 
by the P450 BM3 mutants was 30 to 90-fold higher than the Vmax of P450 2D6[F120A], and the 
slow rates were similar to the Vmax of P450 2D6[F120A] (Table 1). 
For dextromethorphan and benzyloxyresoruﬁn metabolism, the difference between the slow 
phase and the fast phase is approximately 4 to 15-fold, while for MDMA metabolism this 
difference is 100 to 360-fold (Table 1). The rate of inactivation, P2, is similar for dextromethorphan 
and BROD, but for MDMA, P2 is up to 30-fold higher. Further studies are required to elucidate 
the mechanisms underlying this substrate-dependent biphasic behaviour.
To study the substrate concentration dependence of the reaction, product formation was 
plotted against substrate concentration (Figure 3). Because of the non-linear time course 
described above, no enzyme kinetic parameters were assessed. For dextromethorphan 
metabolism, mutant M11 showed the highest activity (Figure 3A). Product formation by M11 
after 20 minutes at 2 mM substrate concentration was 200-fold higher than by the triple 
mutant. Mutant M01 and M02 metabolised dextromethorphan with 20 to 25-fold higher 
turnover compared to the triple mutant, and the evolution from M01 to M05 resulted in a 
further 3-fold improvement. Evolution from M05 to M11 increased the activity another 2.5-
fold. 
For MDMA metabolism, M11 again showed the highest activity, 5-fold higher than the triple 
mutant at 3 mM substrate concentration (Figure 3B). Product formation by M02 after 30 
Figure 3: Substrate concentration dependence of dextromethorphan and MDMA N-demethylation. 
Product formation/[S] curves for dextromethorphan (A) and MDMA (B) N-demethylation by mutants M11 
(open circles), M05 (open squares), M01 (closed squares), M02 (open triangles) and the triple mutant (closed 
triangles).
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minutes was 4-fold higher than by the triple mutant, and by M01 it was 2-fold higher than 
the triple mutant. Evolution from M01 to M05 resulted in a 2-fold increase in activity, and for 
M11 product formation was another 1.5-fold higher.
Mutagenesis results and interpretations from modeling
The mutations present in M01, M02, M05 and M11 were identiﬁed using DNA sequencing 
(Table 2). Computer modeling of the mutants was used to suggest explanations for the 
experimental results. From the models of the mutants it could clearly be seen that the 
F87V mutation, present in all mutants, seems to be responsible for making the catalytic 
site accessible to bulkier substrates by opening up the site directly above the heme-iron, as 
has been shown before by others [28]. R47 is positioned at the entrance of the suggested 
substrate access channel and has been described to be important for substrate recognition, 
forming interactions with and anchoring the negatively charged carboxylate group of the 
natural substrates [9, 23]. The substrates considered in this study both display a positively 
charged amine. The R47L mutation is thus expected to be favourable due to the removal of 
a positive charge in the entrance of the substrate access channel. L188 is also located in the 
entrance of the mainly hydrophobic access channel. Exchanging R47, which is one of the few 
polar side chains, to a leucine could lead to an unfavourably non-polar environment in the 
access channel. Re-introducing a polar side chain with the L188Q mutation could reverse that 
effect [28].
Mutant M01 had two additional mutations compared to the triple mutant: E267V and 
G415S. In the crystal structure, G415 is not in the proximity of the active site, whereas E267 is 
Triple 
mutant
Mutant 
M01
Mutant 
M02
Mutant 
M05
Mutant 
M11
bMutant 
M01a
bMutant
M02a
bMutant 
M02b
R47L R47L R47L R47L R47L R47L R47L R47L
E64G
F81I F81I
L86I L86I
F87V F87V F87V F87V F87V F87V F87V F87V
E143G
L188Q L188Q L188Q L188Q L188Q L188Q L188Q L188Q
E267V E267V E267V E267V
(N319T)a (N319T)a
(G415S)a (G415S)a (G415S)a
aThe mutations in parentheses have been shown not to contribute to the enhanced activities of the 
mutants. bThe mutants M01a, M02a and M02b, in italic, are site-directed mutants.
Table 2: Mutations identiﬁed in the random mutants of P450 BM3 determined by DNA sequencing.
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Figure 4: Crystal structure of the active site of P450 BM3 (PDB ID 1BU7). The heme group is shown in grey. 
The residues that were altered in mutant M02 (A) and M11 (B) are labeled by their amino acid numbers, and 
depicted in light grey in stick format.
Figure 5: View of dextromethorphan in the superimposed active sites of the triple mutant and mutant M01 
(A) or M05 (B) after 1 ns of simulation. The carbon atoms of the triple mutant are colored grey (A and B). The 
M01 and M05 protein carbon atoms are colored black (A and B). Dextromethorphan (DXM) is depicted in 
grey in the triple mutant, and in black in mutant M01 and M05. The side-chain of E267 of the triple mutant 
is directed out from the active site, interacting with K440, whereas V267 of M01 is directed in towards the 
active site, possibly closing off the active site channel exit and forming a hydrophobic pocket together with 
L181, that turns in towards V267. In the M05 mutant the backbone of I81, situated in the B’ helix, is shifted to 
the right in the ﬁgure. This allows for a shift of the backbone around L181, situated in the F helix. The Cα’s of 
the two L181 residues are approximately 3 Å apart in this comparison.
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located in the active site on helix I (Figure 4). To establish the role of the E267V mutation 
in M01 experimentally, the mutation E267V was introduced into the triple mutant using 
site-directed mutagenesis. This resulted in mutant M01a (Table 2). In activity assays with 
dextromethorphan and MDMA, M01a behaved identical to M01 (data not shown), which 
suggests that the E267V mutation is solely responsible for the increased activity of M01.
In the substrate free crystal structure (PDB ID 1BU7) the side-chain of E267 is positioned 
approximately 3 Å from the K440 side-chain and directed away from the active site facing the 
surface of the protein, interacting with K440. It forms part of the active site channel exit as 
described by Haines et al. [29]. During simulation of the model of the E267V mutant, the side 
chain of V267 turns towards the active site, possibly closing off the active site channel exit 
and forming a hydrophobic pocket together with L181, that turns in towards V267 (Figure 5A). 
This may tighten the interactions in the hydrophobic substrate pocket, or allow for substrate 
orientations that are more favourable for metabolism.
In mutant M05, which originated from M01, one additional mutation was found: F81I. F81 is 
located on the B’ helix with its side-chain directed toward the interior of the protein but not 
directly in the active site (Figure 4B). Preliminary data from molecular dynamics simulations 
suggest that in the F81I mutant the side chain of I81 shifts slightly, which as a result induces 
a large conformational changes of L181. This conformational change affects the shape of the 
hydrophobic substrate pocket (Figure 5B). This could also inﬂuence the orientation of the 
ligand in the active site and thus affect the rate of metabolism.
Mutant M11, originating from M05, had the two additional mutations E64G and E143G. Both 
mutations are located on the surface of the P450-domain (Figure 4). In the crystal structure 
of P450 BM3, E64 is located at the interface of the heme domain and the FMN domain (PDB 
code 1BVY, [15]). It remains to be investigated whether both mutations are required for the 
increased activity of M11. Because of their position on the protein surface, they could be 
involved in substrate entrance or product exit, or in interaction with the reductase domain 
and the electron transport chain. 
In M02, which had the triple mutant as template, two additional mutations were found: 
L86I and N319T. L86 is not located in the active site, but in close vicinity of one of the 
propionate side-chains of the heme porphyrin (Figure 4A). The localisation of this residue 
makes it unlikely to be directly involved in substrate binding.  Residue N319 is more distant 
from the substrate binding site and heme than L86 (Figure 4A). To establish the roles of the 
L86I and N319T mutations experimentally, both mutations were introduced into the triple 
mutant separately using site-directed mutagenesis. This resulted in mutants M02a and 
M02b, respectively (Table 2). Enzyme activity assays with dextromethorphan and MDMA 
showed that M02b has the same activity as the triple mutant, while M02a has the same 
activity as mutant M02 (data not shown). This shows that the mutation N319T does not play 
a signiﬁcant role. The increased activity of M02 is therefore caused by the rather conservative 
L86I mutation. Molecular dynamics simulations showed that this conservative substitution 
results in conformational changes in the surrounding residues, but the implications of these 
changes require more detailed studies.
140
NOVEL DRUG METABOLISING MUTANTS OF P450 BM3
Discussion
We recently described a site-directed triple mutant of P450 BM3 that is able to metabolise 
drugs [1]. The aim of the current study was to further increase the activity of this mutant by 
random mutagenesis, since it was still low compared to several human drug metabolising 
P450s. In three generations of random mutagenesis using error-prone PCR, in total 1400 
colonies were picked and screened. Four mutants with a strongly increased activity towards 
dextromethorphan and MDMA were identiﬁed. The largest improvements were observed 
for dextromethorphan, where the product formation was increased up to 200-fold when 
compared to the triple mutant. The initial activities of the random P450 BM3 mutants 
were up to 90-fold higher than of P450 2D6 (Table 1). So far, random mutagenesis studies on 
mammalian P450s have shown that even after several cycles of mutagenesis, the increase in 
activity rarely exceeds a factor 10 [30].
When the incubation with P450 BM3 M11 would be upscaled to 1 L of batch culture (~ 500 nmol 
P450), approximately 200 mg of 3-MM can be produced in 20 minutes. For comparison, the 
only other P450 BM3 mutant described that metabolises drugs, P450 BM3 9C1, can produce 70 
mg propranolol metabolites per L culture in 180 minutes [10]. The biotransformation reactions 
that are currently used in the pharmaceutical industry have a volumetric productivity 
ranging from 0.2 mg/L to 14 g/L [31].
P450 BM3 is one of the most intensively studied P450s, and it has been subjected to several 
random- and site-directed mutagenesis studies. In this study, several unique mutations 
that have a big effect on the catalytic activity of P450 BM3 were identiﬁed that have not 
been investigated before. The most striking effects were observed for the mutations L86I in 
mutant M02, and E267V in mutant M01.
It is very surprising that a conservative substitution like L86I can have such dramatic effects on 
the catalytic activity. Interestingly, a reverse mutation, I115L, was previously found to produce 
the opposite effect in insect P450 6B1 [32]. Sequence alignment of P450 6B1 and P450 BM3 
revealed that I115 and L86 are located at the same position. It was suggested that residue I115 
is positioned along the path of a product exit channel [32]. The conservative mutation I115L 
is suggested to block this channel, signiﬁcantly limiting the catalytic capacity of P450 6B1. 
Accordingly, one hypothesis is that in P450 BM3 the L86I mutation opens up a product exit 
channel, which increases the catalytic efﬁciency of the enzyme. L86 and I115 are positioned 
directly next to the heme (Figure 4); other possibilities are that the I115L and L86I mutations 
inﬂuence the heme group, or electron transport [32]. Molecular dynamics simulations 
showed that for L86I, the small change in the amino acid side-chain has a pronounced effect 
on the conformation of the surroundings. Whether this conformational change results in the 
opening of a substrate channel, or rather inﬂuences the position of the heme in the protein 
or the electron transport chain requires more detailed studies.
It has been reported that a mutant of P450 BM3 where the acidic E267 was converted into 
a glutamine (E267Q) had up to 280-fold decreased activity for several fatty acids [33]. In the 
present study, on the contrary, the mutation E267V resulted in a 25-fold increased catalytic 
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activity towards dextromethorphan compared to the triple mutant. Molecular dynamics 
simulations have shown that the E267V mutation results in a conformational change in the 
hydrophobic substrate pocket, which could affect the orientation of the ligand and thus the 
catalytic activity.
Time dependent inactivation of P450 BM3 was observed previously for lauric acid metabolism 
by the mutants F87G and F87Y [23]. It was hypothesised that during turnover, these mutants 
undergo an irreversible conformational change that results in decreased activity. Also 
in other enzymes, this phenomenon called ‘rapid burst kinetics’ has been observed [34]. 
In the present study, all mutants tested also showed this non-linear behaviour (Figure 2). 
After a fast initial activity the enzyme activities decayed to a much slower linear phase. 
Interestingly, the inactivation rate for MDMA metabolism appeared to be 10-fold higher than 
for dextromethorphan metabolism, and 30-fold higher than for BROD. If it would be possible 
to prevent this inactivation, the catalytic efﬁciency of the enzymes would increase another 4 
to 360-fold (Table 1). 
The mutants described in this study could be used as a starting point for further random 
or site-directed mutagenesis, to further increase their activity, or to further broaden their 
substrate speciﬁcity or alter their metabolic proﬁle. For drug discovery, mutants with a broad 
metabolic proﬁle would be most useful, while for the biosynthesis of speciﬁc drugs or drug 
metabolites, mutants with a high degree of regiospeciﬁcity are required. The combination of 
random mutagenesis and molecular modeling can yield novel insights in the mechanism of 
P450s. Small changes in amino acids can unexpectedly have dramatic effects on the activity, 
as seen in the present study for the conservative mutation L86I.
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STRUCTURAL RATIONALISATION OF P450 BM3 MUTANTS
Abstract
Three newly discovered drug metabolising mutants of cytochrome P450 BM3 have been studied 
at an atomistic level to provide structural explanations for a number of their characteristics. 
In this study computational methods are combined with experimental techniques. Molecular 
dynamics simulations, Resonance Raman and UV-VIS spectroscopy as well as coupling 
efﬁciency and substrate binding experiments have been performed. The computational 
ﬁndings, supported by the experimental results, enable structural rationalisations of the 
mutants. The substrates used in this study are known to be metabolised by human cytochrome 
P450 2D6. Interestingly, the major metabolites formed by the P450 BM3 mutants differ from 
those formed by human cytochrome P450 2D6. The computational ﬁndings, supported by 
Resonance Raman data, suggest a conformational change of one of the heme propionate 
groups. The modeling results furthermore suggest that this conformational change allows 
for an interaction between the negatively charged carboxylate of the heme substituent 
and the positively charged nitrogen of the substrates. This allows for an orientation of the 
substrates favourable for formation of the major metabolite by P450 BM3.
Introduction
Cytochrome P450s (P450s) constitute a large family of heme containing enzymes involved 
in the catalysis of a number of biologically important redox reactions for a variety of 
endogenous and exogenous compounds. With their broad substrate speciﬁcity and high 
regio- and stereoselectivity P450s are interesting targets for use in biotechnological 
applications, as biocatalysts for the production of pharmaceuticals or drug metabolites 
and for the optimisation of lead compounds or existing drugs [1, 2]. The water soluble 
cytochrome P450 BM3 (P450 BM3) from Bacillus megaterium [3] is one of the most studied 
members of the cytochrome P450 family. With its high catalytic activity and high stability, 
P450 BM3 is particularly interesting as a potential biocatalyst. P450 BM3 is a bacterial single-
component enzyme, with the reductase domain fused to the heme domain, and can easily 
be overexpressed in E.coli, which provides additional advantages for using it [4]. Since its 
natural substrates are long-chain fatty acids, wild-type P450 BM3 does not metabolise drug-
like compounds. However, a large number of mutagenesis studies have shown that it can be 
easily manipulated to convert a variety of non-natural substrates, e.g. indole, alkanes, and 
propranolol [5-7].
The ﬁrst crystal structure of the heme domain of P450 BM3 was solved in 1993 [8] and since 
then a number of crystal structures, both substrate-free [9, 10] and co-crystallised complex 
structures [11, 12], have been published. Numerous site-directed and random mutagenesis 
studies have been performed on P450 BM3, which in combination with computer modeling 
studies has resulted in the elucidation of the role of various residues [13-18]. The extensive 
knowledge on P450 BM3 thus obtained has enabled the rational design of mutants with 
desired activities, such as the ability to metabolise alternative substrates, or metabolism 
with altered regiospeciﬁcity [19-21]. Such mutants have good perspectives as biocatalysts. 
Also, the mutagenesis studies in combination with computer modeling can provide useful 
insights into the structure and function of cytochrome P450s in general. 
Recently, a site-directed triple mutant (R47L/F87V/L188Q) able to convert drug-like compounds 
was described [21]. In a follow-up study this triple mutant was used as a template for random 
mutagenesis, resulting in novel mutants of P450 BM3 with signiﬁcantly improved catalytic 
activity, displaying an up to 200-fold increased activity towards the drug substrates 3,4- 
methylenedioxymethylamphetamine (MDMA) and dextromethorphan [22]. The most striking 
effects were observed for the substitutions F81I, L86I and E267V, in mutants M05, M02 and M01 
(see Table 1). As described in the previous random mutagenesis study [22], all these mutants 
produced three metabolites from MDMA, the main one 3,4-methylenedioxyamphetamine 
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(MDA), the second most abundant one N-hydroxy-MDMA and the minor metabolite 3,4-di-
hydroxymethylamphetamine. For dextromethorphan, only the N-demethylated metabolite 
3-methoxymorphinan (3-MM) was observed in all mutants. In Figure 1, V/[S] curves are shown 
for the major metabolites of the mutants. 
Initial computational modeling studies were performed in an attempt to rationalise the 
observed effects structurally [22]. F81 is located in the B’ helix with its side-chain directed 
toward the interior of the protein but not directly in the active site. L86 is not located in the 
active site and cannot directly interact with the substrates. However, since L86 is positioned 
next to the heme, near one of the heme propionate groups, it could affect the heme properties. 
The carboxylate moiety of E267 is positioned approximately 3 Å from the positively charged 
K440 side-chain and directed away from the active site facing the surface of the protein. 
It forms part of the active site exit channel as described by Haines et al. [11]. In Figure 2 an 
overview of the location of the mutated residues is given.
In the present study we use an integrated computational and experimental approach to 
further rationalise the effects of the three mutations in the triple mutant and the additional 
mutations of the random mutants. Two substrates were studied for each mutant, MDMA and 
dextromethorphan. The mutants were modeled based on the substrate free crystal structure 
(PDB code 1BU7) [10] of P450 BM3 and subsequently subjected to molecular dynamics 
simulation. For comparison, molecular dynamics simulation of the substrate-free wild-type 
enzyme was also performed. Furthermore, the two substrates used in this study were docked 
into all the mutant structures and molecular dynamics simulations were carried out starting 
from the docked complex structures. Since the wild-type enzyme shows no activity for these 
substrates, a comparison to wild-type for the substrate-bound structures is not relevant. 
Therefore, the dynamical behaviour of the mutants was compared to wild-type and the triple 
mutant - the origin of all the studied mutants - in the substrate-free case and compared to 
Triple mutant Mutant M01 Mutant M02 Mutant M05
R47L R47L R47L R47L
F81I
L86I
F87V F87V F87V F87V
L188Q L188Q L188Q L188Q
E267V E267V
(N319T)a
(G415S)a (G415S)a
a Mutations in parenthesis were shown not to contribute to the enhanced activity of the mutant [22]. 
These mutations were not included in the modeling studies.
Table 1: Mutations of the P450 BM3 mutants used in this study.
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the triple mutant in the substrate-bound cases. In addition, random acceleration molecular 
dynamics simulations (RAMD) [23] were conducted for MDMA in mutant M02, to explore 
possible entrance/exit routes to the buried active site of the protein.   
To further characterise the mutants, the coupling efﬁciency and spectral dissociation 
constants as well as relative IC50 values of the substrates were determined for the three 
Figure 1: V/[S] curves for dextromethorphan and MDMA N-demethylation. Data is displayed for triple 
mutant (closed triangles), M01 (closed squares), M02 (open triangles) and M05 (open squares). Adapted 
from reference [22].
Figure 2: Crystal structure of Cytochrome P450 BM3. The mutated residues described in this study are 
indicated by labels. For a colour version of this picture, see page 172.
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mutants, M01, M02 and M05. The effect of the different mutations and of ligand binding on 
the heme properties was studied with Resonance Raman (RR). RR is a spectroscopic technique 
in which the wavelength of the laser light irradiating the protein sample is in resonance 
with an electronic transition of the heme, yielding a vibrational spectrum of the catalytic 
active site, which is used to study changes of structural and electronic heme properties [24, 
25]. Changes in oxidation-, spin- and coordination states of the heme can be detected by RR, 
together with conformational changes of the heme’s substituents, i.e. vinyl and propionate 
groups. Recently, RR has been successfully used to study the effects produced on the heme by 
mutations of F393 in P450 BM3 [26].
Based on the experimental results from the previous study the main aim of the present study 
was to provide structural explanations for the following observations:
1. MDMA and dextromethorphan, both substrates for human cytochrome P450 2D6, undergo 
 mainly O-demethylenation and O-demethylation when metabolised by P450 2D6. In 
 contrast, for all the P450 BM3 mutants studied here the major/sole product formed is the 
 N-demethylated metabolite for both substrates. 
2. In mutant M01, it has been shown that only the E267V mutation is responsible for the 
 signiﬁcant increase in activity compared to the triple mutant. 
3. Mutant M05, originating from the M01 mutant, contains only the F81I mutation in 
 addition to the M01 substitutions and displays an even further improved activity for both 
 dextromethorphan and MDMA.
4. In mutant M02 only the conservative mutation L86I has been shown to be responsible for 
 an increase in activity compared to the triple mutant. L86 is not located directly in the 
 active site but on the proximal side of the heme, close to one of the heme propionate 
 groups. Are there direct structural reasons for the increase in activity compared to the triple 
 mutant or can it be attributed to changes in the electronic properties of the heme?
Materials and Methods
Computational details
All the mutants were modeled based on chain A of the substrate-free crystal structure, 
PDB code 1BU7 [10], using the molecular modeling software MOE (Molecular Operating 
Environment) [27]. The residues shown in parentheses in Table 1 were not mutated, since they 
have been shown not to contribute to the improved activity of the mutants and are located 
far away from the active site [22]. The mutants were energy minimised using GROMOS05 [28] 
and the GROMOS force ﬁeld parameter set 45A3 [29, 30]. MDMA and dextromethorphan were 
subsequently docked into the mutants with GOLD [31], using the GOLD scoring function [31] 
as well as the Chemscore scoring function [32, 33] to guide the docking, retaining 50 docked 
poses per ligand and scoring function. All the generated poses were inspected, but docked 
poses with the experimentally determined catalytic atom, i.e. the N-methyl, close to the 
heme iron, were only obtained for MDMA. Therefore, dextromethorphan was superimposed 
on MDMA, using the the aromatic ring and the methoxy-group common to both ligands. 
The docked and superimposed structures were used as starting structures for molecular 
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dynamics simulations. Simulations were carried out on wild-type P450 BM3 and all mutants, 
i.e. triple mutant, M01, M02 and M05 as described in Table 2, with no substrate in the active 
site as well as with MDMA and dextromethorphan in the active site. The wild-type does not 
metabolise MDMA or dextromethorphan and was therefore not simulated with the ligands in 
the active site. The simulations were carried out with the GROMOS05 [28] and GROMACS [34, 
35] biomolecular simulation packages. The ligand parameters were chosen based on building 
blocks of the GROMOS force ﬁeld, parameter set 45A3 [29, 30]. The nitrogen atoms of both 
MDMA and dextromethorphan were modeled as positively charged. The ligand free structures 
and the docked complexes were centred in a periodic truncated octahedron containing 
approximately 14200 SPC water molecules [36] and 16 or 15 Na+ ions to obtain a system 
with a net charge of zero. The number of added ions varied for the ligand free and ligand-
protein simulations because of the net charge of +1 of both the ligands. Initial velocities were 
randomly assigned according to a Maxwell-Boltzmann distribution at 50 K. The systems were 
heated up gradually to 298 K, increasing the temperature every 20 ps, followed by 40 ps of 
equilibration. Subsequently, 1 ns of simulation was performed. Most simulations were carried 
out multiple times with different initial velocities to check for discrepancies. To further study 
their dynamic behaviour, for some of the systems extended simulations were carried out, 
see Table 2 for details. A time-step of 2 fs was used and all bonds were constrained using the 
SHAKE algorithm [37]. All simulations were conducted at constant temperature and pressure, 
using the weak coupling algorithm [38]. The solute and solvent molecules were separately 
coupled to two temperature baths at 298 K with a relaxation time of 0.1 ps. The relaxation 
time for the isotropic pressure scaling was set to 0.3 ps with an isothermal compressibility 
of 2.807·10-5 atm-1 and a reference pressure of 1 atm. Non-bonded interactions within 0.8 nm 
were calculated every time step using a pair-list generated every ﬁfth time-step. Long-range 
interactions, up to 1.4 nm, were calculated every ﬁfth time-step. A reaction-ﬁeld term was 
added to the energies and forces, with an effective dielectric constant of 61.0 to represent the 
electrostatic interactions outside the 1.4 nm cut-off [39]. Coordinates were stored every 0.4 ps 
for the solute and every 2 ps for the whole solvated system. Random acceleration molecular 
dynamics (RAMD) was performed on MDMA in mutant M02, starting form the same pose as 
used in the molecular dynamics simulation. In RAMD an artiﬁcial, randomly directed force, F, 
is applied to the centre of mass of the ligand. After N time-steps the movement of the ligands 
is evaluated. If the ligand has moved less than a distance (r0) since the last evaluation, a 
new direction of the force is randomly chosen [23]. RAMD was implemented in GROMOS05 
[28] and applied with the following sets of parameters: 1) F= 1000 kJ mol-1 nm-1, redistributed 
Wild-type Triple mutant Mutant M01 Mutant M02 Mutant M05
no ligand 3 ns 1 ns a 1 ns a 1 ns a 1 ns a
MDMA - 1 ns 7 ns 1 ns a 1 ns a
dextromethorphan - 1 ns 11 ns 1 ns a 1 ns a
a Multiple simulations applying different starting velocities were performed.
Table 2: Performed simulations of P450 BM3 wild-type and mutants. The simulation time is shown.
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over the ligand atoms; N= 100; r0= 0.05 nm and 2) F= 500 kJ mol-1 nm-1, redistributed over the 
ligand atoms; N= 20; r0= 0.005 nm. All trajectories were analysed using the GROMOS05 [28] 
and GROMACS [34, 35] biomolecular simulation packages.
Enzymes and plasmids
The P450 BM3 mutants Triple, M01, M02 and M05 were prepared as described previously [22]. 
For Raman and UV-VIS spectroscopy, puriﬁed enzymes were required. Therefore, a pET28a+ 
vector system was used, which contains an N-terminal his-tag that allows puriﬁcation. The 
pET28a+ vector containing wild-type P450 BM3 as described in reference [40] was kindly 
provided by dr. Vlada Urlacher (Institut für Technische Biochemie, Stuttgart, Germany). The 
genes of the mutants M01, M02 and M05 were cloned into a pET28a+ vector as described in 
reference [40].
Expression, isolation and purification
The cytosolic fractions of the triple mutant and mutants M01, M02 and M05 in the pT1-
P450BM3 plasmid were prepared as described previously [22]. These cytosolic fractions 
were used for metabolism studies. For puriﬁcation, required for spectroscopic studies, the 
pET28a+ constructs containing P450 BM3 wild-type and mutant M01, M02 and M05 were 
used. The constructs were transformed into E. coli BL21 (DE3) cells using standard procedures. 
The enzymes were expressed and harvested similarly as for the pT1-P450BM3 plasmid, 
with the following modiﬁcations: 0.5 mM isopropyl-D-thiogalactopyranoside (IPTG) was 
used to induce expression and expression was carried out at 30 °C. After expression and 
harvesting, the proteins were puriﬁed from the cytosolic fraction using Ni-NTA. To prevent 
aspeciﬁc binding to the Ni-NTA agarose, 1 mM histidine was added to the cytosolic fraction. 
2 ml Ni-NTA slurry (Sigma) was added, and the cytosolic fraction was incubated at 4 °C for 3 
hours. The Ni-NTA agarose was retained in a polypropylene tube with porous disc (Pierce), 
and washed 3 times with 5 ml KPi-glycerol buffer containing 2 mM histidine. The P450 was 
eluted in 10 ml KPi-glycerol buffer containing 300 mM histidine. The histidine was removed 
by repeated washing with KPi-glycerol buffer in a Vivaspin 20 ﬁltration tube (10,000 MWCO 
PES, Sartorius).
Determination of the coupling efficiencies
To determine to what extent the NADPH consumption of the P450 BM3 mutants is coupled 
to substrate oxidation, incubations were performed with low concentrations of NADPH to 
achieve NADPH depletion. Incubations had a ﬁnal volume of 400 µl, and were performed as 
described in reference [22], with 2 mM substrate (dextromethorphan or MDMA) and cytosolic 
fraction containing 100 nM enzyme (mutant M01, M02 or M05). The reaction was initiated by 
the addition of 20 µM NADPH, or, as a control, an NADPH regenerating system as described 
previously [21]. Incubations were performed at 24 °C. To monitor the progress of the reaction, 
samples of 80 µl were taken at t = 0, 10, 20 and 30 minutes. The incubations were analysed 
by HPLC and the product formation quantiﬁed as described in reference [22]. The percentage 
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of coupling was determined by the ratio of the amount of product formed and the amount 
of NADPH consumed.
UV-VIS spectroscopic measurements
Spectral dissociation constants KS were determined for dextromethorphan and MDMA. Two 
1 ml quartz cuvettes containing 1 µM of puriﬁed enzyme (mutant M01, M02 or M05) in KPi 
buffer (100 mM potassium phosphate pH 7.4) in a ﬁnal volume of 500 µl per cuvette were 
prepared. Aliquots of 5 µl of a 10 mM ligand solution were added to the sample cuvette, while 
the same volume of KPi buffer was added to the reference cuvette. Spectra from 350 to 450 
nm were recorded after every addition, and the differences in absorption at 390 nm and 420 
nm (∆Abs) were determined. This measure is indicative of shifts from the six coordinated low-
spin state of the heme iron (6cLS) to a ﬁve coordinated high-spin state (5cHS). The ∆Abs values 
were plotted against the ligand concentration, and the ‘one site binding hyperbola’ ﬁtting 
module of GraphPad Prism 4.0 was used to estimate the spectral dissociation constant (Ks). 
Note that the spectral shift is only representative of the loss of the sixth heme-iron ligand, 
typically a water molecule. Under the assumption that the substrate displaces this water 
molecule, the measured value of Ks can be interpreted as a dissociation constant.
 
Determination of IC50 values
For all three mutants, the IC50 values of MDMA using dextromethorphan as a substrate, 
were determined. Incubations were performed as described above. The dextromethorphan 
concentration was 100 µM and the enzyme concentrations 200 nM. The incubation time was 
30 minutes. MDMA concentrations were 0 – 3 mM (10 concentrations). Product formation 
was determined and plotted against the logarithm of the inhibitor concentration, and the 
‘sigmoidal dose-response curve’ ﬁtting module of GraphPad Prism 4.0 was used to estimate 
the IC50.
Resonance Raman spectroscopy
Spectroscopic measurements were conducted using a home-built Raman microscope in 
a backscattering conﬁguration: a Zeiss microscope (D-7082 with a 40x objective, NA 0.60, 
working distance 2 mm) was coupled to a Andor Shamrock SR-303i-A single monochromator 
(Andor Technologies DV-420OE, Belfast, N.Ireland) with mounted 2400 g/mm and an Andor 
Newton DU970N CCD camera (Andor Technologies DV-420OE, Belfast, N.Ireland). The 413.1 
nm line of a continuous wave Kr ion laser (Coherent Innova 300c, California, USA) was used 
for excitation. The Rayleigh scattered light was removed using 3rd Millenium edge long pass 
ﬁlter (Omega Optical, Vermont, USA). Laser powers of 8-10 mW at the sample were used 
throughout the experiments. The monochromator slit was set to 120 mm, yielding a resolution 
of approximately 4 cm-1, and the increment per data point was approximately 0.8 cm-1. For all 
measurements, a 1 mm-diameter glass capillary was partially ﬁlled with the sample and put 
in a spinning capillary holder under the Raman microscope. During all measurements the 
capillary containing the sample was kept spinning to avoid photodegradation. The sloping 
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background of the spectra was subtracted using a baseline ﬁtted to the experimental data 
with the Andor CCD camera software.
Resonance Raman spectra of cytochrome P450 BM3 were obtained from a 1 mm diameter 
glass capillary ﬁlled with few mL of 12 mM protein buffered solutions. Binding of various 
substrates to cytochrome P450 BM3 was obtained by adding 1 mL of substrate solution (100 
mM dextromethorphan and MDMA, in buffer, 1% of methanol; 1.5 mM arachidonic acid, in 
buffer, 5% methanol) to 9 mL of buffered protein sample prepared as described above. The 
ﬁnal substrate concentration in the sample was 10 mM for dextromethorphan and MDMA, 
and 150 mM for arachidonic acid. When binding was observed, no further spectral changes 
were detected upon increasing substrate concentration, indicating that all the enzyme in the 
sample contained bound substrate.
Results
The experimental results for all the mutants will be described ﬁrst. Then, structural 
explanations to the four observations listed in the introduction will be suggested based on 
these experimental results combined with the computational ﬁndings. The computational 
observations will be described in more detail in each section.
Determination of the coupling efficiencies
Although wild-type P450 BM3 is well coupled when converting fatty acids (~100%) [41], the 
coupling efﬁciencies of P450 BM3 mutants, and also of P450 BM3 wild-type when converting 
non-natural substrates, can be very low (<1 – 25%) [19, 42]. To determine whether the 
mutations under investigation in the present study inﬂuence the coupling efﬁciency of P450 
BM3, the percentages of uncoupling were determined for the mutants M01, M02 and M05. 
Incubations were performed with dextromethorphan or MDMA, and a low concentration 
of NADPH. To ascertain that all the NADPH was depleted, samples were taken at different 
time points. In the control incubations with an NADPH regenerating system, the metabolite 
% coupling Ks IC50
dextromethorphan MDMA dextromethorphan MDMA MDMA
mutant M01 39.8 ± 7.6 21.5 ± 1.3 nd nd 27.3 ± 3.1
mutant M02 13.3 ± 2.5 16.6 ± 3.9 1063 ± 120 nd 13.4 ± 4.2
mutant M05 48.0 ± 7.3 11.9 ± 4.2 1233 ± 288 nd 25.5 ± 6.2
Percentages of coupling were determined by the ratio of the amount of product formed and the 
amount of NADPH consumed. Ks values and IC50 values are presented in µM. Data represented as the 
average of at least three independent measurements ± SD. nd: not detectable.
Table 3: Percentage of coupling with dextromethorphan and MDMA, spectral Ks values for dextromethorphan 
and MDMA and IC50 values for MDMA relative to dextromethorphan.
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formation increased in time for all the samples taken. The incubations with 20 μM NADPH 
did not show an increase in product formation after 20 and 30 minutes, conﬁrming that the 
NADPH was depleted within the ﬁrst 10 minutes of the reaction. The coupling percentages 
are summarised in Table 3. With MDMA, the percentage of coupling is similar for all three 
mutants, approximately 17-20%. With dextromethorphan, the coupling efﬁciency of M02 is 
again 17%, but for M01 and M05 it is 35-45%.
Determination of spectral dissociation constants
To determine the ability of dextromethorphan and MDMA to displace the water molecule 
that functions as a sixth heme iron ligand in substrate free P450s, the spectral dissociation 
constant Ks was measured using UV-VIS spectroscopy (Figure 3 and Table 3). In Figure 3 overlaid 
spectra are shown of the mutants in the absence and presence of a saturating concentration 
of substrate. From Figure 3A it can be concluded that neither ligand induces a spin-shift in 
mutant M01. For mutant M02 (Figure 3B), a spin-shift from the six-coordinated low-spin (6cLS) 
heme iron to the ﬁve-coordinated high-spin (5cHS) state was observed for dextromethorphan, 
but not for MDMA. Similarly, mutant M05 (Figure 3C) also showed signiﬁcant spectral binding 
with dextromethorphan, but not with MDMA. Displacement of the sixth ligand was only 
observed for mutant M02 and M05 with dextromethorphan resulting in the very similar 
values for Ks in Table 3.
Determination of IC50 values
For MDMA, no Ks values could be determined using UV-VIS. However, the fact that metabolism 
takes place in all mutants proves that the substrate must bind. To study the MDMA binding 
and afﬁnity in more detail, IC50 values were determined for MDMA using dextromethorphan 
as a substrate (Table 3). The IC50 values of the three mutants were very similar, ranging from 
13.4 to 27.3 mM for mutants M01, M02 and M05. Although no spectral binding could be 
determined for MDMA, i.e. no displacement of the water molecule which functions as the 
Figure 3: UV-VIS absorption spectra of the mutants M01 (A), M02 (B) and M05 (C) in the absence (grey) 
or presence (black) of 3 mM dextromethorphan (bottom) or MDMA (top). A change from 6cLS to 5cHS is 
indicated by an increase at 390 nm and a decrease at 420 nm.
dxm dxm dxm
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sixth ligand of the heme iron could be detected, the metabolism data in combination with 
the competitive inhibition of dextromethorphan metabolism show signiﬁcant binding of 
MDMA to all the mutants.
Resonance Raman spectroscopy
To look into the heme characteristics of the mutants in more detail, resonance Raman (RR) 
was performed. The obtained RR spectra indicate that there are substantial differences in 
coordination- and spin-states, and relevant changes in substituent conformations between 
P450 BM3 wild-type and the three mutants M01, M02 and M05 in the oxidised resting state. 
In absence of any substrate, only 6cLS heme is present in the wild-type. The mutants on the 
other hand show both 6cLS and 5cHS heme species. The highest amount of 5cHS species is 
observed for mutant M01, as was also found using UV-VIS spectroscopy (Figure 3A). This is 
clearly indicated by the presence of the 5cHS ν3 band at 1486 cm
-1 together with a concomitant 
increase in intensity of the 5cHS ν2 band at 1567 cm
-1 (Figure 4B), while only the 6cLS ν3 and ν2 
bands at 1486 and 1582 cm-1 were observed in the wild-type [24, 25]. Addition of the natural 
P450 BM3 substrate arachidonic acid yielded an almost complete spin-shift to 5cHS species 
Figure 4: Low frequency region (350-800 cm-1) (A) and spin- and coordination-marker bands frequency 
region (1400-1660 cm-1) (B) of resonance Raman spectra of cytochrome P450 BM3 WT and M01, M05 and 
M02 mutants, in presence and in absence of dextromethorphan (DXM) 10 mM. Enzyme concentration is 
12μM, laser excitation at 413.1 nm, laser power of 8-10 mW at the sample, accumulation times of 600-900 s.
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for all enzymes, while no observable spectral changes occurred upon addition of MDMA. In 
presence of dextromethorphan, no spectral changes were observed for wild-type and mutants 
M01 and M02, whereas in M05 a small but evident increase in the relative amount of 5cHS 
heme species was observed upon addition of this compound, as inferred from the change in 
relative intensities of the 5cHS and 6cLS ν3 bands at 1486 and 1501 cm
-1, respectively (Figure 4B).
In all mutants, the propionates bending mode δCbCcCd was observed at the same frequency 
(381 cm-1) as in the wild-type, while its relative intensity was higher than in the wild-type 
(Figure 4A). Following the interpretation of Chen et al. [26], this observation indicates that 
although there are no differences in the extent of hydrogen bonding of the propionate 
groups between the wild-type and the mutants, the mutations have induced a change in the 
orientation of the propionates with respect to the heme plane [26]. 
In agreement with previous observations for P450 BM3 [26], in the wild-type two low-frequency 
vinyl bending modes δCbCaCb were observed at 394 and 422 cm
-1 (Figure 4A), suggesting two 
distinct vinyl conformations with respect to the heme plane. In all mutants the vinyl mode 
at 394 cm-1 has disappeared, while the other mode has shifted 6 cm-1 to higher frequencies, 
suggesting that the mutations induce a change in the vinyl’s conformation. However, 
dramatic changes in vinyl conformations should be reﬂected in the other vinyl modes (the 
bending modes around 1310 and 1430 cm-1 and the stretching modes at 1621 and 1630 cm-1), 
but since no remarkable changes in frequency or relative intensity are observed (Figure 4B), it 
is probable that the vinyl groups undergo only minor conformational changes.
Addition of the substrates dextromethorphan and MDMA did not induce any observable 
changes in the vinyl or propionate conformations of the mutants.
Computational results
All simulations were started from the crystal structure 1BU7 [10] of the heme domain of 
substrate-free P450 BM3 or mutants modeled based on this structure. The root-mean-square 
deviation (RMSD) of the backbone heavy atoms from the initial structure remained below 
0.3 nm throughout the simulations, indicating a good dynamical stability of the proteins. 
Conformational changes are known to occur in wild-type P450 BM3 upon substrate binding, 
mainly affecting the B’-helix and the F-, and G-helices, as well as the loop between them. 
The RMSD from the initial structure of these three helices varied between 0.1 and 0.35 nm. 
For comparison, the RMSD of the B’-, F- and G-helices with respect to the crystal structure of 
the N-palmitoylglycine-bound wild-type P450 BM3  (1JPZ) [11] were also calculated. This RMSD 
varied between 0.25 and 0.4 nm, only in a few cases increasing to 0.45 nm.
1. N-demethylation of MDMA and dextromethorphan
MDMA and dextromethorphan are substrates for human cytochrome P450 2D6, where they 
mainly undergo O-demethylenation and O-demethylation, respectively. In contrast, the P450 
BM3 mutants mainly N-demethylate these substrates, indicating a different orientation of 
the substrate in the mutants. For MDMA minor amounts of the O-demethylenated metabolite 
have also been detected, as well as the N-hydroxylated product, but the major metabolite is 
the N-demethylated MDA [22].          
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All substrate-bound simulations were started from catalytically active poses with the N-
methyl being oriented towards the heme iron. In the simulations of the mutants one of the 
heme propionates (propionate A) turned ‘upwards’, see Figure 5, with the carboxylate group 
pointing towards the active site, forming a strong electrostatic interaction with the positively 
charged nitrogen present in both substrates. One of the propionate oxygens is at a distance 
of approximately 3 Å from the ligand nitrogen throughout the simulations. The movement of 
the heme propionate corresponds to a change in the second dihedral angle of the propionate 
side-chain, from approximately 175˚ to 75˚. The nitrogen of the ligands being anchored to 
the heme propionate also seems to allow for a favourable orientation of the N-methyl of the 
substrates towards the heme iron, as can be seen in Figure 5.  The distance of the ligand N-
methyl group to the heme iron remains less than 6 Å, a distance considered to be catalytically 
active [43]. Figure 6A displays the normalised distribution, i.e. the probability, of the second 
dihedral angle of the propionate A side chain extracted from all performed substrate-bound 
simulations. These are all distributed around 75˚, except for the MDMA-bound triple mutant 
simulation which is slightly shifted toward 85˚. In all the ligand-bound simulations the heme 
propionate A turns ‘upwards’ towards the active site and interacts with the positively charged 
nitrogen of the substrate.
To study whether the heme propionate movement is an effect of ligand binding, similar 
analysis was performed on the ligand free simulations of the mutants as well as the wild-type. 
In Figure 6B the normalised distributions of the second propionate A dihedral angle for the 
substrate-free wild-type and mutant simulations are displayed. The wild-type simulations 
only display a dihedral angle of around 175˚, whilst in the mutant simulations the second 
dihedral angle of propionate A is distributed both around 75˚ and 175˚.
In the substrate-free crystal structure of P450 BM3 the heme is anchored to the protein 
through hydrogen bonds between propionate D and R398 and W96 as well as through 
interactions between propionate A and K69. Analysing the hydrogen bond pattern between 
propionate A and the protein residues throughout the mutant simulations, it can be found 
that propionate A, although turning ‘upwards’, keeps the hydrogen bond to K69 to some 
extent. Table 4 displays the percentage of hydrogen bonding between the two oxygens of 
heme propionate A and the three hydrogens of K69 in all performed simulations. From 
analysis of the water trajectories it can be observed that water molecules occupy the space 
in between the propionates and near K69 during a major part of the simulations, providing 
H-bond No ligand DXM bound MDMA bound
WT Triple M01 M02 M05 Triple M01 M02 M05 Triple M01 M02 M05
propionate 
A – K69
78 66 39 71 55 95 11 93 60 109 96 78 70
Table 4: The sum of the occurrence (%) of hydrogen bonding between the two carboxylate oxygen atoms 
of heme propionate A and the three hydrogen atoms of the protonated K69 averaged over  all performed 
simulations.
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2. Improved activity of mutant M01 - the role of the E267V mutation
The M01 mutant contains only the E267V mutation in addition to the mutations present 
in the triple mutant, but displays a signiﬁcantly increased activity for both MDMA and 
dextromethorphan (Figure 1). E267 in the ligand free wild-type P450 BM3 crystal structure 
(PDB code 1BU7) [10] is situated in the active site, but with its side-chain directed out from 
the binding pocket, interacting with K440 on the surface of the protein. It is located near the 
exit of the active site channel, also called the solvent channel, described by Haines et al. [11]. 
Crystallographic data has shown that when the natural substrate of wild-type P450 BM3 is 
bound this solvent channel is closed off, preventing bulk solvent from entering the active site, 
thus possibly playing a role in the protection against undesired side-reactions resulting in 
uncoupling [11]. 
Molecular dynamics simulations of the M01 mutant with substrates MDMA and 
dextromethorphan as well as ligand free simulations show that V267 turns in towards the 
active site, oriented towards the side-chain of L181. This corresponds to a shift in the dihedral 
angle of the side-chain of V267 and results in a closing off of the solvent channel in the M01 
mutant. The size of the solvent channel was approximated by placing a virtual atom at the 
centre of geometry of the Cα atoms of the six residues M177, V178, L181, H266, E/V267 and T438 
and measuring the distance from this virtual atom to the nearest protein atom throughout 
the simulations. In this way an estimate of the diameter of the solvent channel can be 
obtained. The comparison of the solvent channel diameter between substrate free wild-type 
P450 BM3 and substrate free as well as dextromethorphan-bound mutant M01 is shown in 
Figure 7. In the wild-type simulation the channel diameter ﬂuctuates between 0.5 and 0.7 
nm, representing the open conformation, as in the substrate free crystal structures. Similar 
Figure 7: Time series of the solvent channel diameter (nm) of substrate-free wild-type P450 BM3 (black), 
substrate-free mutant M01 (dark grey) and dextromethorphan-bound mutant M01 (light grey). The 
diameter represents the biggest sphere possible, centred at the centre of geometry of the Cα atoms of 
M177, V178, L181, H266, E/V267 and T438. The channel diameter of mutant M01 is smaller than in the wild-
type. Substrate-free mutant M01 also displays an ‘opening’ and ‘closing’ of the solvent channel, it being 
completely closed in the dextromethorphan bound M01 simulation. The corresponding table displays the 
amount of open state (%) of the solvent channel for the wild-type and all the mutants, averaged over all the 
performed simulations. A diameter > 0.45 nm is here considered to represent an open state.
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behaviour is observed in the substrate-free triple mutant simulations. The channel diameter 
in the ligand free M01 mutant simulation however varies between 0.3 and 0.6 nm, displaying 
an opening and closing of the channel. In the dextromethorphan bound M01 simulation, 
the channel seems to be continuously closed, displaying a channel diameter that ﬂuctuates 
around 0.3 nm. 
To further investigate the opening and closing of the solvent channel, the water trajectories 
were analysed. The radial distribution function of the water molecules from the same virtual 
atom used for the channel diameter analysis was calculated. Figure 8A shows the number 
of water molecules in a shell at distance r from the virtual atom in the substrate free wild-
type, triple mutant and M01 mutant simulations. Figure 8B displays the number of water 
molecules in a sphere with a radius r centred at the virtual atom in the channel. It can be 
seen that the number of water molecules is clearly lower in the ligand free simulation of 
mutant M01 than in the corresponding simulations of wild-type and triple mutant, which 
display similar results. Figure 8C shows the number of water molecules in a shell at distance 
r from the same virtual atom positioned in the centre of the solvent channel, calculated 
from the dextromethorphan-bound triple mutant and mutant M01 simulations. Figure 8D 
shows that the number of water molecules in the channel (r < 0.5 nm) is lower in the ligand 
bound simulations than in the corresponding ligand free simulations (compare Figure 8B), in 
particular for the triple mutant. As seen previously from comparisons between substrate-free 
Figure 8: Average number of water molecules in a shell of radius r around the centre of geometry of the Cα 
atoms of M177, V178, L181, H266, E/V267 and T438 in (A) substrate free wild-type (black), triple mutant (dark 
grey) and mutant M01 (light grey) simulations and (C) dextromethorphan-bound triple mutant (dark grey) 
and mutant M01 (light grey) simulations. (B) and (D) Integrated values, i.e. the number of water molecules 
in a sphere of radius r.
sphere 
radius r (nm)
average number of 
water molecules
WT triple M01
0.1 0.01 0.12 0
0.2 0.11 0.99 0.08
0.3 0.48 2.1 0.32
0.4 1.3 3.6 1.1
0.5 3.3 5.4 2.5
sphere 
radius r (nm)
average number of 
water molecules
triple + DXM M01 + DXM
0.1 0.02 0
0.2 0.20 0
0.3 0.56 0.09
0.4 1.0 0.70
0.5 1.6 2.5
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residues F/I81 and I263 (Figure 10), located on the B’-, and I-helices, respectively. Similar to the 
M01 mutant analysis, the radius of the channel is described by the distance to the nearest 
protein atom from this virtual atom throughout the simulation. Figure 10 A and B display 
the time series of the channel diameter for substrate free wild-type, triple mutant and M05 
mutant (A) and dextromethorphan-bound triple mutant and M05 mutant (B). The channel 
diameter varies around 0.45 nm for the substrate-free M05 mutant and around 0.2 nm for 
the corresponding wild-type and triple mutant simulations. In the dextromethorphan-bound 
simulation, mutant M05 displays an open (0.5 nm) and closed (0.3 nm) channel, whilst the 
triple mutant is mostly in the closed state.
To further study the channel environment, the radial distribution functions of water 
molecules centred at the same virtual atom were calculated. Figure 11 displays the number 
of water molecules in a shell at distance r from the virtual atom in the substrate free wild-
type, triple mutant and M05 mutant simulations as well as in the  dextromethorphan-bound 
triple and M05 mutant simulations. Both in the substrate-free and the substrate-bound case 
a larger amount of water molecules are present close to the channel centre for mutant M05, 
indicating an opening of a channel connected to the protein surface and bulk water.
4. Mutant M02 - the conservative substitution L86I leads to a large increase of activity
The M02 mutant only contains the L86I mutation in addition to the three mutations present 
in the triple mutant. L86 is not located in the active site but on the proximal side of the 
heme. In the substrate-free crystal structure (PDB code 1BU7) [10] this residue is positioned 
next to one of the heme propionates (propionate D), as shown in Figure 2. Surprisingly, the 
conservative substitution of a leucine to an isoleucine causes a signiﬁcant increase in activity 
both for MDMA and dextromethorphan metabolism.
The molecular dynamics simulations do not show differences in the dynamic behaviour of 
the heme propionates for the M02 mutant compared to the other mutants. However, the 
simulations reveal conformational changes on the residues surrounding I86, in particular F261. 
The distance between the centre of geometry of the carbon atoms of the benzyl of F261 and 
the nearest side chain atom of L86 (Cδ1) in the triple mutant stays around 0.4 nm throughout 
the dextromethorphan-bound simulations. In contrast, the mutant M02 simulation shows 
an ‘opening’ and ‘closing’ movement, with the distance between the nearest side-chain atom 
of I86 (Cδ) and the centre of geometry of the benzyl of F261 regularly varying between 0.4 and 
0.6 nm in one simulation. 
To further investigate the effects of the opening and closing movement of F261, random 
acceleration molecular dynamics (RAMD) simulations were performed for MDMA bound 
mutant M02. In RAMD a random, artiﬁcial force is applied to the centre of mass of the ligand 
throughout the simulation, with the aim to facilitate exit of the ligand from the active site. 
If the ligand has not moved a minimum distance after a speciﬁed number of time steps a 
new force with a new random direction is applied. This way possible exit/entrance routes 
to buried active sites of proteins can be explored. The reason for choosing MDMA instead of 
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dextromethorphan for the RAMD simulation was the smaller size of MDMA. Several RAMD 
simulations were performed and a number of these revealed attempts of MDMA to exit the 
active site starting from the heme and passing in between F261 and I86 and to some extent 
I401 on the proximal side of the heme. In one RAMD simulation MDMA managed to exit 
the active site through this passage, indicating that this could be a possible entrance/exit 
route for the ligands. Figure 12 shows the concerned residues in four snapshots of this RAMD 
simulation.
Discussion
A proportion of 5cHS species was observed with Resonance Raman for all mutants in 
absence of any substrate, which could not be observed for the wild-type. Addition of 
dextromethorphan induced a slight spin-shift from 6cLS to 5cHS in mutant M05 only. These 
results are in agreement with the data as determined by UV-VIS spectroscopy, where a spin-
shift was observed in the case of mutant M05 and dextromethorphan. Additionally, a slight 
spin-shift was also seen with UV-VIS for mutant M02 with dextromethorphan. However, 
since the increase in 5cHS heme species as observed with RR was already small for M05 with 
dextromethorphan, it could be expected that the much smaller spin-shift with M02 and 
dextromethorphan, which was observed with UV-VIS spectroscopy, could not be detected by 
RR. The lack of spectral binding of MDMA to all mutants and dextromethorphan to mutant 
M01 does not imply that no binding of these substrates occurs or that the ligands bind 
far away from the heme, but only that the binding does not displace the water molecule 
functioning as the sixth heme iron ligand. The measured IC50 of MDMA to all mutants shows 
signiﬁcant binding. It can be concluded that MDMA does bind in the active site close enough 
to the heme iron to be metabolised, but does not displace the water molecule in doing so. 
The simulation results indicate a stable distance of 5-6 Å from the N-methyl of the ligands 
to the heme iron, a distance considered to be catalytically active, but with sufﬁcient  room 
for a water molecule coordinated to the heme iron. Varying amounts of substrate-induced 
spin-shift, depending on the nature of the substrate, have been reported before, indicating 
the possibility of the water as the sixth heme-iron ligand to coexist with the substrate in 
the active site [47-49]. It has been proposed that the hydrophobic nature of the natural 
substrates fatty acids, decreases the water afﬁnity to the heme when substrate binds [49]. In 
contrast, the substrates in this study both position a highly hydrophilic group, the protonated 
nitrogen, near the heme iron, which could stabilise the presence of the water molecule as the 
sixth ligand. Protein-substrate conformational changes further on in the catalytic cycle, e.g. 
upon reduction of the heme, have also been proposed [49]. 
The coupling efﬁciency for a number of previously described P450 BM3 mutants has been 
described to be very low (<1-25 %) [6, 19]. For the mutants described here the coupling 
efﬁciency varied between 17-45 %, which seems to correspond to the rates of metabolism 
by the different mutants. Mutant M02, which has similar coupling efﬁciencies for the 
substrates dextromethorphan and MDMA, also metabolised these two substrates with 
similar efﬁciency. For M01 and M05, however, the coupling efﬁciency with dextromethorphan 
was approximately 2-fold higher than with MDMA, which is reﬂected in the 4 to 5-fold 
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the heme propionates (propionate A) turns ‘upwards’ during the simulations, interacting 
with the positively charged nitrogen of the substrates. The RR observation was made in the 
absence of substrate and no change was detected when substrate was added, indicating that 
the conformational change of the heme propionates is an effect of the mutations and not of 
substrate binding. Likewise, as is shown in Figure 6B, the substrate-free simulations of the 
mutants display mainly two conformations of the heme propionate A, whilst the wild-type 
simulation displays only one. All mutants display this bending of the heme propionates, both 
from RR and simulation results, indicating that the bending is an effect of the F87V mutation, 
the only common mutation in the active site in all the mutants. F87 is located directly ‘above’ 
the heme (Figures 2 and 5), near the propionate groups. Substituting the large aromatic 
moiety with the smaller valine side-chain could allow for the turning ‘upwards’ of the heme 
propionates. Similar observations of conformational changes of the heme propionates and 
direct contact between the heme propionates and a substrate have been made previously for 
other heme proteins. Heme propionate conformational changes have been observed in the 
crystal structures of the inactive and active states of the di-heme cytochrome c peroxidase 
of Pseudomonas nautica. During the transition from the inactive to the active state one of 
the heme propionates undergoes large conformational changes. In the crystal structure of 
the ascorbate peroxidase-ascorbate complex [51] the ascorbate is interacting directly with 
one of the heme propionates and in doing so is removed from the heme iron centre [52]. It 
has also been suggested that the heme propionates play an important role in regulation of 
the electron delivery to the heme iron and that the environment of the heme propionates 
can inﬂuence the redox potential [16, 26, 52, 53]. The conformational changes of the heme 
propionates observed for all the mutants in this study could thus inﬂuence the catalytic 
efﬁciency. The conformational changes of the propionate and the following interaction 
with the protonated N of the substrates also provide an explanation for the observed N-
demethylation of dextromethorphan and MDMA by the P450 BM3 mutants described in this 
study.  
It has been suggested that closure of the solvent channel when ligand binds -  preventing bulk 
solvent access to the active site - is important for protection against undesired side-reactions, 
such as uncoupling [11]. The computer simulations indicate a closure of the solvent channel 
in the mutants containing the E267V mutation, i.e. M01 and M05, which correlates with the 
lower degree of uncoupling for dextromethorphan in mutant M01 and M05 compared to 
mutant M02. Also, substrate-free mutant M01 and dextromethorphan-bound M05 show a 
higher degree of 5cHS species. In contrast, for MDMA the uncoupling is similarly high for 
all mutants. However, the amount of uncoupling has been shown to be highly substrate-
dependent, which could explain the low coupling for MDMA in all mutants [18, 54, 55]. Both 
the spin-state and uncoupling presumably  correlates with the amount of water in the active 
site. MDMA is a smaller and more ﬂexible substrate than dextromethorphan, which allows 
for more water molecules in the active site when MDMA is bound. This could partly oppose 
the effect of the closing of the bulk solvent channel observed in mutant M01 and M05 and 
result in both higher uncoupling and lower amount of 5cHS species as well as lower rate of 
metabolism. To be noted is also the documented role of T268 and A264 in conversion from 
6cLS to 5cHS state as well as in uncoupling, by inﬂuencing the local water environment close 
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to the heme iron [11, 13, 18, 56]. In mutants M01 and M05, residue E267, in close vicinity of A264 
and T268 on the I-helix, is mutated, which could cause local changes that could inﬂuence 
the coupling and spin-state conversion. The observed facilitation of solvent channel closure 
in mutants M01 and M05 may not only have an effect of coupling and the presence of more 
5cHS species, but could also provide for more favourable hydrophobic interactions for the 
large lipophilic parts of the substrates.
Molecular dynamics simulations of mutant M05, revealed a shift of the B’-helix, opening up 
a possible ligand access/exit pathway similar to pw2c as described by Wade et al., normally 
not observed in  P450 BM3 wild-type, but in other P450s, e.g. 2C5, 2C8 and 2C9 [46]. Similar 
closing of the solvent channel as described for mutant M01 is also observed in mutant M05. 
The observed shift from an overall conformation similar to the substrate-free wild-type to 
a conformation similar to the substrate-bound wild-type for the B’-, F- and G-helices was 
also observed. This could provide for more favourable substrate-protein interactions. The 
increased activity of mutant M05 is likely a result of multiple mechanisms, leading to both 
more efﬁcient substrate uptake/product release and higher catalytic efﬁciency.
Mutant M02 contains only the conservative substitution L86I in addition to the triple mutant 
mutations. Similar to the increased activity of mutant M02, Wen et al have described a reverse 
mutation I115L, in cytochrome P450 6B1 from Papilio polyxenes, which resulted in reduced 
turnover of furanocoumarins [57]. Sequence alignments show that I115 in this insect P450 6B1 
corresponds to the L86 position in P450 BM3 [58]. L86 is not located in the active site and is 
thus not able to interact directly with the substrate. A possible explanation for the increased 
activity could be the induction of conformational changes either affecting the active site 
or active site access/exit pathways. It could also be possible that these conformational 
changes inﬂuence the heme properties or the electron transfer pathway to the heme. Neither 
Resonance Raman nor molecular dynamics simulations show any signiﬁcant difference in 
the conformation of the heme substituents between mutant M02 and the other mutants. 
The presence of 5cHS species without added substrate differs signiﬁcantly between wild-type 
P450 BM3 and all the mutants. The substrate-free wild-type shows no 5cHS species, whilst 
different amounts of 5cHS species are present in the substrate-free mutants. The differences 
in amount of 5cHS species in the mutants, both with and without substrates, give no clear 
indication whether the effect of the increased activity of mutant M02 is due to the spin-shift. 
However, the position of the mutated residue L86 - in close vicinity to heme propionate D - 
could inﬂuence the heme properties, although not detectable by the experimental methods 
used in this study. Also, the location of the L86 suggests a possible role in the electron transfer 
pathway from the FMN-domain to the heme. Our simulations indicate that the distance 
between F261 and I86 ﬂuctuates more in the mutant M02 simulations than in the other 
simulations. RAMD results show that MDMA can exit between F261 and I86 from the active 
site, which indicates that this could be a possible entrance/exit channel. Wade et al. have 
published various suggested pathways in a number of different cytochrome P450s based on 
RAMD experiments [45, 46]. To our knowledge this particular pathway has not been described 
before for wild-type P450 BM3. This suggests that this pathway would be speciﬁc for mutant 
M02.
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Conclusion
Three newly discovered drug metabolising mutants of cytochrome P450 BM3 have been 
further studied for two substrates, MDMA and dextromethorphan, with computational 
methods, Resonance Raman and UV-VIS spectroscopy and other experimental techniques. 
The main aim of this study was to ﬁnd structural explanations to four observations. 
In contrast to the human P450 2D6 generated product of the substrates, the major metabolite 
for both substrates in all the studied mutants is the N-demethylated one. For all mutants, 
Resonance Raman and computer simulation data show a bending of the heme propionate A 
towards the active site with and without substrate present.  The simulations  further suggest 
an electrostatic interaction between the negatively charged carboxylate of the propionate 
and the positively charged N of the substrates.      
The E267V mutation is responsible for a large increase in activity for both substrates. 
Molecular dynamics simulations suggest a closing of the bulk solvent channel from the active 
site in the mutants containing this mutation. This observation is to some extent supported 
by uncoupling and spin-shift data.
The F81I mutation in combination with the E267V mutation further increases the activity for 
both substrates. Computer simulations suggest an opening of the active site access/entrance 
channel pw2c as described by Wade et al. 
The conservative substitution L86I, not located in the active site, is responsible for an increase 
in activity. Its vicinity to the heme propionate D suggests an inﬂuence of the heme properties 
or electron transfer pathway. No conclusion could be drawn from experiments conducted in 
this study regarding a signiﬁcant difference in the heme properties of the mutant containing 
the L86I mutation compared to the other mutants. Molecular dynamics simulations reveal 
conformational changes in residues surrounding I86 in the mutant. RAMD simulations 
suggest that a possible active site access/exit pathway could be opened up, but another likely 
effect of the conformational changes of residues in the vicinity of the heme is an alteration of 
the electronic properties of the heme or the electron transfer pathway. 
In conclusion, a combination of modeling and experimental techniques has provided 
explanations for the roles of several mutations in three highly active drug metabolising 
P450 BM3 mutants developed by random mutagenesis. This integrated approach can 
provide useful information for development of site-directed mutants with further improved 
characteristics. 
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Abstract
Recently, several mutants of Cytochrome P450 BM3 (P450 BM3) with high activity toward 
drugs have been obtained by a combination of site-directed and random mutagenesis. In the 
present study, the applicability of these mutants as biocatalysts in the production of reactive 
metabolites from the drugs clozapine, diclofenac and acetaminophen was investigated. We 
showed that the four P450 BM3 mutants used in this study formed the same metabolites 
as human P450s, and they had an up to 30-fold higher activity compared to human P450s. 
Producing high levels of those reactive metabolites, that can cause adverse drug reactions 
(ADRs) in humans, would enable their isolation and structural elucidation with NMR, and 
would be very useful for the toxicological characterisation of these reactive metabolites.
Introduction
Cytochromes P450 (P450s) are involved in the metabolism of approximately 80% of the drugs 
currently on the market [1, 2]. Most often, metabolism by P450s increases solubility of the 
compound and facilitates urinary and biliary excretion. However, in some cases, metabolism 
of drugs by P450s can lead to the formation of reactive electrophilic metabolites that can 
subsequently react with macromolecules and give covalent adducts to proteins. These events 
are thought to be related to rare but serious adverse drug reactions (ADRs) and idiosyncratic 
drug reactions (IDRs). Consequently, it is important to assess the potential of novel drug 
candidates to form reactive electrophilic metabolites early in the drug discovery process [3]. 
The most common way to determine the formation of electrophilic metabolites is to screen 
for the formation of glutathione (GSH) adducts by LC-MS/MS analysis. Currently several 
methods exist for the sensitive and selective detection of GSH conjugates [4-6]. Although this 
strategy proves valuable to screen for the formation of reactive intermediates (RIs), for the 
structural elucidation of the reactive species involved NMR experiments are essential. NMR 
requires µg-mg amounts of pure compounds. Since the chemical synthesis of all possible 
reactive metabolites of drugs is generally too time-consuming, RIs are usually generated 
in in vitro enzymatic incubations using rat or human liver microsomes in the presence of 
GSH. However, generally only low concentrations of reactive metabolites are formed by these 
microsomes due to the low activity of human P450s and the occurrence of suicide inhibition 
of the enzymes by the RIs [7]. Producing high levels of those reactive species, and consequently 
of the corresponding GSH adducts, would greatly improve this process.
The soluble Cytochrome P450 BM3 (P450 BM3) from Bacillus megaterium is one of the most 
studied members of the Cytochrome P450 family. P450 BM3 would be a good candidate for use 
as a biocatalyst in biotechnology, because this very stable enzyme has the highest catalytic 
activity ever recorded for a P450 [8]. In a previous study we described a site-directed mutant of 
P450 BM3, R47L/F87V/L188Q, that is able to metabolise various drug-like molecules, including 
acetaminophen. Acetaminophen is metabolised by this triple mutant into the reactive N-
acetyl-p-benzoquinoneimine (NAPQI) intermediate, albeit with an activity still 15-fold lower 
than human P450 3A4 [9]. In a previous study, this mutant was subjected to several rounds 
of random mutagenesis, which resulted in four mutants with an up to 200-fold increased 
activity towards drug substrates compared to the triple mutant [10] (Table 1). 
In the present study we evaluated whether these novel drug metabolising P450 BM3 mutants 
can be used as biocatalysts for the biosynthesis of high amounts of reactive metabolites of 
drugs. We chose clozapine, diclofenac and acetaminophen as model compounds since these 
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drugs have been involved in serious ADRs in humans [11-13]. Moreover, these compounds are 
known to be bioactivated to several reactive electrophilic intermediates that can be trapped 
by GSH [14-18]. We therefore investigated whether the P450 BM3 mutants (Table1) were able 
to metabolise these drugs and to produce GSH adducts. The metabolites formed were 
subsequently compared to those formed by the human P450s known to be involved in the 
oxidative metabolism of these compounds. Consistently, it was determined whether the 
same metabolites were formed and assessed if higher levels of GSH adducts were obtained 
in comparison with human enzymes. In previous studies, E. coli cytosolic fractions were used 
for metabolism studies with these mutants. However, to prevent conjugation of the reactive 
metabolites to cytosolic components instead of GSH, for this study we used His-tagged P450 
BM3 mutants which were puriﬁed by nickel column chromatography.
Materials and Methods
Enzymes and plasmids
The P450 BM3 mutants M01, M02, M05 and M11 were prepared in the pT1-P450BM3 plasmid 
as described previously [10]. These mutants were cloned into a pET28a+ vector system, which 
contains an N-terminal His-tag that allows puriﬁcation by nickel column chromatography. 
The pET28a+ vector containing wild-type P450 BM3 as described in [19] was kindly provided 
by dr. V. Urlacher (Institut für Technische Biochemie, Universität Stuttgart, Germany). The 
genes of the mutants M01, M02, M05 and M11 were cloned into a pET28a+ vector as described 
in [19].
The plasmids pCWh3A4 and pCWh1A2 and pLCMhOR, containing P450 3A4, P450 1A2 and 
human NADPH P450 reductase, respectively, were a kind gift from dr. M. Kranendonk 
mutant M01 mutant M02 mutant M05 mutant M11
R47L R47L R47L R47L
E64G
F81I F81I
L86I
F87V F87V F87V F87V
E143G
L188Q L188Q L188Q L188Q
E267V E267V E267V
(N319T)a
(G415S)a (G415S)a (G415S)a
amutations in parenthesis were shown not to contribute to the 
enhanced activity of the mutant [10].
Table 1: Mutations in the P450 BM3 mutants used in this study.
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(Department of Genetics, Faculty of Medical Sciences, Universidade Nova de Lisboa, Portugal) 
and were expressed as described in [20]. The plasmid pCWh2C9/hOR, containing P450 2C9, 
bicistronically co-expressed with human NADPH P450 reductase, was a kind gift from dr. F. 
Guengerich and was expressed as described in [21].
Expression and purification
The His-tagged pET28a+ constructs were transformed into E. coli BL21(DE3) cells using standard 
procedures. For expression, 300 ml Terriﬁc Broth (TB) medium (24 g/L yeast extract, 12 g/L 
tryptone, 4 ml/L glycerol) with 30 µg/ml kanamycin was inoculated with 15 ml of an overnight 
culture. The cells were grown at 150 rpm and 37 °C until the OD600 reached 0.8. Then, protein 
expression was induced by the addition of 0.6 mM isopropyl-β-D-thiogalactopyranoside 
(IPTG), the temperature was lowered to 30 °C, and 0.5 mM of the heme precursor δ-
aminolevulinic acid was added. Expression was allowed to proceed for 5 hours. Cells were 
harvested by centrifugation (4000 g, 4 °C, 15 minutes), and the pellet was resuspended in 15 
ml KPi-glycerol buffer (100 mM potassium phosphate (KPi) pH 7.5, 10% glycerol, 0.5 mM EDTA 
and 0.25 mM dithiothreitol). Cells were disrupted using a French press (1000 psi, 2 repeats), 
and the cytosolic fraction was separated from the membrane fraction by ultracentrifugation 
(120,000 g, 4 °C, 60 minutes). The mutants were puriﬁed using Ni-NTA agarose (Sigma). To 
prevent aspeciﬁc binding, 1 mM histidine was added to the cytosolic fraction. 2 ml Ni-NTA 
slurry was added, and the cytosolic fraction was equilibrated at 4 °C for 3 hours. The Ni-NTA 
agarose was retained in a polypropylene tube with porous disc (Pierce, Rockford, USA), and was 
washed 3 times with 5 ml KPi-glycerol buffer containing 2 mM histidine. The P450 was eluted 
in 10 ml KPi-glycerol buffer containing 300 mM histidine. The histidine was subsequently 
removed by repeated washing with KPi-glycerol buffer in a Vivaspin 20 ﬁltration tube (10,000 
MWCO PES, Sartorius) (4000 g) until the histidine concentration was below 300 nM.
Formation of GSH aducts from clozapine, diclofenac and acetaminophen
Incubations had a ﬁnal volume of 250 µl and consisted of 100 mM potassium phosphate (KPi) 
buffer, pH 7.4, with 250 nM of puriﬁed P450 BM3 mutant (M01, M02, M05 or M11), 1 mM of 
substrate (clozapine, diclofenac or acetaminophen) and 5 mM GSH. Reactions were initiated 
by the addition of an NADPH regenerating system resulting in ﬁnal concentrations of 0.4 mM 
NADPH, 0.3 mM glucose-6-phosphate and 0.4 units/ml glucose-6-phosphate dehydrogenase. 
The reaction was allowed to proceed for 60 minutes at 24 °C, before it was terminated by the 
addition of 25 µl 10% HClO4. Only for diclofenac, the reaction was terminated by the addition 
of 250 µl cold methanol instead of HClO4. Samples were centrifuged to remove precipitated 
protein (4000 g, 15 minutes), and the supernatant was analysed on HPLC. Metabolites were 
separated using a C18 column (Phenomenex, Luna 5µ, 150 x 4.6 mm). The following gradient 
was used at a ﬂow rate of 0.5 ml/minute: from 0 to 5 minutes 0% eluens B, followed by an 
increase to 100% eluens B from 5 to 30 minutes, followed by a decrease to 0% eluens B from 
30 to 35 minutes, and ﬁnally 0% eluens B from 35 to 40 minutes. Eluens A consisted of 1% 
acetonitril and 0.2% formic acid; eluens B consisted of 99% acetonitril and 0.2% formic acid. 
Metabolites were detected using a UV detector at 254 nm. The Shimadzu Class VP 4.3 software 
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package was used to determine peak areas of the metabolites. Quantities of metabolites were 
estimated using standard curves of the substrates, assuming that the extinction coefﬁcients 
of the substrates and their metabolites are comparable.
To determine which peaks represent metabolites, control incubations without NADPH were 
performed. To establish which of the metabolites are GSH adducts, control incubations in the 
absence of GSH were also performed.
To compare the activity and the metabolic proﬁle of the P450 BM3 mutants to those formed 
by mammalian P450s, incubations were also performed with human P450s 1A2, 2C9 and 3A4, 
and with non-induced rat liver microsomes (RLM) that were prepared as described in [22]. For 
the human P450 incubations, 250 nM enzyme was used. For the RLM, a microsomal protein 
concentration of 2 mg/ml was used, corresponding to 2 µM total P450. These incubations 
were performed as described above, at 37 °C instead of 24 °C. 
The time dependence of product formation was determined for the three substrates, each 
with one representative P450 BM3 mutant. For clozapine and acetaminophen, M11 was used, 
and for diclofenac, M01 was used. Incubations were performed as described above, with 
incubation times of 0, 15, 30, 45 and 60 minutes.
To determine whether drug metabolism by the four mutants could be further increased by 
the addition of caffeine, as was described previously for P450 3A and for P450 BM3 R47L/F87V/
L188Q with acetaminophen [9, 23], incubations were performed as described above in the 
presence of 10 mM caffeine.
To identify the metabolites, LC-MS analysis was performed on representative samples. For 
acetaminophen and clozapine, incubations with M11 were used, and for diclofenac incubations 
with M05 were analysed because these incubations contained highest levels of metabolites. 
The runs were carried out under the same conditions as described above. An LCQ Deca mass 
spectrometer (Thermo Finnigan) was used, with positive electron spray ionisation (ESI). N2 
was used as sheath gas (60 psi) and auxiliary gas (10 psi), the needle voltage was 5000 V and 
the heated capillary was at 150 °C.
Results and discussion
Biotransformation of clozapine by human P450s and P450 BM3 mutants
For clozapine, three major GSH adducts have been described previously to be formed  by RLM 
and HLM [14]. Mainly responsible for the formation of these metabolites were P450 3A, 2C and 
2E [15]. The m/z values of these GSH adducts corresponded to clozapine+SG (m/z 632). 
In incubations performed with RLM, three GSH adducts were indeed observed (CG-1, CG-2 and 
CG-3) with an m/z value of 632, corresponding to clozapine+SG (Table 2). CG-1 and CG-2 were 
also formed by recombinant P450 3A4. The amount of CG-2 formed by P450 3A4 could not 
be quantiﬁed, because of background interference in the UV trace; this metabolite could be 
detected only by MS. In addition, as described in literature, several non-GSH metabolites were 
observed. P450 1A2, P450 3A4 and RLM all formed clozapine N-oxide and demethyl clozapine 
(C-2 and C-3), that were identiﬁed by their m/z values (m/z 343 and 313) [14, 15]. In addition, 
an unknown metabolite at tr= 20.4 minutes was formed by P450 1A2 and 3A4 (C-1). Two more 
unknown metabolites, C-4 and C-5 (tr= 15.7 and 14.2 minutes), were formed by RLM. 
185
C
H
A
PTER
8
The P450 BM3 mutants were able to form all the metabolites that were formed by human and 
rat P450s, except for C-1 (tr= 20.4 minutes) (Figure 1A, Table 2). However, the mutants showed 
different metabolic proﬁles. Mutant M11, that had the highest overall activity, did not form C-4 
(tr= 15.7 minutes), and was the only mutant that formed C-5 (tr= 14.2 minutes). Mutant M02, 
that had the lowest activity, did not form CG-2, C-2 and C-5. MS analysis of incubations 
performed with M11 also showed traces of two ions of m/z 618 at tr= 15.7 minutes and tr= 16.1 
minutes. Whether these signals correspond to the desmethyl clz+SG adducts mentioned in [14] 
has to be further investigated. The formation of the major GSH adduct CG-1 by M11 was 3.5-
fold higher than by P450 3A4. M11 was 50- and 6-fold more active than RLM in the formation 
of CG-2 and CG-3, respectively. For comparison, Figure 2A shows the formation of the major 
GSH adduct and the major non-GSH metabolite by the four mutants and P450 3A4, plotted in 
a bar graph. A proposed biotransformation scheme of clozapine is shown in Figure 3.
tr M01 M02 M05 M11
human/
rat
m/z proposed 
structure
GSH-conjugates
CG-1 16.0 22.0 ± 1.8 9.1 ± 0.1 59.6 ± 7.3 168.3 ± 8.4 6  (rlm)
51 (3A4)
632 cloza+SG
cloza+SG
CG-2 15.8 9.0 ± 1.5 - 20.7 ± 4.0 53.4 ± 2.7 1  (rlm)
+a (3A4)
632 cloza+SG
CG-3 15.5 1.3 ± 0.5 0.7 ± 0.2 2.5 ± 0.1 6.0 ± 2.4 1  (rlm) 632 cloza+SG
Stable metabolites
C-1 20.4 - - - - 17 (1A2)
23 (3A4)
?
C-2 17.4 13.3 ± 2.4 - 44.7 ± 9.2 115.8 ± 7.9 32 (rlm)
16 (1A2)
37 (3A4)
343 cloza+O
C-3 16.4 95.5 ± 14.5 7.5 ± 1.9 171.2 ± 20.3 465.2 ± 77.0 38 (rlm)
48 (1A2)
32 (3A4)
313 cloza-Me
C-4 15.7 7.9 ± 1.2 15.1 ± 2.6 10.1 ± 1.2 - 1 (rlm) ?
C-5 14.2 - - - 5.0 ± 1.2 4 (rlm) ?
Metabolites formed from clozapine by four mutants of P450 BM3, human P450s 1A2 and 3A4, and 
rat liver microsomes (RLM). tr is in minutes. Product formation is in nmol product/nmol enzyme/60 
minutes.
All GSH adducts are indicated in bold. m/z values corresponding to the protonated molecular ion [MH+] 
obtained by MS are indicated. a+: not quantiﬁable due to background interference.
Table 2: Metabolism of clozapine.
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Figure 1: Chromatograms of clozapine, diclofenac and acetaminophen metabolised by P450 BM3 mutants. 
Black line: standard incubation. Grey line: incubation without GSH. Light grey line: incubation without 
NADPH (negative control). A: clozapine metabolised by mutant M05. B: diclofenac metabolised by mutant 
M01. C: acetaminophen metabolised by mutant M11. GSH adducts are indicated in bold.
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In literature, four GSH adducts have been described for diclofenac metabolism by HLM, 
generally referred to as M1-M4 [17]. In the UV trace, no diclofenac metabolites could be 
observed after incubation with P450 3A4. However, with MS, trace amounts of one GSH adduct 
were detected (DG-3; Table 3). The m/z value corresponded to hydroxydiclofenac+SG (m/z 617). 
This adduct DG-3 probably corresponds to metabolite M1 or M3, that have the same m/z value 
and have been described in literature as P450 3A4 metabolites [24]. In the incubations with 
P450 2C9, one GSH adduct with m/z 617 could be detected by MS that could not be observed 
in the UV trace (DG-2b). This adduct DG-2b could correspond to the 4’-OH-3’-SG-diclo adduct, 
often referred to as M2, that has been described as the P450 2C9 metabolite [24]. These 
Figure 2: The formation of the major GSH adduct (black) and the major non-GSH metabolite (grey) in 
nmol/nmol/60 minutes, by the four mutants and human P450s. A: for clozapine, CG-1 and C-3 are shown. 
B: for diclofenac, DG-3 and D-1 are plotted, and C: for acetaminophen, NAPQI is shown.
Figure 3: Proposed biotransformation scheme of clozapine.
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ﬁndings were conﬁrmed with a more sensitive Agilent 1100 VL-series MSD ion trap MS, using 
solid phase extraction (SPE)-LC-MS/MS. On this MS, two metabolites with m/z 617 could be 
detected for P450 3A4, and one for P450 2C9, as has been described in literature [24]. 
One non-GSH metabolite was formed by P450 2C9, D-1, that could be identiﬁed as a hydroxy-
diclofenac (tr= 25.2 minutes; m/z 312). RLM formed the same hydroxydiclofenac metabolite, 
which, according to literature, represents 4’-hydroxydiclofenac [25]. 5-hydroxydiclofenac, 
which is described in literature as a P450 3A4 metabolite [24, 26], was not observed in the 
incubations with P450 3A4. This conﬁrms that the 4’-hydroxy-isomer is the major oxidative 
metabolite of diclofenac [26, 27]. 
Diclofenac was metabolised by the P450 BM3 mutants to 4’-hydroxydiclofenac (D-1) and 
ten different GSH adducts (Figure 1B, Table 3). The GSH adducts DG-1 and DG-2 (tr= 20.9 and 
20.2 minutes) were formed by all four mutants. According to MS analysis, the peak of DG-2 
consisted of two overlapping metabolites, one with an m/z value of 583 (DG-2a), corresponding 
to hydroxydiclofenac+SG-HCl, and the other with an m/z value of 617 (DG-2b, also formed by 
P450 2C9). A metabolite with the same m/z value as DG-2a has been described in literature as 
a P450 2C9 metabolite [17]. DG-3, a metabolite also formed by P450 3A4 (tr= 20.1 minutes; m/z 
617), was formed by all mutants except M02. DG-4 and DG-5 (tr= 19.5 and 19.1 minutes) were 
formed by all mutants. The mass of DG-4 could not be detected on MS under the conditions 
used. For DG-5, an m/z value of 922 was found, which corresponds to a double conjugated 
hydroxydiclofenac+2SG. Only mutant M01 formed DG-6 (tr= 18.5 minutes). DG-7 to DG-9 
(tr= 18.4, 17.5 and 17.2 minutes) were formed by all mutants except M02, and DG-10 (tr= 15.4 
minutes) was formed by all mutants. For DG-7, an m/z value of 888 was found, corresponding 
to hydroxydiclofenac+2SG-HCl. For DG-8, an m/z value of 854 was found, corresponding to 
hydroxydiclofenac+2SG -2HCl. Recently, Yu et al. described the detection of GSH adducts in 
incubations with human liver microsomes that correspond to the m/z values of DG-7 and DG-
8 [28]. DG-9 and DG-10 could not be detected on MS under the conditions used.
For diclofenac metabolism, the activities of mutants M01, M05 and M11 were similar. Only 
M02 showed a signiﬁcantly lower activity. Mutant M11 was 4-fold more active than P450 2C9 
for the formation of D-1, and 30-fold more active than RLM. The mutants also formed DG-2b 
and DG-3 with much higher activity than P450 2C9 and P450 3A4, but since the peaks of the 
human P450s could only be detected on MS, they could not be quantiﬁed. For comparison, 
Figure 2B shows the formation of the major GSH adduct and the non-GSH metabolite by the 
four mutants and P450 2C9, plotted in a bar graph. A biotransformation scheme of diclofenac 
is presented in Figure 4, proposing several possible structures for the glutathione conjugates 
detected in this study.
Biotransformation of acetaminophen by human P450s and P450 BM3 mutants
Similar to what has been described previously [18], acetaminophen was metabolised by P450 
1A2 and 3A4 into NAPQI (Table 4), as measured by GSH-conjugation. All P450 BM3 mutants and 
RLM also produced NAPQI-SG conjugates (Figure 1C, Table 4). NAPQI-SG (m/z 457) was formed 
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with the highest speciﬁc activity by mutant M11, which was 30-fold higher than the activity of 
mutant M02, P450 1A2 and P450 3A4. The data is plotted in a bar graph in Figure 2C.
Time dependence of metabolite formation
It is known that reactive intermediates sometimes react with the enzyme resulting in 
suicide inhibition of the enzyme. For example, mechanism-based inhibition was observed 
previously with rat P450 2C11 with diclofenac [7]. The time dependence of product formation 
was determined to see whether such inhibition occurred. From a previous study on the P450 
BM3 random mutants it was known that these mutants show non-linear time course; after 
an initial fast phase, the reaction continued at a lower activity [10]. In the present study, the 
initial phase has not been investigated. The product formation was linear from 15 minutes 
to 60 minutes (data not shown), indicating that suicide inhibition by reactive metabolites 
does not occur in this time frame.
Heterotropic cooperativity: activation by caffeine
In a previous study, we showed that acetaminophen metabolism by the P450 BM3 triple mutant 
R47L/F87V/L188Q could be activated up to 70-fold by the addition of caffeine [9]. To determine 
whether this activation also occurs for the four random mutants, incubations with clozapine, 
diclofenac and acetaminophen were performed in the presence of 10 mM caffeine. Activation 
Figure 4: Proposed biotransformation scheme of diclofenac.
191
C
H
A
PTER
8
was observed only for mutant M02 with acetaminophen; this activation was approximately 
10-fold (Figure 5). For mutant M01, 4-fold inhibition was observed in the presence of 10 mM 
caffeine, and for mutant M05 and M11, the presence of caffeine did not have any effect on the 
catalytic activity. For the other two substrates, no activation or inhibition was observed in the 
presence of caffeine (data not shown). Apparently, the additional mutations in M01, M05 and 
M11 compared to the triple mutant and mutant M02 changed the active site of the mutants 
so that heterotropic cooperativity no longer occurs. The active site mutation that these three 
mutants have in common is E267V, a mutation that was suggested to alter the shape of the 
active site [10]. 
Conclusion
The aim of the present study was to evaluate the applicability of highly active mutants 
of P450 BM3 for the biosynthesis of high amounts of reactive metabolites of drugs, using 
tr M01 M02 M05 M11
human/
rat
m/z proposed 
structure
GSH-conjugates
NAPQI+SG 15.1 150.0 ± 43.7 38.0 ± 3.5 417.0 ± 77.4 904.5 ± 189.3 17  (rlm)
35(1A2)
37  (3A4)
457 NAPQI+SG
Metabolites formed from acetaminophen by four mutants of P450 BM3, human P450s 1A2 and 3A4, 
and rat liver microsomes (RLM). tr is in minutes. Product formation is in nmol product/nmol enzyme/60 
minutes.
All GSH adducts are indicated in bold. m/z values corresponding to the protonated molecular ion 
([MH+]) obtained by MS are indicated.
Table 4: Metabolism of acetaminophen.
Figure 5: Effect of caffeine on acetaminophen metabolism by P450 BM3 mutants. % Activity in the absence 
(white bars) and presence (black bars) of 10 mM caffeine.
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clozapine, diclofenac and acetaminophen as model compounds. The P450 BM3 mutants 
formed the same reactive metabolites as human and rat P450s for these three substrates, 
which is important for the application of these enzymes as biocatalysts. The pharmaceutical 
industry is mainly interested in the identiﬁcation and characterisation of drug metabolites 
that are formed by human drug metabolising enzymes, and are thus clinically relevant. 
The use of the drug metabolising P450 BM3 mutants has several advantages over the currently 
used methods that involve RLM, HLM, or heterologously expressed human P450s. Because 
of their higher activity, minor metabolites can be detected that are below the detection 
limit in incubations with mammalian P450s. Additionally, in this study we showed that 
suicide inhibition of the P450 BM3 mutants by reactive metabolites does not occur, while this 
phenomenon has been described for human P450s [7]. 
This study shows how drug metabolising mutants of P450 BM3, which have been developed by 
directed evolution, can be used for the generation of large quantities of reactive metabolites. 
They can be used to determine the potential of new chemical entities to form reactive 
electrophilic metabolites, and for subsequent structural elucidation and toxicological 
characterisation of these metabolites. These enzymes can be applied as novel tools in the 
development of safer drugs.
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SUMMARY
Summary
In recent years, an interest in the application of Cytochromes P450 (P450s) as versatile, 
efﬁcient, selective and environmentally friendly biocatalysts has risen. With DNA mutagenesis 
techniques such as site-directed mutagenesis and directed evolution, it has now become 
possible to generate enzymes that are customised for biotechnology. In this thesis, several 
applications of mutagenesis techniques on human and bacterial P450 enzymes with respect 
to potential biotechnological applications are explored. The research focused on two main 
topics: (i) validation of protein homology models and elucidation of the roles of active 
site residues in substrate binding and catalysis by means of site-directed mutagenesis, to 
increase our understanding of the structure and mechanism of human P450s; (ii) the use 
of structure-guided site-directed mutagenesis and random mutagenesis to generate highly 
active drug metabolising mutants of bacterial P450 BM3, that could be used as biocatalysts 
for drug discovery and synthesis, and could function as a model system for human P450s.
In chapter 1, it is explained that P450s have a high potential as biocatalysts, because of the wide 
variety of reactions they can catalyse and their broad substrate range [1-4]. The mammalian 
drug-metabolising enzymes have practical limitations for use in biotechnology, such as low 
stability, low activity, low expression levels and the need for a separate reductase. Bacterial 
P450s on the other hand are generally more stable, have a higher activity and are easier to 
overexpress, but a disadvantage is their narrow substrate speciﬁcity [4, 5]. In recent years, 
when novel mutagenesis techniques such as directed evolution became available, these 
limitations have been solved to some extent by protein engineering.
In part I of this thesis, site-directed mutagenesis of the human P450 2D6 was used to 
investigate the role of aromatic active site residues. P450 2D6 is particularly important, 
because it plays a role in the metabolism of 30% of the drugs currently on the market, and 
because of the occurrence of genetic polymorphisms that result in large interindividual 
differences in P450 2D6 activity [6]. Extensive structural knowledge of P450 2D6 would help 
to develop structural computational models that can accurately predict P450 2D6 afﬁnity and 
sites of oxidation of new clinical candidates. Typical P450 2D6 substrates usually contain one 
or more basic nitrogens and aromatic moieties [7]. Based on a homology model developed 
in our laboratory, phenylalanine 120 (F120) was predicted to be involved in interactions 
with the aromatic moiety of the substrate. The aromatic moieties of the P450 2D6 inhibitor 
quinidine and the P450 2D6 substrate sparteine were suggested to undergo π-stacking with 
the aromatic F120 [8].
SUMMARY, CONCLUSIONS AND PERSPECTIVES
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In chapter 2, site-directed mutagenesis was used to determine the role of this residue 
experimentally. The phenylalanine residue was mutated to the smaller, non-aromatic 
alanine (F120A), and the effect of this mutation on the metabolism of several typical 
P450 2D6 substrates was studied. The effects of this mutation were shown to be strongly 
substrate-dependent: while 7-methoxy-4-(aminomethyl)-coumarin (MAMC) was not at all 
metabolised by the mutant, metabolism of bufuralol was hardly affected by the mutation. 
For dextromethorphan and 3,4-methylenedioxymethylamphetamine (MDMA), the metabolic 
proﬁle was affected. In addition to O-demethylation, double (O- and N-) demethylation was 
observed for P450 2D6[F120A]. For MDMA, which is mainly O-demethylenated by wild-type 
P450 2D6, two additional metabolites were observed for the F120A mutant [9]. Furthermore, 
the binding afﬁnity of quinidine, that is proposed to undergo π-stacking with F120, was 
decreased 6-fold in the F120A mutant. The results from this study conﬁrmed the hypothesis 
that F120 has an important role in ligand binding and metabolism. The bulky F120 residue 
probably inﬂuences substrate orientation by steric interactions, thus affecting the metabolic 
proﬁle, and it may have a role as an aromatic interaction point. 
A second aromatic residue that was proposed by several homology models to be important 
for P450 2D6 afﬁnity is F483 [8, 10-12]. In chapter 3, the role of F483 in P450 2D6 activity was 
also investigated experimentally by site-directed mutagenesis. P450 2D6 wild-type and 
P450 2D6[F483A], where the aromatic phenylalanine was replaced by an alanine, were again 
characterised using four typical P450 2D6 substrates [13]. Similar to what was observed for 
P450 2D6[F120A], the effects of the F483A mutation were strongly substrate dependent. 
MAMC metabolism was completely abolished in P450 2D6[F483A], as was also seen for P450 
2D6[F120A]. Apparently, both phenylalanines are essential for MAMC metabolism. Bufuralol 
metabolism was severely hampered in P450 2D6[F483A], while MDMA metabolism decreased 
only 2-fold. For dextromethorphan metabolism, the metabolic proﬁle was changed as an 
effect of the F483A mutation: N-demethylation of dextromethorphan was much more 
pronounced in P450 2D6[F483A] compared to wild-type, and two additional metabolites 
were formed. The binding afﬁnities of MDMA, dextromethorphan and bufuralol were similar 
for P450 2D6[F483A] and wild-type, suggesting that F483 undergoes steric interactions with 
ligands rather than aromatic interactions.
In part I, site-directed mutagenesis was used successfully used to elucidate the role of the 
aromatic active site residues F120 and F483 in P450 2D6 substrate binding and catalysis. Our 
experimental ﬁndings were in agreement with the predictions made based on the P450 2D6 
homology model built in our laboratory.
Part II of this thesis was dedicated to P450 BM3, one of the most intensively studied bacterial 
P450s. In chapter 4, the ﬁrst ﬂuorescent screening assay for P450 BM3 was developed [14]. 
7-Alkoxyresoruﬁns are drug-like compounds that are known to be metabolised to highly 
ﬂuorescent resoruﬁn by various mammalian drug metabolising P450s. Wild-type P450 BM3 
is not able to metabolise any of the 7-alkoxyresoruﬁns tested. A series of P450 BM3 mutants 
was created to obtain enzymes that could metabolise these substrates. From literature, three 
different residues were selected for site-directed mutagenesis that were shown to enable 
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P450 BM3 to convert non-natural substrates such as polycyclic aromatic hydrocarbons (PAHs) 
and indole [15, 16]. These mutations, R47L, F87V and L188Q, were introduced in different 
combinations, resulting in ﬁve mutants. The highest activity was observed for the triple 
mutant, containing all three mutations (R47L/F87V/L188Q). This novel triple mutant was 
subsequently used in a high-throughput inhibition screening assay with 7-benzyloxyresoruﬁn 
as a substrate. 45 Drugs were thus screened for P450 BM3 afﬁnity. Using this assay, six 
compounds were identiﬁed that inhibited the activity of the triple mutant by more than 
50% at an inhibitor concentration of 50 µM. Using E. coli cells with LPS-deﬁciency to increase 
cell permeability, the assay could also be performed in whole cells, thus circumventing 
time consuming enzyme isolation procedures. This novel cellular assay enabled the high-
throughput screening of compounds for P450 BM3 afﬁnity. Alternatively, the assay could be 
applied to screen libraries of P450 BM3 mutants for their ability to metabolise different 7-
alkoxyresoruﬁns. Finally, this could also lead to the discovery of novel mutants that are able 
to convert drugs or drug-like substrates.
Based on the inhibition assay described in chapter 4, it was established that the triple mutant 
of P450 BM3 has afﬁnity for drug-like ligands. In chapter 5, the ability of this mutant to 
metabolise several drugs that are known to be metabolised by mammalian drug metabolising 
P450s, was studied. The results showed that the drugs acetaminophen, MDMA, amodiaquine 
and dextromethorphan, and the steroids androstenedione, nandrolone, progesterone and 
testosterone were all metabolised by the triple mutant, but not by wild-type P450 BM3 [17]. 
The versatility of the triple mutant was illustrated by the number of different types reactions 
it catalysed, including C-hydroxylation, N-hydroxylation, N-dealkylation, O-demethylenation 
and dehydrogenation.
Some of the mammalian drug metabolising P450s exhibit atypical kinetics, such as 
heterotropic and homotropic cooperativity. Especially the P450 3A family is known for its 
atypical behaviour [18]. Interestingly, atypical kinetics were also observed for the P450 
BM3 mutant described in this study. For all steroids, sigmoidal V/[S] curves were obtained, 
indicative of positive homotropic cooperativity. This phenomenon has also been described 
for testosterone metabolism by P450 3A4 [18]. For MDMA and acetaminophen metabolism, 
strong heterotropic cooperativity was shown to occur in the presence of caffeine, a known 
activator of acetaminophen metabolism by P450 3A [19]. Since P450 BM3 enzymes are easier 
to study than mammalian P450s, P450 BM3 mutants could be used as a model system to 
increase our understanding of the mechanisms underlying atypical kinetics in mammalian 
P450s using biophysical approaches.
In chapter 6, the triple mutant R47L/F87V/L188Q described in chapter 5 was subjected to 
random mutagenesis in order to further increase its catalytic activity. The 7-alkoxyresoruﬁn 
screening assay described in chapter 4 was used to screen the libraries of random mutants. In 
addition, an LC-MS screening assay was developed using dextromethorphan as a substrate 
[20]. In three generations of error prone PCR, four mutants were identiﬁed with up to 200-fold 
increased activity towards drug-like compounds compared to the P450 BM3 triple mutant. 
The initial activity of the most active random mutant, M11, towards dextromethorphan was 
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90-fold higher than of P450 2D6, a benchmark P450 for this substrate. Sequence analysis of 
these mutants led to the discovery of several active site and non-active site residues in P450 
BM3 that are important for catalytic activity. The largest increases in activity were caused by 
the mutations F81I, L86I and E267V, which led to a 20 to 75-fold increase in dextromethorphan 
metabolism compared to the triple mutant.
A better understanding of the role of the mutations described in chapter 6 would contribute 
to our structural and mechanistic knowledge on P450 BM3. This could eventually enable 
rational design of P450 BM3 mutants with speciﬁc properties for biotechnological 
applications. In addition, structural and mechanistic knowledge on P450 BM3 could also help 
in understanding the mechanisms of P450s in general. Therefore, in chapter 7, three of the 
mutants described in chapter 6, M01, M02 and M05, were characterised with a combination 
of computational and experimental techniques. Molecular dynamic simulations as well as 
Resonance Raman spectroscopy suggested that one of the heme propionates has ﬂipped up 
in all three mutants. This seemed to be caused by the extra space above the heme plane 
resulting from the F87V mutation, present in all three mutants. This propionate is suggested 
to undergo electrostatic interactions with the basic nitrogen of the substrates, which could 
explain why N-demethylation is the favoured reaction in these mutants. Molecular dynamics 
simulations suggested that the E267V mutation present in M01 and M05 would cause closing 
of the bulk solvent channel. This was supported by a high proportion of high-spin heme 
observed by UV-VIS and Resonance Raman spectroscopy in the substrate-free M01 mutant, 
which is indicative for a lower number of water molecules in the active site. Closure of the 
solvent channel is known to take place in wild-type P450 BM3 after substrate binding, and is 
thought to protect the active site from undesired side reactions [21]. By facilitating the closure 
of the solvent channel, the E267V mutation could inﬂuence the rate of product formation by 
the P450 BM3 mutants. The F81I mutation, present in mutant M05, was shown by molecular 
dynamics simulations to induce a shift in the B’-helix. This shift could result in the opening 
of a channel connected to the protein surface, which might facilitate substrate entrance 
and/or product exit. The conservative L86I mutation in mutant M02 is located next to the 
heme. Molecular dynamics simulations of mutant M02 indeed revealed conformational 
changes in the residues surrounding I86. These changes could result in the formation of a 
ligand entrance/exit pathway. Random acceleration molecular dynamics (RAMD) studies [22] 
showed that the ligand MDMA was indeed able to exit through this passage. However, since 
I86 is located near one of the heme propionates, the conformational changes around this 
residue could also have an effect on the electronic properties of the heme, or the electron 
transport to the heme.
Some drugs can be converted into reactive electrophilic metabolites by P450s in the human 
liver. These reactive metabolites can form protein adducts and result in serious adverse 
drug reactions [23]. Therefore, it is considered important to establish in an early stage in 
drug discovery whether a clinical candidate has the potential to form reactive metabolites. 
The drugs clozapine, diclofenac and acetaminophen are known to be converted by human 
P450s into reactive metabolites. However, many of these reactive metabolites cannot 
readily be synthesised by organic chemistry, thus complicating the availability of reference 
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standards. The amounts of reactive metabolites formed by human P450s are generally too 
low to allow puriﬁcation and identiﬁcation by for example NMR [24]. In chapter 8, it was 
investigated whether the four drug metabolising random mutants described in chapter 6 
could be applied for the generation of reactive metabolites in quantities allowing chemical 
characterisation. The results described in chapter 8 show that the four drug metabolising 
random mutants of P450 BM3, M01, M02, M05 and M11, were all able to convert clozapine, 
diclofenac and acetaminophen into several reactive metabolites, that could be detected as 
glutathione (GSH) adducts. All GSH adducts that were formed by rat liver microsomes (RLM) 
and human P450s 1A2, 3A4 and 2C9 were also formed by the P450 BM3 mutants. In addition, 
the mutants formed several novel GSH adducts that have not been identiﬁed in incubations 
with human or rat P450s. The activity of the random mutants of P450 BM3 was 3 to 30-fold 
higher than the human P450s.
In part II, a combination of structure-guided site-directed mutagenesis and directed evolution 
was used to obtain highly active drug metabolising mutants of P450 BM3. These mutants 
were able to metabolise several drugs with up to 90-fold higher activity than human P450s, 
and they formed metabolites that are also formed by human P450s. Such mutants have great 
perspectives as biocatalysts in drug synthesis, discovery and development.
Conclusions and perspectives
The focus of the research described in this thesis was to explore the application of mutagenesis 
techniques on P450 enzymes to obtain biocatalysts that could be used in pharmaceutical 
industry. Two main aspects have been evaluated: (i) the use of site-directed mutagenesis for 
the elucidation of the roles of active site residues in substrate binding and catalysis, and 
subsequent validation of the protein homology model, to increase our understanding of the 
structure and mechanism of P450s; (ii) the use of a combination of site-directed and random 
mutagenesis for the development of P450 BM3 mutants that are able to metabolise a wide 
range of drug molecules, that could be used as biocatalysts in drug discovery and synthesis.
Site-directed mutagenesis for novel insights
An iterative process of site-directed mutagenesis, subsequent characterisation of the mutant, 
and computer modeling can be used integratively to gain structural and mechanistic 
information on P450s. In this thesis, the role of two aromatic active site residues that 
were suggested by our homology model to be involved in ligand binding in P450 2D6, was 
investigated experimentally using site-directed mutagenesis. The fact that our experimental 
ﬁndings were in agreement with the predictions from the homology model increased our 
conﬁdence in the quality of this model, which was based on the substrate-bound X-ray 
structure of rabbit P450 2C5. During the last stage of this research project, the ﬁrst, substrate-
free, X-ray crystal structure became available for P450 2D6 [25]. This crystal structure was 
in very good agreement with our homology model. For 88% of the Cα-atoms, the distance 
between the coordinates in the homology model and in the crystal structure was less than 2 
Å, which is comparable to the resolution of the crystal structure [12]. Furthermore, differences 
204
SUMMARY
between the computational model and the crystal structure can also be attributed to the 
fact that the crystal structure was substrate-free, while the homology model was based on a 
substrate-bound structure.
Our studies have shown that site-directed mutagenesis of residues involved in substrate 
binding can lead to altered metabolic proﬁles (chapter 2 and 3). Structure-guided redesign of 
the active site can be used to manipulate the regioselectivity of P450 enzymes. This approach 
can be used to elucidate active site topologies and to design biocatalysts that produce 
pharmaceutically interesting metabolites with high speciﬁcity.
Highly active drug metabolising random mutants of P450 BM3
Mutant P450 enzymes that are able to produce high amounts of drug metabolites can be 
very valuable as biocatalysts. They could be applied to generate metabolites from novel drug 
candidates for structural, toxicological and pharmacological characterisation. Also, they 
could be used for the biosynthesis of known pharmacologically active compounds. In drug 
discovery, a library of diverse mutant P450s could be used to functionalise lead compounds 
in order to identify potential novel drugs and drug candidates.
When the research described in this thesis started, only few reports on directed evolution of 
mammalian drug metabolising P450s were known. In 1999 and 2001, two directed evolution 
studies had been published on P450 1A2 and P450 2A6 that described only a 2 to 10-fold 
increase in catalytic activity toward several substrates (chapter 1, Figure 11). During the course 
of the present research project, several more directed evolution studies on mammalian 
P450s came available, however, the accomplished increases in catalytic activity still rarely 
exceeded 10-fold (chapter 1, Figure 11). The random mutagenesis attempts on mammalian 
P450s have so far yielded only marginal improvements. On the other hand, at the start of 
the present research project numerous directed evolution studies had been published for 
bacterial P450s, in particular P450cam, P450eryF and P450 BM3. The outcome of these studies 
ranged from increased catalytic activity and increased solvent resistance, to the conversion 
of non-natural substrates with turnover numbers that far exceeded the turnover numbers of 
human P450s (chapter 1, Figure 11).
Therefore, at the start of this research project, the choice was made to use the bacterial P450 
BM3 as a starting point. A combination of structure-guided site-directed mutagenesis and 
random mutagenesis was subsequently used to generate highly active drug metabolising 
mutants of P450 BM3. That this approach was very successful is illustrated by the fact that 
we identiﬁed several novel mutants of P450 BM3 that are able to convert many structurally 
diverse drug-like compounds with catalytic activities that exceed the activities of mammalian 
drug metabolising P450s by 100-fold (chapter 6 and 8). The catalytic activity observed for the 
most active mutant, M11 (314 min-1, chapter 6, Table 1), was in the same range as described for 
other P450 BM3 mutants with several non-natural substrates (110 – 287 min-1 for indole and 
several polycyclic aromatic hydrocarbons, chapter 1, Figure 11). 
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Over the past seven years, attempts to broaden the substrate speciﬁcity of cytosolic bacterial 
P450s including P450 BM3, by us and by others, have been very successful (chapter 1, Table 7 
and Figure 11). Directed evolution attempts on membrane bound mammalian P450s, on the 
other hand, have so far resulted in only slight increases in the catalytic activity. Apparently, 
the low intrinsic catalytic activity of mammalian drug metabolising P450s is difﬁcult to 
increase by directed evolution. The ﬁnding that the substrate speciﬁcity of P450 BM3 can 
be broadened by directed evolution without loss of the intrinsic high catalytic activity of 
this enzyme, conﬁrms our initial assumption that directed evolution of P450 BM3 is a more 
effective approach to obtain highly active drug metabolising P450 enzymes than directed 
evolution of mammalian P450s.
Computational and mechanistic studies on P450 BM3
In the drug metabolising random mutants of P450 BM3 described in this thesis, several 
residues could be identiﬁed that have a large effect on the catalytic activity of the enzyme 
(chapter 6 and 7). The role of these residues could be rationalised using a combination of 
computational and experimental studies. This resulted in novel insights in substrate binding 
and catalysis in P450 BM3 and P450 BM3 mutants. This information can be used in future 
research, to aid the development of novel P450 BM3 mutants for pharmaceutical industry by 
using a combination of site-directed and random mutagenesis. Furthermore, the mutants 
described in this thesis can be used for detailed mechanistic studies on for example the 
mechanisms of atypical kinetic behaviour or uncoupling in P450s. The high stability and 
solubility of the mutants makes them more suitable for many biophysical studies than 
mammalian P450s, and the fact that they show similar catalytic mechanisms as mammalian 
P450s makes them representative models for this class of enzymes.
Unresolved issues: further research 
In this thesis we describe the development of several highly active drug metabolising P450 
BM3 mutants with very good perspectives as biocatalysts. However, for successful application 
of these mutants as biocatalysts, some issues remain to be resolved. First of all, as described in 
chapter 6 (Figure 2), all mutants showed a very fast initial activity that decreased 4 to 360-fold 
during the ﬁrst 60 seconds of the reaction. If this inactivation could be prevented, the total 
amount of product formed by the mutants would increase enormously. Therefore, further 
research on the cause and prevention of this inactivation is desired. For example, cytochrome 
c reduction measurements could be used to investigate whether the inactivation takes place 
in the reductase domain rather than the heme domain.
Secondly, the whole-cell incubations as they were performed in our studies still require the 
addition of the expensive cofactor NADPH, which is not desirable for large-scale incubations. 
This could be solved by performing the incubations under non-lytic conditions, in order 
to allow the use of the endogenous NADPH supply of the cells. Under such conditions, the 
substrate uptake into the cells might become rate limiting; this could be tackled, however, by 
further increasing the cell wall permeability, or by stimulating active uptake of the substrate 
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into the cell. The use of expensive NADPH can in principle also be circumvented using mutants 
of P450 BM3 that are able to use the much cheaper NADH as electron donor. Such mutants, 
containing mutations in the reductase domain, have recently been described by others [26]. 
Further research could also focus on alternative electron sources, such as electrochemical 
reduction [27] or the use of hydrogen peroxide as oxygen source [28].
In summary, mutagenesis techniques provide a powerful tool to manipulate enzyme 
properties. Several interesting applications of mutagenesis to facilitate the use of P450s in 
the pharmaceutical industry have been explored in this thesis. In the ﬁrst part of this thesis we 
have described the use of site-directed mutagenesis to elucidate the role of active site residues 
of P450s. We showed that this technique can be used to gain insight on ligand binding and 
catalysis, and thus to increase our understanding of the fundamental catalytic mechanisms of 
P450s. Furthermore, site-directed mutagenesis of residues involved in substrate binding can 
be used to alter the metabolic proﬁle and regiospeciﬁcity of the enzymes. Subsequently, in part 
II we demonstrated how a combination of structure-guided site-directed mutagenesis and 
random mutagenesis can be used to create stable, highly active drug metabolising mutants 
with a broad substrate speciﬁcity that have great perspectives in drug discovery, development 
and safety assessment. Such mutants can be used to synthesise drugs, or to generate drug 
metabolites in such amounts that toxicological and pharmacological characterisation 
of the metabolites is possible. In addition, functionalisation of lead molecules by diverse 
libraries of mutants could be used for the discovery of novel, pharmacologically active 
molecules. Furthermore, we have shown that (mutants of) bacterial P450 BM3 can be used 
as a convenient model system to study the mechanisms of mammalian drug metabolising 
P450s, such as atypical kinetics. In conclusion, mutagenesis techniques are efﬁcient tools to 
create customised biocatalysis tools for a wide variety of industrial applications, as has been 
demonstrated in this thesis for Cytochromes P450.
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LIST OF ABBREVIATIONS
P450 cytochrome P450
P450 BM3 cytochrome P450 BM3
P450 2D6 cytochrome P450 2D6
BROD benzyloxyresoruﬁn O-dealkylation
EROD ethoxyresoruﬁn O-dealkylation
MROD methoxyresoruﬁn O-dealkylation
PROD  pentoxyresoruﬁn O-dealkylation
MDMA  3,4-methylenedioxymethylamphetamine
MDA  3,4-methylenedioxyamphetamine
3,4-OH-MA 3,4-dihydroxymethylamphetamine
N-OH-MDMA N-hydroxy-3,4-methylenedioxymethylamphetamine
NAPQI(-SG) N-acetyl-p-benzoquinoneimine (glutathione conjugate)
GSH  glutathione (reduced)
α-NF  α-naphthoﬂavone
tr  retention time
FAD  ﬂavin adenine dinucleotide
FMN  ﬂavin mononucleotide
PAH  polycyclic aromatic hydrocarbon
KPi  potassium phosphate
TCA  trichloroacetic acid
LPSd  lipopolysaccharide defective
pNCA  p-nitrophenoxycarboxylic acid
CPR  cytochrome P450 reductase
AU   arbitrary units
HAMC  7-hydroxy-4-(aminomethyl)-coumarin
MAMC  7-methoxy-4-(aminomethyl)-coumarin
SD  standard deviation
RR  resonance raman
RLM  rat liver microsomes
HLM  human liver microsomes
ADR  adverse drug reactions
IDR  idiosyncratic drug reactions
RI  reactive intermediates
5cHS  5-coordinated high-spin heme
6cLS  6-coordinated low-spin heme
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Nieuwe biokatalysatoren voor het ontwikkelen
en synthetiseren van geneesmiddelen
De laatste jaren is er vanuit de industrie een toenemende interesse om Cytochroom P450 
(P450) enzymen te gebruiken als veelzijdige, efﬁciënte, selectieve en milieuvriendelijke 
biokatalysatoren. Omdat P450s in de mens betrokken zijn bij de afbraak van geneesmiddelen 
in de lever, ligt de toepassing van P450s in de farmaceutische industrie voor de hand. Het 
nadeel van het gebruik van enzymen in de industrie is dat hun eigenschappen maar 
zelden optimaal zijn. Vaak is het enzym niet stabiel onder de gebruikte procescondities, of 
voert het net niet de juiste omzetting uit, of is het te traag om een economisch haalbaar 
productieproces op de leveren. Met DNA manipulatie technieken (mutagenese), die sinds 
de jaren ’80 een grote vlucht hebben genomen, is het mogelijk om mutante enzymen te 
creëren waavan de eigenschappen speciaal zijn afgestemd op gebruik als biokatalysator. In 
dit proefschrift wordt een aantal mogelijke toepassingen van DNA mutagenese van P450 
enzymen van zowel menselijke als bacteriële oorsprong verkend, waarbij vooral gekeken 
wordt naar toepassingen van deze mutante enzymen in de farmaceutische industrie. 
De twee hoofdonderwerpen die in dit boekje worden behandeld zijn (i) het gebruik van 
gerichte mutagenese van P450s om onze structurele en mechanistische kennis van P450s te 
verhogen, en (ii) het gebruik van een combinatie van gerichte en willekeurige mutagenese 
om mutanten te maken van het bacteriële P450 BM3 die met hoge activiteit geneesmiddelen 
kunnen omzetten. Zulke mutanten zouden gebruikt kunnen worden voor het ontwikkelen 
en synthetiseren van geneesmiddelen.
Een heel belangrijk P450 in de menselijke lever is Cytochroom P450 2D6 (P450 2D6). Dit enzym 
is betrokken bij de afbraak van 30% van de geneesmiddelen op de markt. Bovendien verschilt 
de hoeveelheid P450 2D6 activiteit zeer sterk van mens tot mens, waardoor verschillende 
mensen heel verschillend kunnen reageren op dezelfde dosis van hetzelfde geneesmiddel. 
Het is daarom van groot belang voor de farmaceutische industrie om goed te begrijpen hoe 
P450 2D6 werkt, om zodoende van tevoren te kunnen voorspellen of een nieuw geneesmiddel 
door P450 2D6 afgebroken zal worden. Daarom is in ons laboratorium een computermodel 
van P450 2D6 gemaakt wat kan helpen om het gedrag van P450 2D6 te voorspellen. Een 
computermodel is slechts een model van de werkelijkheid; het is dus essentieel om met 
behulp van experimenten de nauwkeurigheid van het model te testen. Dit aspect wordt 
behandeld in deel I van dit proefschrift.
In deel I wordt beschreven hoe het aanbrengen van veranderingen (mutaties) in P450 2D6 
gebruikt kan worden om meer te weten te komen over het werkingsmechanisme van 
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dit enzym. Door het computermodel van P450 2D6 goed te bestuderen kon de hypothese 
opgesteld worden dat twee aminozuren in het actieve centrum, de fenylalanines 120  (F120) 
en 483 (F483), waarschijnlijk betrokken zijn bij het binden en omzetten van geneesmiddelen 
door P450 2D6. Deze hypothese kon experimenteel onderzocht worden door de twee grote, 
aromatische fenylalanines te veranderen (muteren) in veel kleinere, niet-aromatische 
alanines, en vervolgens de effecten van deze veranderingen op de activiteit van P450 2D6 te 
bestuderen. Dit heeft geleid tot het inzicht dat deze twee aminozuren inderdaad betrokken 
zijn bij het binden en omzetten van geneesmiddelen, en dat ze allebei een andere rol spelen 
in deze processen, zoals beschreven in hoofdstuk 2 en hoofdstuk 3.
Mensen zijn een stuk complexere organismen dan bacteriën, dus het is niet verbazend dat de 
menselijke P450 enzymen complexer zijn om te bestuderen dan P450 enzymen uit bacteriën. 
In deel II van dit proefschrift is daarom aandacht besteed aan het bacteriële enzym P450 BM3. 
Dit enzym zet van nature geen geneesmiddelen om, en de doelstelling van dit onderzoek was 
om mutanten van P450 BM3 te genereren die wel in staat zijn om geneesmiddelen om te 
zetten. Omdat bacteriële P450s vaak een veel hogere activiteit hebben dan menselijke P450s 
zouden zulke mutanten een toepassing kunnen vinden in de farmaceutische industrie als 
supersnelle ‘geneesmiddelfabriekjes’. In hoofdstuk 4 en hoofdstuk 5 wordt beschreven hoe 
met behulp van het computermodel van P450 BM3 een aantal mutaties werd uitgezocht 
die het enzym in staat stellen om geneesmiddelen om te zetten, zij het met een lage 
activiteit. In hoofdstuk 6 werden extra, willekeurige, mutaties aangebracht in deze mutant 
zodat een aantal mutanten ontstonden met een sterk verhoogde activiteit. In hoofdstuk 7 
is computermodeling gebruikt om te verklaren waarom deze mutaties een gunstig effect 
hebben op de activiteit van P450 BM3; deze verworven kennis kan van pas komen bij het 
ontwikkelen van nog meer mutanten met speciﬁeke eigenschappen, en helpt ook bij het 
begrijpen van het werkingsmechanisme van P450s in het algemeen. Een mogelijke toepassing 
van de mutanten is beschreven in hoofdstuk 8. Daarin werden de mutanten gebruikt om 
grote hoeveelheden te synthetiseren van geneesmiddelmetabolieten die zeer reactief zijn, en 
daardoor moeilijk te synthetiseren via klassieke organische chemie.
Het onderzoek beschreven in dit proefschrift heeft aangetoond dat mutagenese van 
enzymen een nuttig hulpmiddel is voor het veranderen van enzymeigenschappen. We 
hebben laten zien hoe mutagenese technieken gebruikt kunnen worden om meer te weten 
te komen over de werking van een enzym, en om de kwaliteit van computermodellen van 
een enzym te testen, zoals beschreven in deel I. Verder is in deel II aangetoond dat met een 
combinatie van gerichte en willekeurige mutaties enzymen gemaakt konden worden die 
met hoge activiteit een breed scala aan geneesmiddelmoleculen kunnen omzetten. Zulke 
mutanten kunnen uiteenlopende toepassingen vinden in onder andere de ontwikkeling 
van nieuwe geneesmiddelen en de risicoschatting en synthese van geneesmiddelen. In een 
breder perspectief kan geconcludeerd worden dat mutagenese technieken gebruikt kunnen 
worden voor de ontwikkeling van aangepaste biokatalysatoren voor verscheidene industriële 
toepassingen, zoals in dit proefschrift gedemonstreerd is voor P450s.
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DANKWOORD
Aan het eind van mijn promotieonderzoek heb ik de eer een aantal geweldige mensen mogen 
te bedanken waar ik de afgelopen vier jaar mee heb samengewerkt. Om bovenaan te beginnen 
ben ik in de allereerste plaats veel dank verschuldigd aan mijn promotor en copromotor, Nico 
Vermeulen en Jan Commandeur, die dit alles mogelijk gemaakt hebben. Ik heb van jullie altijd 
de vrijheid gekregen mijn promotieonderzoek naar eigen inzicht in te vullen, en jullie bleken 
steeds bereid om grote investeringen te doen wanneer het onderzoek dit vereiste. Dank 
voor het in mij gestelde vertrouwen. Ook ben ik de leden van mijn leescommissie veel dank 
verschuldigd voor het beoordelen van mijn manuscript. Lubbert Dijkhuizen, Hubertus Irth, 
Michel Kranendonk, Rolf Schmid en Martine Smit, bedankt voor jullie tijd, moeite en aandacht.
Naast mijn begeleiders hebben ook mijn collega’s op de werkvloer een grote impact gehad 
op mijn onderzoek. Met stip op de eerste plaats staat hierbij het ‘BM3 dream team’, een 
samenwerkingsverband dat in het laatste jaar van mijn promotie tot spectaculaire resultaten 
heeft geleid. Mijn dank gaat uit naar de leden: mijn collega-AIOs Eva, Micaela en Alois, en 
mijn studenten Jeroen en Stephanie. Ik heb onze samenwerking als zeer prettig ervaren. 
Chris ’77, opperhoofd ‘BM3 dream team’ afdeling modelingzaken: bedankt voor al je hulp, en 
natuurlijk dank dat je mij, als ‘experimentalist’, liefdevol hebt opgenomen in het ‘modeling-
lunchclubje’.
Peter Keizers en Chris de Graaf, mede-AIOs, jullie beider projecten overlapten deels met het 
mijne en ik heb daardoor veel van jullie kunnen leren. Het was me een genoegen een aantal 
P450 2D6-publicaties met jullie te co-fabriceren. Jeroen Kool en Sebastiaan van Liempd: bij die 
enge kluwens tubing die jullie op het HPLC lab in elkaar hadden geknoopt bleef ik het liefst een 
heel eind uit de buurt, maar ik heb met plezier een zitkamer met jullie gedeeld. Jullie zijn nu 
alle vier uitgevlogen: het eind van een tijdperk! Jelle en Jolanda, mijn ‘kamergenoten tweede 
lichting’, wil ik bedanken voor de gezellige stonden die we in P2.54 hebben doorgebracht. 
Jelle, jouw enthousiasme voor alle sociale activiteiten waar op een of andere wijze bier bij 
betrokken is, is roerend. Ik wens jullie beiden veel succes met jullie promotieonderzoek!
Gelukkig heb ik niet alles wat in dit boekje staat zelf bij elkaar hoeven pipetteren: ik heb het 
voorrecht gehad een aantal studenten te mogen begeleiden. In min of meer chronologische 
volgorde: Ruth, Letty, Bernardo, Jan-Simon, Dianne, Lloyd, Azadeh, Sanne, Azra, Stephanie en Jeroen. 
Allemaal bedankt voor jullie inzet!
Tot slot: Richard, bedankt voor het vormgeven van dit boekje; ik heb van nabij mogen 
aanschouwen wat een enorm karwei het was, en het resultaat mag er zijn. Maar natuurlijk 
bovenal dank voor al je liefde en steun!
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Barbara van Vugt werd geboren als Barbara Medea Alice Lussenburg op 6 juni 1979 in
’s-Gravenhage.
In 1997 behaalde ze haar Gymnasium diploma aan het Stedelijk Gymnasium te Leiden, en 
twee maanden daarna vertrok ze naar het hoge noorden voor een studie Scheikunde aan de 
Rijksuniversiteit Groningen.
Ze koos voor de specialisatierichting Biochemie, en deed in dit kader een hoofdvakonderzoek 
in de groep ‘Enzymology of Membrane Proteins’ van prof. dr. Bert Poolman. Haar onderzoek 
betrof de gefaciliteerde diffusie van xylose via het mannose fosfotransferase systeem in 
Lactobacillus pentosus. Haar bijvakonderzoek voerde ze uit in Cambridge, UK, aan de Dunn 
Human Nutrition Unit. In het lab van dr. Edmund Kunji deed ze onderzoek naar mitochondriële 
transporters in gist. Na terugkomst in Nederland studeerde ze vervolgens af in september 
2001.
Na haar studie werkte ze een jaar bij BiOMaDe Technologies in Groningen als Junior Researcher. 
Omdat ze bij BiOMaDe had gemerkt dat ze het opzetten, uitvoeren en interpreteren 
van een eigen onderzoek heel leuk vond, besloot ze al snel tot het beginnen van een 
promotieonderzoek.
In oktober 2002 begon ze daarom aan een project in de groep van prof. dr. Nico Vermeulen 
aan de Vrije Universiteit Amsterdam, met als onderwerp de ontwikkeling van Cytochromen 
P450 tot biokatalysatoren voor geneesmiddelsynthese en -ontwikkeling met behulp van 
mutagenese.
Na het afronden van haar promotieonderzoek is ze in oktober 2006 begonnen aan een postdoc 
met directed evolution als onderwerp, bij prof. dr. Fred Hagen aan de TU Delft.

